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Summary
Nitric oxide (NO) is now recognised as an important regulatory molecule in the 
cardiovascular system. NO is synthesised from the amino acid L-arginine by a family of 
three isoenzymes, the nitric oxide synthases (NOS). NOS III is the isoform constitutively 
expressed in the endothelium, but its expression can be regulated by shear stress and 
oestrogens among other factors. Endothelium derived NO seems to play a role in preventing 
atherosclerosis, but its role in hypertension is less clear. Some animal and human studies 
favour an important role, whereas others do not. Gender differences in cardiovascular 
disease, endothelial function and NO are well recognised, but the underlying mechanism 
remains unclear. There are theoretical reasons, and indeed experimental evidence, to 
implicate oestrogens, although again there is some debate about possible mechanism(s). The 
process of ageing is thought to be related to oxidative stress and hypertension has been 
described as an accelerated form of ageing, but the role of superoxide anion (0 2‘) and 
superoxide dismutase (SOD) in hypertension and ageing is only now becoming clearer.
To determine blood pressure and gender differences in NO availability, rings of thoracic 
aorta from 16 week old males and females, normotensive Wistar-Kyoto rats (WKY) and 
stroke prone spontaneously hypertensive rats (SHRSP) were studied in classic organ bath 
experiments. Stimulated NO availability was assessed by carbachol relaxation (10'8 - 10'5 
mol/L) and basal NO availability was assessed by contraction to the NOS inhibitor NG-nitro- 
L-arginine methyl ester (L-NAME, lOOpmol/L). The contribution of the 0 2'/S0D system 
was assessed in the organ bath by examining the effects of inhibiting endogenous SOD with 
diethyldithiocarbamate (DETCA, 10 mmol/L) and adding exogenous SOD (45U/mL). In 
vitro NOS III activity was assessed in the 4 groups using the L-arginine/L-citrulline assay. 
Endothelial NOS gene (Nos3) expression was measured by reverse transcription-polymerase
chain reaction. Expression of intracellular copper zinc SOD (Sodl) and mitochondrial 
manganese SOD (Sod2) mRNA was measured by northern blotting and expressed as a ratio 
to glyceraldehyde phosphate dehydrogenase (GAPDH) mRNA. The effect of age on 
endothelial function was assessed by measuring the response to L-NAME (100pmol/L) in 
aortic rings from the same 4 groups of rats at 4, 6 and 12 months of age. The effect of 
oestrogen was assessed by administering 17(3-oestradiol (20pg per day, intraperitoneally, 
for 2 weeks) to a group of 1 year old WKY females and comparing basal and stimulated 
NO availability and Nos3 gene expression, as above, with a group of controls.
In the organ bath, maximum relaxation to carbachol (Emax) was significantly greater in aortic 
rings from WKY compared to rings from SHRSP (p=0.015). Within the SHRSP strain the 
carbachol concentration causing 50% relaxation (EC5o) was significantly less in females 
compared to males (p=0.003). There were no other significant gender differences in 
carbachol Emax or EC5o. These data suggest that stimulated NO availability may be greater in 
WKY compared to SHRSP and perhaps SHRSP females compared to SHRSP males. The 
contraction of aortic rings to L-NAME was significantly greater in WKY compared to 
SITRSP (p=0.015). Further, this contraction in rings from WKY females was significantly 
greater than WKY males (p=0.00004). Similarly, the contraction in rings from SHRSP 
females was significantly greater than SHRSP males (p=0.0006). These data suggest that 
basal NO availability is greater in WKY compared to SHRSP and in females compared to 
males in both strains. The SOD inhibitor DETCA attenuated the relaxation to carbachol o f- 
SHRSP significantly more than WKY (p=0.0008). There were no strain or gender 
differences in the effect of adding exogenous SOD to the water bath. These data suggest 
that in aortas of SHRSP, SOD is more active, or 0 2 accumulates faster, or a combination 
of both.
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NOS III activity was significantly greater in the aortas from SHRSP compared to WKY 
(p=0.016). In both strains NOS III activity tended to be higher in males compared to 
females, but the differences did not reach statistical significance. NosS mRNA expression 
was greater in SHRSP compared to WKY, although the difference just failed to reach 
statistical significance when corrected for triple comparisons (p=0.02). Again there was a 
tendency for Nos 3 expression to be greater in males compared to females in both strains. 
These data combined suggest that the reduced NO availability in SHRSP is not due to 
reduced NO production. Sod2 gene expression was significantly greater in SHRSP males 
compared to WKY males (p=0.02), suggesting that Sod2 deficiency is not responsible for 
strain differences in NO availability. Nos3 and Sod2 may be upregulated to compensate for 
increased 0 2 in SHRSP.
In WKY females the response to L-NAME was significantly lower at 12 months compared 
to 4 months (p=0.0009). In the SHRSP females the response to L-NAME was also 
significantly lower at 12 months compared to 4 months (p=0.0054). In males from both 
strains there was no significant difference in the response to L-NAME between 4 months 
and 12 months. When 1 year old WKY females were treated with 17P-oestradiol, the 
response to L-NAME was greater compared to the control group (p=0.05). There was no 
significant difference in the carbachol Emax or EC50 when oestrogen treated animals were 
compared to controls. Nos3 mRNA expression was significantly greater in aortas from 
WKY females at 12 months of age compared to aortas from WKY females at 4 months of 
age (p=0.01). 17p-oestradiol did not significantly affect Nos3 expression in 1 year old 
animals.
It can be concluded from these studies that basal NO availability is reduced in SHRSP, in 
males and in older females. This does not appear to be due to reduced NO production,
suggesting increased scavenging by 0 2‘ instead. Differences in 0 2' are not explained by 
differences in SOD gene expression, and are most likely due to increased 0 2' generation 
within the vessel wall. Increased 0 2' is likely responsible for the age related decline in 
endothelial function. Gender differences in NO are likely due to oestrogen, but mechanisms 
other than increased Nos3 expression are likely to contribute.
1 Introduction
1.1 Nitric oxide
For many years nitric oxide (NO) was regarded as a noxious pollutant in car exhaust fumes, 
fossil fuel smoke and cigarette smoke, responsible for acid rain and depletion of the ozone 
layer. However, interest in the physiological role of this simple diatomic molecule has risen 
exponentially in the 10 years since the endothelium derived relaxing factor (EDRF), first 
proposed by Furchgott and Zawadski in 19801, was identified by Palmer et al as NO2. 
Between 1981 and 1986, 10 papers relating to NO biosynthesis were published. In the next 
5 years, there were more than 500 such publications. A computer search for the keyword 
‘nitric oxide’ generated more than 4,500 publications in the world literature during the 
calendar year 1996. In 1992, interest was such, that NO was voted “molecule of the year” 
by Science.
Several independent lines of investigation led to this explosion. As far back as 1916, it had 
been realised from dietary balance studies that humans excrete more nitrate than they 
ingest3. This excess had been thought to be produced by intestinal micro-organisms and was 
thought to be of little relevance to mammalian biology. Several decades later in 1981, Green 
and colleagues showed that urinary excretion of nitrates was maintained in germ-free rats4, 
and could therefore not be solely derived from bacterial metabolism. They also showed that 
the nitrate was being biosynthesised mainly outside the intestine. A marked increase in 
nitrates was detected in rats exposed to bacterial endotoxin, but was abolished in mice with 
a genetically determined absence of macrophages. A ninefold increase in excretion of nitrate 
was observed in a human subject during an episode of fever and diarrhoea. Thus, interest in 
this area was renewed. Around the same time, studies on carcinogenesis revealed that
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mammalian cells metabolised L-arginine to produce a reactive nitrogen oxide compound5. 
Moreover, the cytotoxic and cytostatic actions of activated macrophages were found to 
require L-arginine as a substrate and NG-substituted analogues of L-arginine or NO 
scavengers blocked cytotoxicity. Indeed, NO was identified as the effector molecule of 
these cytostatic functions6.
In the field of neuroscience, interest was also growing. It had been known since the mid- 
1970’s that neurotransmitters, especially excitatory amino acids, produce increases in 
guanosine-3’,5’-cyclic monophosphate (cGMP) concentrations in many regions of the brain. 
This cGMP accumulation was abolished in the absence of extracellular calcium. Cyclic 
GMP is synthesised by the enzyme guanylate cyclase (EC 4.6.1.2), which is not regulated by 
calcium, therefore the mechanism underlying the cGMP rise was not clear. In 1988, 
Garthwaite et a l7 demonstrated that stimulation of N-methyl-D-aspartate (NMDA) 
receptors led to Ca2+-dependent production of an NO-like material in brain slices which, in 
turn, stimulated soluble guanylate cyclase in the tissue. Also in the 1970’s, work on 
autonomic non-adrenergic non-cholinergic (NANC) neurotransmission was also fitting into 
the jig-saw. The neurotransmitter turned out to be NO8.
In the meantime, another fascinating story had developed in the cardiovascular area. The 
discovery of EDRF by Furchgott and Zawadski1 and its subsequent identification as NO2 
fuelled the increasing interest. NO had brought together the disparate fields of immunology, 
neurobiology and vascular biology.
The physiological roles of NO are at least as protean as those discovered for corticosteroids 
in the 1940s-1960s and eicosanoids in the 1960s-1980s - all three the products of haem 
containing oxygenases. In addition to being an important immunological effector molecule9,
NO has now been confirmed as a new class of neurotransmitter10 and paracrine signalling 
molecule11. Classical mediator molecules have complex structures, are frequently stored in 
granules, released specifically, and depend for their action on a complimentary fit to a 
specific receptor. However, NO is a simple diatomic gas which is not stored and diffuses 
freely to its site of action, where it binds covalently to produce its effect. Carbon monoxide 
(CO) is another diatomic gaseous molecule in this class, which may act as a 
neurotransmitter and a regulator of cardiovascular function.
The property of NO which allows it to diffuse so easily in the environment of the cell is its 
solubility in water (2 mmol/L at 20°C and 1 atmosphere) and lipid. In solution, NO 
undergoes rapid oxidation to nitrite and nitrate with an estimated half-life of <4 minutes. In 
biological systems, NO has an estimated half-life of only 3-5 seconds as it interacts with 
superoxide anion and haem-containing proteins.
Because of this very short half-life in vivo, there is some debate about whether NO can exist 
long enough to accomplish its biological actions. However, NO has a diffusion coefficient 
1.4-fold higher than 0 2, and can diffuse over the 100pm or so from the endothelium to the 
underlying vascular smooth muscle cells within a few seconds. Nonetheless, some 
investigators feel that the molecule must be stabilised in some way by binding to high or low 
molecular weight thiol groups. There are theoretical reasons why NO cannot be transported 
in a more stable form. Classical receptors can easily distinguish between two closely related 
molecules produced by distant endocrine systems (e.g. adrenaline and noradrenaline) 
because of subtle differences in their shape. With only two atoms, NO encodes information 
not by its shape, but by changes in its local concentration. If NO were transported in a more 
stable form, the target guanylate cyclase would become saturated, thus obliterating any
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information being transferred. Therefore, stabilisation of NO is not necessary and may even 
be detrimental.
Although not thought to be stored, there is evidence that NO can exist in the circulation 
bound to macromolecules such as albumin and haemoglobin (Hb), which retain some 
biological actions by releasing active NO via low molecular weight S-nitrosothiols. The 
interaction of NO with haemoglobin is via two highly conserved sulphydryl groups. The 
formation of nitroso-Hb is favoured when haemoglobin is in the oxy-Hb state, whereas 
dissociation of NO is more likely in the deoxy-Hb state. This interaction with haemoglobin 
may permit NO to become associated with haemoglobin in the pulmonary vasculature and 
to be released from haemoglobin in the systemic circulation12.
The vascular regulatory and neurotransmitter functions of NO share a common mechanism. 
NO diffuses from the endothelium to the vascular smooth muscle layer or across the 
synapse. After entering the target cell, NO binds to the haem moiety of guanylate cyclase 
and activates the enzyme13 by inducing a conformational change that displaces iron out of 
the plane of the porphyrin ring. Guanylate cyclase then catalyses the production of cGMP 
from guanosine 5’-triphosphate (GTP). Direct evidence has now been obtained that NO 
mediates glutamate stimulation of cGMP formation in the cerebellum via NMDA 
receptors14.
Cyclic GMP is believed to elicit vascular smooth muscle relaxation through several 
mechanisms. One important mechanism involves reducing [Ca2+] i , but the precise 
mechanism for this remains poorly understood. Cyclic GMP-dependent kinase is thought to 
be involved through inositol 1,4,5-triphosphate (IP3) production and action; Ca2+-ATPase 
activation; activation of Ca2+-activated K+ channels; and even via alteration of the
cytoskeleton. Another proposed mechanism again involves cGMP-dependent protein kinase 
phosphorylation, and thus inactivation, of the enzyme myosin light chain kinase (MLCK). 
This, in turn, reduces cross-bridge cycling of the 20kDa myosin light chain (LC2o), and 
hence causes relaxation.
A recent, elegant study by Bolotina et a l 15 demonstrate a novel direct action of NO on 
Ca2+-dependent K+ [K+(Ca)] channels. They showed that, even when guanylate cyclase was 
inhibited by methylene blue, considerable NO-dependent relaxation of rabbit aorta persisted. 
This relaxation was blocked by the specific K+(Ca) channel inhibitor, charybdotoxin. They 
consolidated these findings by showing that, in cell-free membrane patches, NO can directly 
activate K+ (Ca) without requiring cGMP.
Endothelium-derived NO can also diffuse into the lumen of the vessel where it can prevent 
platelet aggregation16 and their adhesion to the endothelium17,18 by a cGMP-dependent 
mechanism18. This is thought to be one mechanism whereby NO prevents atherogenesis and 
will be discussed in more detail in section 1.1.3.4.
Interestingly, guanylate cyclase is inhibited by physiological concentrations of [ C a 2+] i; which 
would minimise cGMP production in cells stimulated to produce NO by agonist induced 
increases in [ C a 2+]i. This may, therefore, represent a control mechanism by which activated 
cells release NO to stimulate guanylate cyclase selectively in target cells.
The effects of the relatively large amounts of NO produced by macrophages are more 
complex and less well understood. These effects will be discussed in section 1.1.1.2.
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1.1.1 Nitric oxide synthases (EC 1.14.13.39)
NO is synthesised from the abundant amino acid L-arginine by the nitric oxide synthase 
(NOS) family of oxidoreductases19, through a hitherto unrecognised pathway - namely the 
L-arginine-nitric oxide pathway. In the presence of molecular oxygen and reducing 
equivalents in the form of nicotinamide adenine dinucleotide phosphate (NADPH), one of 
the guanidino nitrogen atoms of L-arginine undergoes a five-electron oxidation to yield the 
free radical NO and L-citrulline19 via an NG-OH-L-arginine intermediate (Figure 1). 
Interestingly, L-citrulline has been shown, in endothelial cells at least, to be recycled back to 
L-arginine by the incorporation of one nitrogen atom from urea20, which not only 
regenerates substrate for further NO production, but also eliminates excess nitrogen created 
by the cell’s metabolism (Figure 1).
There are three known isoforms of NOS (Table 1, Figure 2), which are products of three 
distinct genes2123. The unique characteristics of each isoform will be discussed in detail 
below, but as they each catalyse the same reaction, it is no surprise that they share several 
common features. The C-terminal domain of each isoform shows significant homology with 
NADPH cytochrome P-450 reductase (Figure 2). For this reason, and also because of its 
rare spectral characteristics, NOS was thought to belong to the P-450 superfamily of 
enzymes. However, NOS lacks the decapeptide around the haem binding cysteine present in 
almost all P-450s characterised, which is not surprising considering that the substrates for 
the P-450s are hydrophobic molecules, whereas L-arginine is very hydrophilic. It would 
therefore appear that NOS lies outside the P-450 superfamily and has converged on using 
the P-450 chromophore for the chemistry that it carries out. All NOS isoforms have binding 
sites for, and rely for their action on, the cofactors flavin mononucleotide (FMN)21, flavin 
adenine dinucleotide (FAD)21, haem24, calmodulin (CaM)25 and tetrahydrobiopterin (BH4)26.
As NOS is known to be a haemoprotein and NO is known to interact with such 
haemoproteins12, it is thought that NO exerts a negative feedback inhibition of NOS27.
The importance of NOS is indicated by its evolutionary conservation. NOS enzymes have 
been identified in many vertebrates and even invertebrates. A Ca2+/CaM-dependent NOS 
has been identified in Apis mellifera and Drosophila melanogaster. In Drosophila, the gene 
has been cloned and termed dNOS. The dNOS cDNA encodes a protein of 152kDa with 
43% amino acid identity with rat neuronal NOS. Like the mammalian protein, dNOS 
contains putative binding sites for CaM, FAD, FMN and NADPH. In Drosophila NO has 
been shown to regulate fluid secretion in the Malpighian tubule and is also involved in 
controlling the size of body structures during development. NOS also shares some 
homology with flavohaem proteins found in yeasts and bacteria, suggesting conservation for
1.8 billion years, provided that cross-species gene transfer has not occurred.
The mammalian genes are very highly conserved. In general, the same isoforms from 
different species are essentially identical. For example, there is 94% sequence identity 
between bovine and human NOS III28. By contrast, the different isoforms from the same 
species share only 50-55% sequence identity with each other28"30
+NH
H,N
c o o -H2N 
L-citrulline
NO-
Figure 1 - Biosynthesis o f nitric oxide (NO) from L-arginine, via N°-OH-L-arginine, by 
incorporating molecular oxygen (O2). L-citrulline can be recycled back to L-arginine by 
incorporation of ammonia (NH3).
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1.1.1.1 Neuronal nitric oxide synthase (NOS I)
1.1.1.1.1 Biochemistry
Neuronal NOS was the first isoform of NOS to be isolated, and consequently the enzyme is 
termed NOS I, while the gene is termed Nosl, under the newly agreed nomenclature31. It 
was purified 6000-fold to homogeneity from rat cerebellum by a 2’,5’-ADP column eluted 
with NADPH25 and almost simultaneously isolated by another group from porcine 
cerebellum by ammonium sulphate precipitation and affinity chromatography on 2’,5’-ADP- 
Sepharose32. The purified enzyme migrated as a single 150kDa band on sodium dodecyl 
sulphate/polyacrilamide gel electrophoresis (SDS/PAGE). The native enzyme initially 
appeared to be a monomer25, although subsequent evidence suggests that the enzyme is 
cytosolic and exists as a homodimer under native conditions33.
1.1.1.1.2 Physiology
NOS I is a highly regulated enzyme. As mentioned above, it was found to have an absolute 
requirement for C a M 34, which is the first indication that its activity is dependent on [Ca2+];. 
The gene for the enzyme (Nosl) is constitutively expressed25 centrally in discrete neuronal 
populations of the brain and posterior pituitary; and peripherally in the non-adrenergic non- 
cholinergic (NANC) nerves of the myenteric plexi of the intestine, adrenal medulla and 
perivascular nerves34. Therefore, in these cells the enzyme is always present, but inactive at 
the resting [ C a 2+] ; of «80 nmol/L. It becomes active when the [ C a 2+]i increases to above 500 
nmol/L, allowing C a M  to bind to, and activate, the enzyme.
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A further potential mechanism for regulating NOS I is phosphorylation. The enzyme can be 
phosphorylated stoichiometrically by adenosine 3’,5’-cyclic monophosphate (cAMP)- 
dependent protein kinase, protein kinase C and calcium/calmodulin-dependent protein 
kinase, with each kinase phosphorylating a different serine residue on NOS I. Activation of 
protein kinase C in cells transfected with Nosl cDNA reduces activity of NOS I by «77% in 
intact cells and by «50% in protein homogenates from these cells. As the enzyme is 
cytosolic, phosphorylation must reduce NOS I activity independently of membrane binding.
In the brain, the stimulus for the increase in [ C a 2+]i is glutamate binding to the N-methyl-D- 
aspartate (NMDA) receptor35. In the hippocampus, this is thought to be associated with 
long-term potentiation (LTP) and memory. In the spinal cord, it is thought to be involved in 
nociception.
1.1.1.1.3 Pathology
In addition to these neuortrasmitter functions, NO is thought to be responsible for 
neurotoxicity in certain circumstances. The first indication that this was the case came from 
the observation that NOS containing neurons (identified by NADPH diaphorase staining and 
in situ hybridisation) are relatively resistant to the toxic effects of excitatory amino acids 
such as quinolinic acid and glutamate and ischaemia. These cells also selectively survive the 
degenerative processes in the corpus striatum of Huntington’s Disease, suggesting that the 
gene defect is modifiable by the local biochemical environment. They are also relatively 
resistant to the neurodegenerative processes of Alzheimer’s disease and aluminium-induced 
neurofibrillary degeneration, which is thought to be a very similar disease. It was postulated 
that NOS containing neurons released NO to the surrounding cells in toxic quantities as 
many of the neurotoxic insults could be limited by NOS inhibitors, although ischaemic insult
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seems to be affected less by NOS inhibition. The NOS containing neurons themselves may 
be protected by their high levels of NADPH, which is required for NOS function and could 
reduce oxidative neurotoxins.
Further evidence that NO is important in neurotoxicity comes from mice with targeted 
disruption of the Nosl gene36. These Nosl ‘knock out’ mice are resistant to neurotoxicity 
and sustain smaller infarct volumes 24 and 72 hours post-middle cerebral artery occlusion 
(MCAO). The infarct volume increased if the knock out mice were pre-treated with the 
NOS inhibitor nitro-L-arginine. This suggests that, whereas NOS I may be deleterious, 
NOS III may be protective. Indeed, Nos3 ‘knock out’ mice sustain larger infarcts 24 hours 
post-MCAO, even when blood pressure is normalised with hydralazine. This effect was 
attenuated by nitro-L-arginine, confirming the neuroprotective effect of NOS III.
1.1.1.1.4 Molecular biology
The human Nosl gene was originally localised to 12ql4-qter on chromosome 12 by using 
human-rodent hybrid cell line panels37. The same group later used fluorescent in situ 
hybridisation (FISH) to more accurately localise human Nosl to 12q24.2 - 24.3138. The 
structural organisation of the full length genomic sequence of human Nosl has been 
determined by restriction enzyme mapping, subcloning and DNA sequence analysis of 
bacteriophage- and yeast artificial chromosome-derived genomic DNA29. The open reading 
frame is encoded by 29 exons spanning at least 160kb, with translation initiation in exon 2 
and termination in exon 29. The deduced amino acid sequence of human NOS I revealed 
93-97% identity with rat NOS I21,39, with binding sites for all of the co-factors being 
present.
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1.1.1.2 Inducible nitric oxide synthase (NOS II)
| 1.1.1.2.1 Background
j Mammals, including humans, excrete more nitrate in their urine than they ingest3. The
original perception that this nitrate imbalance represented synthesis by intestinal flora, 
proved incorrect when it was determined that germ-free rats synthesised the same amount 
of nitrate as control animals. Subsequent reports demonstrated that injection of rats with 
Escherichia coli lipopolysaccharide (LPS) markedly increases urinary nitrate excretion40.
| This triggered the search for mammalian cells capable of synthesising nitrate which, in 1985,
I
; led to the discovery that macrophages could be induced with LPS to produce significant
i
amounts of both nitrite and nitrate41. Further work demonstrated that L-arginine is the 
| substrate for this pathway9 and that the effector molecule is NO6,9. The pathway was also
i
| found to be stimulated by the endogenous cytokine interferon-y (IFN-y)42. The enzyme
responsible for NO synthesis in LPS/IFN-y-stimulated macrophages was reported to have 
been localised in the cytosolic fraction42.
1.1.1.2.2 Biochemistry
This cytosolic NOS activity was purified 426-fold from an LPS/IFN-y-stimulated mouse 
macrophage cell line by sequential anion-exchange, affinity, and gel filtration 
chromatography43. SDS/PAGE of the purified NOS, later termed NOS II31, gave three 
closely spaced silver-staining protein bands between 125 and 135 kDa. L-arginine was 
confirmed as the substrate and, like NOS I, NADPH, BH4, FAD and FMN were necessary 
for activity. Gel filtration chromatography indicated that the induced NO synthase was
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catalytically competent as a dimer of «250 kDa, but could be dissociated into inactive 
monomers of «130 kDa in the absence of L-arginine, FAD, and BH4.
1.1.1.2.3 Physiology
Unlike NOS I, addition of Ca2+ with or without CaM did not increase the activity of the 
purified enzyme, and NO synthesis was not altered by CaM inhibitors43. The apparent lack 
of dependence on Ca2+ and CaM for activity came to distinguish this so-called ‘inducible’ 
NOS from the ‘constitutive’ NOS I and NOS III. Despite this, when the gene encoding 
NOS II (Nos2) was cloned and sequenced from activated mouse macrophages22, researchers 
were surprised to find a consensus CaM recognition site44.
The answer to this puzzle was revealed by Cho et al, who showed that NOS II contains, as 
a tightly bound subunit, a molecule with the immunologic reactivity, high performance 
liquid chromatography retention time, tryptic map, partial amino acid sequence, and exact 
molecular mass of CaM45. In contrast to most CaM-dependent enzymes, NOS II binds CaM 
tightly without a requirement for elevated Ca2+. This explains why NOS II appears to be 
regulated by transcription and activated simply by being synthesised.
1.1.1.2.4 Molecular biology
Nos2 cDNA has been cloned and sequenced from a variety of species and tissues22,30,46"49. 
When the Nos2 cDNA was cloned from rat hepatocytes46, and the sequence compared to 
that cloned from mouse macrophages22, the predicted amino acid sequences were 94% 
identical. This was very suggestive that the NOS II enzyme was produced in different 
tissues by a single Nos2 gene, and that the 6% difference observed was a species difference.
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The Nos2 cDNA was subsequently cloned from rat vascular smooth muscle cells47 and the 
amino acid sequence was found to be identical to rat hepatocyte NOS II46, confirming the 
existence of a single Nos2 gene.
NOS II activity was demonstrated in human macrophages (RAW 264.7 cells) in 199250, but 
human Nos2 cDNA was first cloned and sequenced from human chondrocytes48 and 
hepatocytes30, then later in vascular smooth muscle cells49. Nos2 mRNA has now been 
identified in so many different tissues in different species that one may speculate that any 
mammalian cell can produce NOS II if the cocktail of pro-inflammatory agents and 
cytokines is right.
The full length genomic human Nos2 gene was isolated on overlapping cosmid clones from 
a human genomic library using both the murine macrophage and the human hepatocyte 
Nos2 cDNAs as probes51. All isolated cosmids were part of a single genomic locus and no 
other genomic loci were identified or isolated. Analysis of this locus indicated that the 
human Nos2 gene is -37 kb in length and consists of 26 exons and 25 introns. Polymerase 
chain reaction analysis of a human/rodent genomic DNA somatic cell hybrid panel and FISH 
indicated that the human Nos2 gene is located on chromosome 17 at position 17cen-ql 1.2. 
Similar analysis by another group52 revealed the Nos2 open reading frame to be encoded by 
27 exons, with translation initiation and termination in exon 2 and exon 27, respectively.
The 5'-flanking region contains several consensus sequences for the binding of transcription 
factors involved in the inducibility of other genes by cytokines. These include an IFN-y 
responsive element and binding consensus sequences for nuclear factors NF-IL6 and NF- 
kB49. Interestingly, the human Nos2 gene contains a shear-stress responsive element, which 
was also found to exist in human NOS III (see section 1.1.1.4), but not in murine NOS II.
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NOS II differs from NOS I (and, as we shall see later, NOS III) in that the enzyme activity 
is negligible in unstimulated macrophages41,42. Enzyme activity appears about 4-6 hours 
after induction42 and relies on RNA transcription and protein synthesis. When the enzyme 
has been induced, it produces large quantities of NO and its activity can be present for many 
days42. The large quantity of NO produced by NOS II is involved in host defence.
1.1.1.2.5 Immunology
The immunological properties of NO may have originated as an ancient first-line defence for 
metazoan cells against intracellular parasites (e.g. Leishmania major, Toxoplasma gondii, 
and Mycobacterium leprae), evolving only later for signalling. Knowledge of this 
antimicrobial principle can be traced back to the Sumerians, who used nitrite to cure meat 
and inhibit Clostridium botulinum.
In addition to immunity to parasitic infections, NO is involved in destroying tumour cells. 
NO gas under anaerobic culture conditions has been shown to be cytotoxic to guinea pig 
hepatoma cells, by causing intracellular iron loss, inhibition of mitochondrial respiration, 
inhibition of aconitase, inhibition of DNA synthesis and hence cytostasis in the tumour 
cells6.
Despite these apparent toxic effects, NO does not directly attack DNA, inhibit the glycolytic 
enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH), inhibit mitochondrial 
respiration, or inactivate iron/sulphur centres of tumour cells, unless it is allowed to oxidise 
to higher nitrogen oxides. The higher oxide of nitrogen most commonly implicated is 
peroxynitrite (ONOO )53.
21
Peroxynitrite is formed by the diffusion limited reaction of 0 2" with NO54 with the release of 
22 kcal/mol Gibbs energy (thermodynamically equivalent to the hydrolysis of two ATPs), 
making the reaction essentially irreversible. The reaction rate for the formation of 
peroxynitrite has recently been determined to be 6.7 ± 0.9 x 109 M~‘.s'1, which is over 3-fold 
faster than the rate at which superoxide dismutase (SOD) removes 0 2‘ at physiological ionic 
strength (Figure 3)55. Only when NO is produced in micromolar concentrations, such as 
after NOS II induction, can it compete with SOD for 0 2' to produce toxic amounts of 
peroxynitrite. Similarly, NOS I can also produce micromolar concentrations of NO, and 
hence toxic amounts of peroxynitrite, when enough cells in one region produce NO 
simultaneously, such as during cerebral ischaemia. This would explain the neurotoxic effects 
of NOS I described in section 1.1.1.1.3. Therefore, peroxynitrite can be described as a 
binary toxin, which is assembled when cells make large amounts of both NO and 0 2', as is 
the case with activated macrophages and neutrophils.
1.1.1.2.6 Pathology
As an adverse consequence of this immune function, NO has been implicated in a number of 
chronic inflammatory diseases including rheumatoid and osteoarthritis, inflammatory bowel 
disease and asthma. Indeed, treatment with NOS inhibitors reduces the degree of 
inflammation in rats with acute inflammation or adjuvant arthritis, whereas L-arginine 
increases it.
NO has now been established as contributing to septic shock56. Sepsis and its associated 
syndromes represent a potentially devastating systemic inflammatory response estimated to 
occur in 1% of hospitalised patients, 10-20% of whom die. Mortality approaches 60-90% in 
those who develop septic shock. Patients and animals with septic shock lose peripheral
vascular tone, and the responsiveness of vessels to constricting agents, both in vitro and in 
vivo, is diminished56,57. In patients with septic shock, the levels of NO metabolites in plasma 
are significantly elevated58, and the infusion of NOS inhibitors in such cases59 and in animal 
models of septic shock60 can lead to a rapid and reproducible rise in systemic vascular 
resistance61 where other vasoconstrictors are ineffective. However, this treatment can be 
associated with increased mortality60, even to 100%62.
Glucocorticoids have been used as anti-inflammatory agents since the early 1950’s, but the 
precise mechanism of their anti-inflammatory action was poorly understood. As NO is 
involved in inflammation, the role of NOS II in glucocorticoid action was a theoretical 
possibility. This involvement has now been confirmed. Glucocorticoids have been shown to 
prevent NOS II induction, and hence NO production, in intact organs of the rat, 
macrophages, neutrophils, vascular smooth muscle cells and endothelial cells. This effect is 
via specific glucocorticoid receptors, and is not elicited by other steroid hormones such as 
progesterone. This effect can be shown clinically by normalisation of the increased NO 
exhalation in asthma by systemic or inhaled glucocorticoids. In contrast to inhibiting 
endotoxin induced NOS II by L-arginine analogues where mortality increases60’62, inhibiting 
NOS II induction in rats with glucocorticoids 1 hour before and 2 hours after endotoxin 
administration prevented hypotension and reduced mortality from 40% to 0% in one animal 
study62.
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Figure 3 - The fate of superoxide (0 2‘) depends on its reaction rates with target molecules 
and the concentrations of those molecules. Superoxide dismutase (SOD) is usually present 
in micromolar concentrations, therefore this is the major route of 0 2’ elimination. However, 
if nitric oxide (NO) concentrations rise into the micromolar range, such as after NOS II 
induction, then peroxynitrite (ONOO') will form preferentially due to the high rate constant.
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1.1.1.3 Endothelial nitric oxide synthase (NOS III)
1.1.1.3.1 Background
For a long time the endothelium had been regarded as a simple inert barrier between the 
blood in the lumen and the underlying vascular smooth muscle cells. However, the 
endothelium is now known to be a metabolically and physiologically dynamic tissue with 
multiple functions. The first clue that the endothelium and NO may be important in 
cardiovascular regulation came in 1980, when Furchgott and Zawadski1 demonstrated that 
an intact endothelium was essential for the vasodilator action of acetylcholine (ACh) in 
isolated arterial strips or rings. Removal of the endothelium prevented the relaxant effects of 
ACh and even led to contraction. They concluded that endothelial cells release a substance, 
which they called endothelium-derived relaxing factor (EDRF). They also demonstrated that 
its action was destroyed by oxyhaemoglobin and enhanced by superoxide dismutase. Unlike 
the other known endogenous vasodilator, prostacyclin, its activity was not inhibited by 
indomethacin.
Throughout the early 1980’s the nature of this novel substance remained elusive. NO was a 
candidate16, but there was much debate about whether such a simple molecule could be 
responsible for what would turn out to be such an important function63. Other candidates 
included S-nitrosocysteine, dinitrosyl-iron-cysteine complexes, nitrosyl and 
hydroxylamine63. Several studies suggested that EDRF and NO were identical63, but others 
studies found differences, albeit subtle, between the two64. The definitive study by Palmer 
and colleagues in 1987 showed that NO exhibited all of the properties of EDRF2. In their 
study NO was determined by chemiluminescence and the biological activity of EDRF was 
determined by bioassay. EDRF and NO produced identical relaxation in bioassay tissues.
Both substances were equally unstable. Bradykinin caused dose-dependent release of NO 
from the cells in amounts sufficient to account for the biological activity of EDRF. The 
relaxations induced by EDRF and NO were inhibited by haemoglobin and enhanced by 
superoxide dismutase to a similar degree. All of theses observations were taken as sufficient 
evidence that EDRF was in fact NO.
1.1.1.3.2 Biochemistry
Despite the fact that endothelial cells were the first cell type described to carry out NO 
synthesis2, the endothelial isoform (NOS III) was the third and last to be isolated. The main 
reason for this delay was that, whereas the other isoforms are present in the cytosolic 
fraction of the cell, NOS activity was located in the particulate fraction of endothelial cells. 
It was eventually purified 3419-fold to homogeneity from the crude particulate fraction of 
cultured and native bovine aortic endothelial cells by a 2’,5’-ADP-Sepharose column 
followed by Superose 6 gel electrophoresis65. This resulted in a single protein band after 
denaturing PAGE that corresponded to «135kDa. Later studies suggested that NOS III 
exists as a homodimer66.
This was the first example of a membrane bound NOS. The nature of the membrane binding 
was initially unclear, but when the bovine Nos3 gene was cloned and sequenced23, a 
myristoylation consensus sequence was identified at the N-terminus, which was not present 
on NOS I or NOS II. It was subsequently confirmed that endothelial cells metabolically 
incorporate myristate into NOS III67. As no recognised transmembrane domains were 
identified23, this fatty acylation of the protein was thought to ‘anchor’ the enzyme into the 
membrane, either directly or via another membrane-bound protein. Further studies, using 
oligonucleotide-directed mutagenesis of the myristoylation consensus sequence of Nos3
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cDNA, convincingly showed that myristoylation is critical for the membrane association of 
this isoform68.
It is natural to assume that the membrane, with which NOS III associates, is the plasma 
membrane. However, recent electron-micrographic studies on endothelial cells from guinea- 
pig ileum submucosal arterioles, capillaries and venules showed NOS III immunoreactivity 
predominately in association with the Golgi complex and membranes of some vesicles. Only 
small amounts of immunoreactivity were present in association with the plasma membrane 
and rough endoplasmic reticulum69.
NOS III has a consensus sequence for phosphorylation by cyclic AMP dependent protein 
kinase23. As alluded to with NOS I in section 1.1.1.1.2, Michel et al have demonstrated that 
NOS III in bovine aortic endothelial cells is serine phosphorylated when the cells are 
stimulated by a NO dependent agonist such as bradykinin70. They also showed that such 
phosphorylation changes the subcellular location from particulate to cytosolic. If, as 
suggested above, membrane association is important for NOS III activity , then 
phosphorylation and dissociation from the Golgi complex would result in reduced activity. 
This may represent a novel control mechanism to inactivate the enzyme once it is activated 
by an agonist. In addition to this potential post-translational control of NOS III function, 
there are many well described transcriptional control mechanisms, which will be discussed in 
section 1.1.1.5.
1.1.1.3.3 Molecular biology
The full length Nos3 cDNA was first cloned from a bovine aortic endothelial cell (BAEC) 
cDNA library23. Sequencing revealed a 3615 bp transcript with consensus sequences for
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CaM, FMN, FAD and NADPH binding, myristoylation, and phosphorylation by the cAMP- 
dependent protein kinase (PKA)23. Human Nos 3 cDNA was subsequently cloned from a 
human umbilical vein endothelial cell (HUVEC) cDNA library28. Two years later, the full 
length genomic sequence of human Nos3 was determined71. Later that year Nos3 was 
localised to the 7q35 - 7q36 region of human chromosome 7 by Southern blot hybridisation 
of human-rodent somatic cell hybrid lines and FISH72, and independently by mapping a 
highly polymorphic dinucleotide repeat (CA)n within intron 1373.
The human Nos3 gene contains 26 exons spanning «22 kb of genomic DNA, encodes a 
messenger RNA of 4052 nucleotides, and is present as a single copy in the haploid human 
genome. The 5’ promoter region is “TATA-less”, which has been described for some 
housekeeping genes with multiple transcription start sites. The Nos3 mRNA does not 
correspond to these criteria, but the presence of multiple other potential transcription factor 
binding sites within the promoter region could account for the lack of a TATA-like element. 
These other potential transcription factor binding sites include, among others, a shear-stress 
responsive element (SSRE)71’73, which has been identified in the promoter region of other 
shear-stress inducible endothelial genes, and at least two oestrogen receptor binding 
elements71, which have also been identified in the promoter region of bovine Nos374. The 
significance of these particular response elements, with regard to Nos3 expression, will be 
discussed in section 1.1.1.5.1.
1.1.1.3.4 Pathology
Alterations in the endothelial L-arginine NO pathway have been implicated in hypertension 
and other cardiovascular diseases. These will be discussed in greater detail in sections 1.1.2- 
3, but NOS III appears to be involved in pathology over and above cardiovascular control.
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The role of NOS I in neurodegenerative diseases has been discussed in section 1.1.1.1.3. 
However, recent work has also implicated NOS III in the neuronal pathology of end stage 
Alzheimer disease and Down’s syndrome75.
1.1.1.4 The arginine paradox
There is an increasing body of evidence suggesting that L-arginine supplementation, either 
by feeding or intravenous infusion, is beneficial in animal models76,77 and humans78. These 
effects of L-arginine appear to involve the NOS pathway as they are associated with 
increased tissue cGMP76,77, and can be inhibited by the NOS inhibitor NG-monomethyl-L- 
arginine (L-NMMA)78. It is tempting to conclude from these studies that a deficiency of L- 
arginine exists, such that this amino acid is rate limiting in terms of NOS activity. However, 
in cultured endothelial cells, intracellular concentrations of L-arginine are in the range 0.1- 
O.8mmol/L20. This is 35-275 times greater than the substrate concentration at which the 
NOS reaction velocity is half maximal (Km), which is 2.9pmol/L in vitro65. Therefore, it 
seems unlikely that that L-arginine could ever be rate limiting in vivo. The term “arginine 
paradox” has been coined for this discrepancy.
A clue to the solution may come from the fact that the L-arginine effect is usually only 
apparent when added in vivo, and not detected in in vitro studies19. A number of possible 
explanations exist as described below.
1.1.1.4.1 Asymmetric dimethyl arginine
An endogenous inhibitor of the enzyme may be present in vivo, resulting in an increased 
requirement for L-arginine. One such endogenous NOS inhibitor may be the L-arginine
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metabolite asymmetric dimethyl arginine (ADMA). This has been shown to accumulate in 
hypercholesterolaemia79 and chronic renal failure, perhaps contributing to the hypertension 
associated with this latter condition80. Indeed, part of the beneficial effect of oral L-arginine 
supplementation in hypercholesterolaemic rabbits is thought to be produced by correcting 
the plasma L-arginine/ADMA ratio79.
1.1.1.4.2 L-Glutamine
As discussed in section 1.1.1, it has recently been discovered that endothelial cells can
i
recycle L-citrulline back to L-arginine, which would prevent L-arginine becoming rate
i
limiting for NOS even during sustained NO production20. The same researchers 
demonstrated that this recycling could be inhibited by the amino acid L-glutamine at 
concentrations below those encountered in plasma20. Therefore, the reduced L-arginine 
production in the presence of in vivo concentrations of L-glutamine may make L-arginine
! rate limiting.
|
1.1.1.4.3 Insulin
Another possible explanation for the in vivo, in vitro discrepancy exists. Giugliano et al 
recently demonstrated that when L-arginine is administered in vivo intravenously, insulin 
secretion is stimulated from the pancreatic p cells81, which is a well recognised 
phenomenon. Insulin is known to have a vasodilator effect, which is NO dependent82. 
However, Giugliano et al have shown that the other beneficial effects of L-arginine, 
including reduced platelet aggregation, are insulin mediated, as they are abolished by 
octreotide, a somatostatin analogue which inhibits insulin secretion81.
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1.1.1.4.4 NOS independent NO generation
A further twist in the story has recently been added by Nagase et al, who have shown that 
L-arginine (and D-arginine) can interact with hydrogen peroxide (H20 2) to produce NO 
non-enzymatically83. H20 2 accumulates under conditions of increased oxidative stress such 
as hypercholesterolaemia, which may explain some of the beneficial effects of L-arginine on 
endothelial function under these conditions. The concentrations of L-arginine and H20 2 
required to drive this reaction are in excess of 10 mmol/L, but the authors argue that such 
concentrations may exist within the atheromatous plaque.
1.1.1.4.5 L-arginine and NOS independent hypotension
There are some studies which suggest that L-arginine can lower blood pressure completely 
independently from the NOS pathway. The amino acid is also a substrate for arginine 
decarboxylase, which converts L-arginine to agmatine, an endogenous non-catecholamine 
ligand for central a 2 adrenoceptors84. Therefore, supplemental L-arginine may act as an a - 
agonist via agmatine.
In addition, Higashi et al showed that giving intravenous L-arginine at a rate of 500 mg/kg 
over 30 minutes reduced blood pressure in healthy young males by significantly reducing 
serum angiotensin converting enzyme activity and angiotensin II levels, with surprisingly no 
effect on plasma renin activity85.
Therefore, there are many possible solutions to the arginine paradox, which are not all 
mutually exclusive. L-arginine may act via several non-NOS dependent mechanisms. Even 
as far as the NOS pathway is concerned, there are many possible competitive inhibitors, the
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local in vivo concentrations of which we do not know, which can interfere with L-arginine 
transport and/or NOS activity.
1.1.1.5. Regulation of Nos3 transcription
NOS III has traditionally been classified as a constitutive enzyme, not requiring protein 
synthesis for its action19. However, this has more recently been called into question86. As 
discussed in section 1.1.1.3.3 above, several features of Nos3 are compatible with a 
constitutively expressed, poorly regulated gene, including absence of a TATA box and 
numerous Sp-1 sites. The promoter also contains a number of putative binding domains, 
which suggest that it may be regulated by a variety of transcription factor mediated signals. 
NOS III activity and Nos3 mRNA levels have been found to be influenced by a number of 
factors indicating that the gene is constitutively expressed, but is subject to a modest degree 
of regulation by important physiological influences.
1.1.1.5.1 Shear stress
In 1921 Thoma first suggested that blood flow may regulate vessel tone87. Twelve years 
later Schretzenmayr demonstrated this experimentally88. It is now accepted that increased 
blood flow reduces arterial tone, whereas reduced flow results in vessel contraction. 
Therefore, when an artery is constricted pharmacologically or neurochemically, the 
increased blood flow and consequent shear stress cause a compensatory vasorelaxation to 
restore vessel tone. Although the arterial circulation does not consist of rigid tubes of 
circular cross-section, and blood is a non-Newtonian fluid, Hagen-Poiseuille’s Law still 
holds that, under a laminar steady state flow, shear stress is inversely proportional to the 
third power of the vessel radius, but directly proportional to changes in flow and viscosity.
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Therefore, relatively small changes in vessel diameter at constant flow can markedly affect 
shear stress within the vessel. The endothelium is now recognised as the principal vascular 
signal transducer that responds to changes in flow89. The major effector molecule of this 
pathway is NO89. The mechanism of mechanotransduction by the endothelium remains 
obscure. Alterations of the endothelial cytoskeleton have been implicated, and these 
possibilities have recently been reviewed89.
There are at least two distinct mechanisms whereby shear stress increases NO production. A 
sustained increase in flow results in increased transcription of Nos3 mRNA in endothelial 
cells and this will be described in detail later. In addition, there are a number of rapid and 
reversible signalling mechanisms which are responsible for the minute-to-minute 
adjustments of arterial diameter. Not all of these mechanisms are fully understood, but in 
cultured endothelial cells, there appears to be an initial Ca2+ dependent peak in NO release, 
which is independent of the magnitude of shear stress. This is followed by a more sustained 
increase, which is Ca2+ independent, but dependent on the magnitude of the shear stress 
stimulus. However, in vivo, it appears that the Ca2+ independent phase predominates.
A chronic increase in shear stress induces transcription of a number of genes, most notably 
Nos3. Several studies have been published recently examining the effects of chronic shear 
stress on Nos3 expression90,91. Again the precise mechanism for this effect is also poorly 
understood, but Davies’ recent, comprehensive review discusses what is known89. It seems 
that shear induced changes in cytoskeletal organisation activate second messenger systems, 
such as [ C a 2+]i, which are coupled to “third messenger” transcription factors, such as 
immediate early response genes (IERG) including c-myc, c-fos and c-jun. These 
transcription factors in turn upregulate other transcription factors, such as nuclear factor 
kappa B (NFkB). Fos/Jun heterodimers interact directly with a nuclear factor activator
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protein 1 (AP-1) cis-acting element, while NFkB may bind to a shear stress response 
element, both of which have been identified in the promoter region of Nos3lx'13 and other 
shear stress inducible endothelial genes.
There is an abundance of epidemiological evidence that regular aerobic exercise improves 
cardiovascular morbidity and mortality. Exercise has a number of potentially beneficial 
effects, which have recently been reviewed92, including lowering percentage body fat, 
improving lipoprotein profile, improving carbohydrate tolerance and insulin sensitivity, 
reducing neurohormonal release (catecholamines, renin, aldosterone, vasopressin) and 
reducing blood pressure. Over and above these effects, exercise increases heart rate, blood 
flow and hence shear stress, which we now know increases endothelial NO production. This 
has been shown acutely in healthy subjects, detected by increased forearm vasodilatation 
and increased exhaled NO, which is likely due to increased activity of existing NOS III. It 
has also been shown chronically in animal studies in which 10 days of treadmill running 
increased Nos3 mRNA expression in canine aortic endothelial cells and NOS III activity in 
coronary vessels90.
Interestingly, shear stress may have other beneficial effects in preventing cardiovascular 
disease, including increased cytosolic copper zinc superoxide dismutase (Cu/Zn SOD) 
expression93, which would reduce 0 2’ levels (see section 1.2.2). Shear stress also appears to 
reduce leukocyte adhesion to the endothelium, which is an early event in atherogenesis.
1.1.1.5.2 Oestrogen
The oestrogen response element (ERE) was first described in 1987 by Klock et a t 4. They 
had previously identified the 15 bp glucocorticoid response element, which was also
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recognised by the progesterone receptor complex. They subsequently defined another 15 bp 
palindromic sequence in the promoter region of the frog and chicken vitellogenin gene, 
which conferred oestrogen inducibility on a heterologous promoter94. Oestrogen interacts 
with a 67kDa intranuclear receptor, causing a conformational change, allowing it to bind 
with high affinity to EREs upstream from target genes, thus modulating their transcription. 
The precise binding of the ER to an ERE is realised through two Zn2+ binding motifs folded 
to form a single structural unit. ERE half-palindromic motifs bind the oestrogen receptor 
weakly, but several copies of the motif separated by more than lOObp can act synergistically 
to enhance transcription in response to oestrogen95
Since the gene for the human oestrogen receptor (ER) was cloned and sequenced over 10 
years ago96, searches for other ERs proved unsuccessful, suggesting only one existed. 
However, recently a second oestrogen receptor (ERP) has been cloned from rat prostate 
and ovary97 and human testis98. The unlikely sources of these cDNAs is perhaps the reason 
that ERP has remained so elusive. The discovery of a second ER raises many important 
questions and these have been recently reviewed99. It would appear that the original 
receptor (ERa) and ERP have a very similar high affinity for natural oestradiol, although 
some synthetic ligands show receptor selectivity100. The tissue distribution of the two 
receptors also appears to be different100.
ERa mRNA and protein have been detected in HUVEC and BAEC101, therefore this 
receptor was thought to be responsible for the effect of oestrogen on endothelial function. 
However, ERp mRNA has now also been detected in mouse aorta by reverse transcription 
polymerase chain reaction (RT-PCR), although not specifically localised to the 
endothelium102. Of greater interest was the fact that the same authors showed in ERa
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‘knock out’ mice (homozygous -/-, therefore expressing no ERa), that 17p-oestradiol still 
inhibited the extent of vascular injury after endothelial denudation of the carotid artery, as 
much as it did in wild-type mice102. They concluded that ERa could not be the sole receptor 
responsible for the vascular effects of oestrogen, or perhaps ERp can substitute for ERa. 
However, the same oestrogen receptor ‘knock out’ (ERKO) mice have been shown to have 
reduced basal NO release103, suggesting that ERa may be responsible for some oestrogen 
effects and not others. In humans, some of the vascular effects of oestrogen also appear to 
rely on an intact ERa. Sudhir et al have just recently reported that a 31 year old man with 
oestrogen resistance caused by a disruptive mutation in the ERa gene, has impaired 
endothelium-dependent vasodilatation of the brachial artery, with intact endothelium- 
independent vasodilatation104.
The literature is now abundant in animal and human studies which examine the effects of 
gender and/or oestrogen on endothelial function and/or cardiovascular disease. These will 
be discussed in greaiter detail in section 1.3. Nos3 has several copies of the ERE half 
palindrome in its promoter region71’74, but only a few studies have directly examined the 
effects of oestrogen on Nos3 expression (Table 2). Some of these studies show that the 
effect can be inhibited by tamoxifen, suggesting that it is mediated through the oestrogen
. 105-107receptor
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1.1.1.5.3 Other factors
Atherosclerosis impairs endothelium-dependent vasodilatation. Oxidised low-density 
lipoprotein (ox-LDL), which is a key factor in atherogenesis (see section 1.1.3.3), was 
thought to be responsible for the impaired endothelium-dependent vasodilatation. However, 
in vitro experiments, using a ribonuclease (RNase) protection assay and western blotting in 
BAEC, have shown that ox-LDL, but not native LDL, increases Nos3 transcription and 
NOS III protein levels109. The authors conclude that ox-LDL is not responsible for the 
impaired endothelium-dependent vasodilatation, although they do not consider the fact that 
NOS III function may be reduced.
1.1.2 Nitric oxide in hypertension
Human essential hypertension and several animal models of hypertension are associated 
with increased peripheral vascular resistance. The crucial structures of the circulation that 
determine peripheral vascular resistance are arteries of diameter <200pm; the so-called 
‘resistance arteries’. As NO is accepted as an endogenous vasodilator2, there are theoretical 
reasons why reduced NO production or bioavailability would lead to vasoconstriction and 
hence increased peripheral vascular resistance. NO has been found to regulate the tone of 
normal vessels110, including resistance vessels111. In addition, NO causes renal vasodilatation 
with consequent diuresis and natriuresis112. These actions would tend to lower blood 
pressure, therefore a reduction in this mechanism is another way in which NO deficiency 
may theoretically contribute to hypertension. However, there are many conflicting reports 
about the role of NO deficiency in experimental models of hypertension and human essential 
hypertension.
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1.1.2.1 Nitric oxide in experimental hypertension
Since the identification of NO as an endogenous vasodilator2, there have been many studies 
examining the role of NO in experimental hypertension. These have been comprehensively 
reviewed recently113. Some studies indicate reduced NO in hypertensive animals compared 
to normotensive controls, while others show increased NO or no difference. On balance, it 
would appear that the NO system may be overactive in the spontaneously hypertensive rat 
(SHR) model of genetic hypertension, but depressed in the related stroke prone 
spontaneously hypertensive rat (SHRSP) model and in experimental mineralocorticoid and 
renal hypertension However, some studies remain contradictory.
The reason for the above discrepancy remains unclear, but may reflect the different methods 
employed to assess the NO system in different studies. It may be that NO production is 
normal or even increased in experimental hypertension, but the bioavailability of NO may be 
reduced by a scavenger such as 0 2". Grunfeld et al used organ bath experiments to 
demonstrate that excess 0 2' in aortas of SHRSP could exactly account for the reduced 
bioavailability of NO detected at the cell surface by their porphyrinic microsensor114. The 
following year, Tschudi et al confirmed normal NO production, but increased 
decomposition by 0 2' in the mesenteric resistance vessels of SHRSP115. Mian and Martin 
have shown that basal NO is more sensitive to destruction by 0 2‘ than stimulated NO116.
They speculate that under basal conditions, endogenous SOD keeps 0 2' at such low 
concentrations that only the low levels of basal NO can be scavenged, but when NO is 
stimulated by ACh, there is insufficient 0 2' to scavenge it all. However, if  endogenous SOD 
is inhibited, then the levels of 0 2' rise to such high levels that even ACh stimulated NO can 
be scavenged. The precise role of scavenging by 0 2' in other situations of apparent 
differences in NO, such as gender differences, remains to be determined.
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Despite the large number of endogenous vasoconstrictors and vasodilators which can 
potentially affect blood pressure, the importance of the L-arginine/nitric oxide system is 
apparent in models where the system is manipulated. Exogenous L-arginine, but not D- 
arginine, normalises blood pressure in salt-sensitive Dahl/Rapp rats made hypertensive by 
high salt chow117. Conversely, NOS can be inhibited by a variety of L-arginine analogues118 
and this model of hypertension will be discussed in section 1.1.2.3. However, such 
pharmacological intervention affects all isoforms of NOS, therefore their individual 
contribution to blood pressure control cannot be distinguished.
Very specific interruption of the endothelial L-arginine/nitric oxide has recently become 
possible with the advent of mice with targeted disruption of the Nos3 gene119,120. 
Homozygous -/- mutants have no NOS III protein in their endothelium, which has been 
confirmed by immunohistochemical staining120. These so-called Nos3 ‘knock out’ mice have 
increased blood pressure compared to +/+ homozygotes and +/- heterozygotes119,120 
suggesting that NOS III is indeed important in blood pressure regulation, although they also 
have increased plasma renin concentration, despite a modest decrease in kidney renin 
mRNA120.
An unexpected curiosity was revealed when Nos3 ‘knock out’ mice were exposed to the 
NOS inhibitor L-nitroarginine (L-NA). One might have expected no change in blood 
pressure as they have no NOS III to block, or an increase in blood pressure if NO from 
other NOS isoforms is important in blood pressure regulation. Surprisingly, their blood 
pressure fell when treated with L-NA, while that of the +/+ homozygotes rose as 
anticipated119. The hypotensive effect of L-NA was prevented by L-arginine, but not D- 
arginine. These observations would suggest that one of the other NOS isoenzymes is 
producing a vasoconstrictor substance which can be blocked by L-NA. Alternatively, L-NA
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may be exerting a completely different and unknown action. A candidate vasoconstrictor is 
0 2, which Pou et al have shown to be produced by rat NOS I, albeit when purified in 
121. They also showed that 0 2 production is inhibited by L-NAME, but not L-NMMA.
It is conceivable that when NOS III is absent, as in Nos3 ‘knock out’ mice, NOS I 
generated 0 2' predominates and contributes to the hypertension. Like L-NAME, L-NA may 
block NOS I generation of 0 2' and thus lower blood pressure.
Despite the implication from ‘knock out’ mouse studies that the Nos3 gene is important in 
blood pressure regulation, using mapping studies Deng and Rapp failed to link the Nos3 
locus on rat chromosome 4 to hypertension in the Dahl salt-sensitive rat122. Instead, they 
found genetic linkage between hypertension and the Nos2 locus on rat chromosome 10 in 
the same model123, although the Ace locus, encoding angiotensin I converting enzyme, also 
mapped to this region. This implicates Nos2 in genetic hypertension, but Nos2 ‘knock out’ 
mice have also been generated, and while they have reduced immunity to parasitic infections 
in keeping with the known role of NOS II, they have normal blood pressure124.
Another interesting model of genetic hypertension is the hypertension-prone Sabra rat 
(SBH) versus the hypertension resistant Sabra rat (SBN). SBH are more sensitive to 
deoxycorticosterone acetate-salt (DOCA-salt) than SBN. In addition, although still within 
the normal range, SBH have a significantly higher basal mean arterial blood pressure than 
SBN. Rees et al used the pressor response to L-NMMA in this model to convincingly show 
reduced basal NO in SBH125. Using the L-arginine/L-citrulline assay to measure NOS III 
activity, they demonstrated that the reduced basal NO was due to reduced production, 
although they did not exclude increased break-down in addition.
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1.1.2.2 Nitric oxide in human essential hypertension
Similar controversy exists regarding the role of NO in human essential hypertension. There 
have been many studies employing forearm venous occlusion plethysmography to examine 
stimulated NO release in response to intrabrachial ACh. When essential hypertensive 
patients are compared to matched normotensive controls, the majority of the studies show a 
reduction in stimulated NO release126'128, although another study found no difference129. 
Basal NO production, as measured by the reduced forearm blood flow in response to L- 
NMMA, has also been shown to be reduced in patients with hypertension compared to 
normotensive controls130.
The use of forearm venous occlusion plethysmography to measure endothelium dependent 
vasodilatation may be prone to errors caused by effects of different basal blood flow and 
conduit vessel length131. These effects are seldom considered in these studies and may partly 
explain some of the above discrepancies. Using flow-mediated vasodilatation of the brachial 
artery as an alternative method of quantifying stimulated NO production, Laurent et al 
found no difference between essential hypertensives and normotensive controls132.
In a further attempt to circumvent the limitations of forearm venous occlusion 
plethysmography, Forte et al employed yet another method of estimating NO production133. 
They fed a group of essential hypertensive patients, and a group of matched normotensive 
controls, a fixed low-nitrate diet for two days and thereafter found 24 hour urinary nitrate 
excretion to be reduced in the hypertensive group. They also administered the stable isotope 
L- [15N] 2-guanidino arginine intravenously and found 15N excretion also to be reduced in the 
hypertensive group. This is certainly more direct evidence for reduced NO synthesis in 
hypertensive patients, but gives no indication that NOS III is involved. NOS II could be
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induced in these patients due to subclinical infection or inflammation, although attempts 
were made to exclude such patients from the study.
A polymorphism in the Nos3 gene has been associated with smoking related coronary heart 
disease134, and this will be discussed in greater detail in section 1.1.3.5. However, 
Bonnardeaux et al failed to find linkage between a highly polymorphic marker in the Nos3 
gene and hypertension in 145 hypertensive pedigrees (269 sib pairs, 346 subjects)135. They 
concluded that their data do not suggest involvement of common molecular variants of the 
endothelial nitric oxide synthase gene in essential hypertension.
Over and above the methodological problems, another reason for the discrepancies in the 
above studies may be that patients with essential hypertension represent a heterogeneous 
group in whom a small, as yet undefined, subgroup may have NO deficiency, while others 
have normal or even increased NO release as a compensatory mechanism. To distinguish 
those with NO deficiency from the rest of the hypertensive population in a practical way 
would require a simple screening test. Such a simple test may have been discovered by Jilma 
et al who measured NO in parts per billion (ppb) in a single breath and found it to be higher 
in females (34ppb) compared to males (20ppb)136. Such gender differences in NO 
production will be discussed later, but the point is that such a test, while subject to the 
vagaries of dietary nitrate and non-NOS III production, may be easily employed to screen 
large numbers of hypertensive patients. Confirmation of these data from other groups would 
first be necessary.
1.1.2.3 Hypertension induced by inhibition of nitric oxide synthase
There have been many animal studies examining the effects of acute or chronic blockade of 
NOS by a variety of L-arginine analogues, but they are too numerous to describe in any 
detail here. Without exception, they demonstrate sustained elevation of blood pressure, 
suggesting a role for NO, although not necessarily endothelium-derived NO, in blood 
pressure regulation. This relatively novel model of experimental hypertension has helped 
shed light on some of the hitherto unrecognised roles of NO on cardiovascular function. For 
instance, renal blood and glomerular filtration rate are reduced in Sprague-Dawley rats 
given L-NA for 3 weeks137. This would explain why NOS inhibition produces an 
antidiuresis and antinatriuresis112, suggesting that part of the hypotensive action of NO is via 
diuresis and natriuresis.
A peculiarity of this model of hypertension is the relative absence of vascular structural 
changes. Amal et al gave oral L-NAME to Wistar rats for 8 weeks and found no cardiac 
hypertrophy in the majority of animals138. They did find cardiac hypertrophy in some 
animals, but these were the animals with the highest blood pressure and stimulated renin 
angiotensin system (RAS) detected by increased plasma renin activity. Devlin et al from our 
group found cardiac hypertrophy and aortic VSMC polyploidy in WKY rats after only 3 
weeks of L-NAME treatment, and again these changes were associated with a stimulated 
RAS139. Chronic NOS inhibition has been shown to produce glomerular damage140, and the 
subsequent stimulation of the RAS may be responsible for the vascular structural changes. 
This is confirmed by Takemoto et al, who produced coronary vascular remodelling and 
myocardial hypertrophy in WKY after 4 and 8 weeks of NOS inhibition with L-NAME141. 
They showed that the cardiovascular structural changes could be prevented by co-
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administration of the angiotensin converting enzyme inhibitor temocapril, but not with 
hydralazine, despite producing a similar reduction in blood pressure.
The different susceptibility of various strains of rats to NOS inhibitor induced vascular 
changes may reflect altered sensitivity to renal damage and subsequent stimulation of the 
RAS, rather than altered sensitivity of heart and blood vessels per se. This altered sensitivity 
to renal damage may in turn reflect divergent genetic backgrounds.
As with other forms of hypertension, compensatory mechanisms come into play in an 
attempt to normalise blood pressure. In a previous study, we demonstrated increased 
activity of NOS and SOD in the aortas of Sprague-Dawley rats made hypertensive by 2 
weeks of oral L-NAME treatment142. This may implicate an imbalance in NO and 0 2' 
contributing to this form of hypertension. A relative excess of other vasoconstrictors has 
been suggested, although Bank et al failed to correct L-NA hypertension in Sprague- 
Dawley rats with intravenous infusion of receptor antagonists for angiotensin II, 
thromboxane, adrenaline and endothelin-1137.
Although local intrabrachial infusions of L-arginine analogues have been given to humans in 
many studies to investigate endothelial function, a systemic infusion of a pharmacological 
dose of a NOS inhibitor was given to humans for the first time by Haynes et al142. A five 
minute infusion of L-NAME (3mg/kg) in healthy volunteers produced a 10% increase in 
mean arterial pressure, a 19% decrease in heart rate and 25% decrease in cardiac index, 
resulting in a 46% increase in calculated total peripheral resistance. Creatinine clearance 
was unchanged, but in contrast to the animal studies, they found a natriuresis with NOS 
inhibition, which they attributed to a pressure natriuresis.
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1.1.3 Nitric oxide in atherosclerosis
1.1.3.1 History
Manipulation of the L-arginine/nitric oxide pathway has been employed since the days of 
early Chinese civilisation. Panax ginseng is a medicinal plant which has been used in 
traditional Chinese medicine since antiquity. More recently, it has been discovered that 
ginsenosides, saponins extracted from the plant, can protect against myocardial and cerebral 
ischaemia, and that these effects are attributable to increased NO production144.
Manipulation of the L-arginine/nitric oxide pathway entered more conventional medicine in 
the management of atherosclerotic disease still more than a century before the L-arginine/ 
nitric oxide pathway was conceived, or the mechanisms underlying atherosclerosis 
elucidated.
The disease angina pectoris was described by William Heberton in the Medical Transactions 
of the College of Physicians as far back as 1768145. It remained resistant to treatment with 
“brandy, ether, chloroform, ammonia, and other stimulants” for nearly a century until, in 
1867, Sir Lauder Brunton successfully employed amyl nitrite146. In later life, Sir Lauder 
Brunton himself developed angina pectoris, for which he repeatedly used amyl nitrite to 
terminate attacks.
Meanwhile in America, nitroglycerine was being used in the treatment of “coronary 
involvements, angina pectoris, cardiac edema, headache, epilepsy and cerebral 
involvements, among other disease conditions”. In 1897, William Murrell published his first 
independent paper in Lancet147 comparing and contrasting the effects of nitroglycerine with
the known effects of amyl nitrite. He described in great detail the duration and effect of both 
compounds on symptoms, pulse rate and volume. In addition, he clearly presented three 
cases of classical angina pectoris, which were successfully treated with sublingual 
nitroglycerine.
1.1.3.2 Current concepts
Over the course of the next century, much knowledge has been gained about the 
pharmacological properties of organic nitrate esters. However, until fairly recently, it was 
not understood how they worked. Sodium nitrite was known to be a vasodilator, albeit a 
weak one148, and it had been known since the last century that inorganic nitrite appears after 
incubating glyceryl trinitrate (GTN) with blood149. Therefore, it was thought that the action 
of nitroglycerine and other nitrates was via reduction to nitrite.
In the early 1980’s, evidence was accumulating that sodium nitroprusside (SNP) and other 
nitrovasodilators activate guanylate cyclase150, perhaps involving thiols, but the precise 
mechanism remained unclear. NO was also known to activate guanylate cyclase13, therefore 
biotransformation to NO became a possible mechanism for nitro vasodilator-induced 
relaxation. It was not until after NO had been identified as an endogenous vasodilator2, that 
this mechanism was accepted151.
The involvement of thiols in the biotransformation of nitrovasodilators was thought to be 
behind the well described phenomenon of nitrate tolerance. Prolonged use of a 
nitrovasodilators leads to depletion of reduced thiol groups, which prevents further 
biotransformation152. Vasodilating S-nitrosothiols, which in effect provide their own thiol 
groups, can circumvent GTN induced tolerance153. This is further evidence for the
importance of thiol groups. However, the mechanisms of nitrate tolerance are likely to be 
more complex, and involve multiple sites on the nitrovasodilator-guanylate cyclase 
cascade154.
There is some evidence for the involvement of 0 2' in tolerance. Increased levels of 0 2’ have 
been found in aortic rings of rabbits made tolerant to GTN155. Indeed, the aortas of these 
animals were found to have increased activity of the membrane-bound, 0 2 generating 
enzyme NADH oxidase156. This increased activity may be related to increased circulating 
angiotensin II, which is found in chronic GTN treatment157. Hydralazine, which reduces 
NADH oxidase activity, has been shown to reduce tolerance to nitrovasodilators in a model 
of heart failure156.
1.1.3.3 Mechanisms of atherosclerosis
Many of the complex steps involved in atherogenesis were comprehensively reviewed 
almost 10 years ago158 (Figure 4). Endothelial injury is thought to be a very early stage. This 
need not be denudation, and in fact may consist of altered endothelial function, which is 
what we would nowadays call ‘endothelial dysfunction’. Hyperlipidaemia, hypertension, 
diabetes mellitus, obesity, smoking, immune injury, and other risk factors may contribute to 
this endothelial dysfunction in different ways, and sometimes in combination. In the severely 
hypercholesterolaemic patient, such as one with familial hypercholesterolaemia, 
hyperlipidaemia is alone sufficient to cause atherosclerosis in the absence of other risk 
factors. Some factors may cause both endothelial dysfunction and hypertension, thus 
increasing their risk contribution.
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Another early phenomenon appears to be trapping of low density lipoproteins (LDL) within 
the intima. The resulting increase in residence time may facilitate oxidation of the 
lipoproteins to oxidised LDL (ox-LDL) by macrophages, which, in turn, may damage the 
endothelium and act as a chemotactic signal for other monocytes to enter the intima.
The dysfunctional endothelium allows circulating monocytes to adhere and penetrate, at 
endothelial cell junctions, to the innermost layer of the artery wall, the intima, where they 
effectively become macrophages. The macrophages take up native LDL and ox-LDL by 
conventional and ox-LDL receptors respectively. Ox-LDL can also be taken up at an 
enhanced rate by the ‘scavenger pathway’ via acetylated LDL (ac-LDL) receptors. The ox- 
LDL is hydrolysed to form large quantities of cholesterol and cholesterol esters. These lipid 
laden macrophages are called ‘foam cells’. Activated T-lymphocytes are also recruited, and 
the resultant ‘fatty streak’ is the earliest recognisable atherosclerotic lesion. Alarmingly, 
such fatty streaks are found in the coronary arteries of 50% of children aged 10 to 14 at 
post mortem158. Fatty streaks often form at sites of pre-existing vascular smooth muscle cell 
(VSMC) proliferation, as the latter is also associated with endothelial dysfunction.
VSMC exist in at least two different phenotypic forms159. In a contractile phenotype they 
respond to vasodilator agents such as NO and prostacyclin and vasoconstrictor agents such 
as endothelin and angiotensin II. However, they can also display a synthetic phenotype, 
when they are capable of producing a number of growth factors and cytokines and can 
synthesise extracellular matrix. Within the fatty streak VSMC, together with macrophages 
and lymphocytes, release such growth factors and cytokines resulting in further monocyte 
and lymphocyte migration and VSMC proliferation to form an ‘intermediate lesion’. VSMC 
also produce a connective tissue matrix of fibro-elastic proteins, collagen and 
proteoglycans, which form a ‘fibrous cap’ on what has become a more advanced, complex,
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occlusive lesion called a ‘fibrous plaque’. The fibrous plaque contains a central core of 
necrotic debris and lipid in the form of free and esterified cholesterol from foam cell lysis 
and continued uptake from the circulation.
The formation of a fibrous lesion can be regarded as a form of wound healing. However, 
unlike in other tissues, within the arterial wall connective tissue is produced principally by 
VSMC and the insults (hypertension, hypercholesterolaemia, diabetes mellitus, obesity, 
smoking etc.) are likely to be chronic. Therefore, the progression from fatty streak to 
fibrous plaque is unlikely to be interrupted.
As the fibrous plaque grows, the overlying endothelium becomes increasingly damaged, 
which further propagates the whole process. At the same time the plaque projects further 
into the lumen and impedes blood flow. In the coronary circulation this would be manifest 
as stable angina pectoris. As the plaque grows, the large number of macrophages at the 
margins of the fibrous cap produce areas of weakness. This makes the plaque ‘unstable’, 
allowing cracks and fissures to appear, revealing the underlying thrombogenic surface. 
Platelets adhere forming a thrombus, which may occlude the artery, or the plaque may 
completely rupture, resulting in haemorrhage into the plaque, thrombosis and occlusion of 
the artery. Again, in the coronary circulation, this end stage would be manifest as a 
myocardial infarction160.
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Figure 4 - Schematic representation of the steps towards atherosclerosis.
LDL: low density lipoprotein. ox-LDL: oxidised low density lipoprotein. VSMC: vascular 
smooth muscle cell.
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1.1.3.4 Role of nitric oxide
There are many points in the pathway towards atherosclerosis where NO may have a 
beneficial effect, which is probably why NO donors have been employed so successfully for 
over a century. Firstly, the endothelial dysfunction, described as a very early stage in the 
development of atherosclerosis, refers to impaired release of NO, among other mediators.
By virtue of its reaction with superoxide anion, NO is an anti-oxidant that can prevent 
oxidation of LDL161, which is another of the early steps in fatty streak formation. Ox-LDL 
is produced by the enzyme lipoxygenase. NO has been shown to reduce lipoxygenase 
activity in vitro162, which would further reduce the amount of ox-LDL available for uptake 
by macrophages.
NO has also been shown to inhibit monocyte adhesion to cultured porcine aortic endothelial 
cells163, and together with prostacyclin NO inhibits monocyte migration163. These are 
important steps in the generation of the initial fatty streak. Other than acute vasodilator 
effects, NO donors can inhibit the proliferation of VSMC in culture164 and NO itself can 
inhibit lymphocyte proliferation165; both of which are involved in the progression from fatty 
streak to fibrous plaque. NO can also prevent the aggregation of platelets in vitro16 and 
their adhesion to endothelial cells in culture17, which are involved in thrombogenesis later in 
the pathway.
There are, therefore, many theoretical reasons, backed up with in vitro evidence, why NO 
may act as an antiarthrogenic molecule. Most of the in vivo evidence of a beneficial effect of 
NO comes from extrapolation of the beneficial effects of L-arginine supplementation76"78. 
However, as discussion of the arginine paradox revealed in section 1.1.1.4, there are many 
possible roles for L-arginine other than acting as a precursor of NO synthesis. More direct
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in vivo evidence for the beneficial role of NO in atherogenesis came from two recent studies 
where NOS inhibition with L-NAME worsened endothelium-dependent relaxation and 
increased lesional surface area in the thoracic aortas of hypercholesterolaemic rabbits166,167. 
In the study where L-NAME was given orally166, NOS inhibition was associated with 
increased serum cholesterol levels, which is interesting in itself, but leads to a confounding 
effect. In the other study, L-NAME was administered subcutaneously by minipump167, 
which did not significantly alter the lipid profile, but still produced the same adverse effects.
Probably the most compelling evidence for a beneficial effect of endothelium derived NO in 
preventing vascular lesion formation comes from a study by Dzau’s group168. They used 
balloon injury to denude rat carotid arteries, then restored NOS III activity by transfecting 
the arteries with a recombinant bovine Nos3 gene, using the highly efficient Sendai 
virus/liposome in vivo gene transfer technique. This intervention restored NO production 
and vascular reactivity to normal, and reduced neointima formation at 14 days by 70% 
compared to denuded, but non-transfected arteries. This is, of course, a model of neointimal 
hyperplasia of re-stenosis and not primary atherogenesis, however there are a number of 
similarities between the two.
Despite these apparent beneficial effects of NO in the early stages of atherogenesis, there is 
some evidence that NO may be deleterious in the established plaque. All of the cell types 
within the fibrous plaque (VSMC, macrophages and lymphocytes) can be, and probably are, 
induced to produce NO via NOS II169. NO produced in such great amounts can interact 
with superoxide anions, also produced by activated macrophages170, to produce 
peroxynitrite, which can further oxidise LDL171 and damage the endothelium172. In addition, 
VSMC within the plaque increase its stability. Therefore, by inhibiting VSMC proliferation, 
NO may cause plaque instability and subsequent rupture.
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1.1.3.5 Smoking, coronary heart disease and NO
Another interesting study which indirectly implicates NO in atherosclerosis looked at a 
genetic polymorphism within the human Nos3 gene134. The authors identified a rare allele 
present in only 17% of a control population with no history or symptoms of coronary artery 
disease. Only 0.7% of the control population were homozygous for the rare allele.
However, when they genotyped a group of 549 patients consecutively referred for coronary 
angiography, they found 3.3% were homozygous for the rare allele i.e. 4.7 times as high as 
the control population. Not all of the patients referred had significant stenosis (defined as 
>50% occlusion) demonstrable at angiography. In the subgroup of 401 referred who had 
significant stenosis in 1, 2 or 3 coronary arteries, the frequency of homozygotes for the rare 
allele rose to 4.2% i.e. 6 times as high as the control population. This represents a 
significant association between homozygosity for the rare allele and coronary artery disease.
As discussed above, cigarette smoking is a known risk factor for coronary artery disease 
and also endothelial dysfunction. Therefore, the authors went further and divided the 
coronary population into smokers (past and present) and non-smokers (never). Among the 
smokers they found a 35% excess risk for significant stenosis in 1,2 or 3 coronary arteries 
associated with homozygosity for the rare allele compared to non-smoking homozygotes. 
While there is as yet no evidence that this polymorphism affects endothelial NOS function, it 
suggests a gene-environment interaction whereby there is a genetically determined 
predisposition to increased smoking-associated coronary risk in subjects homozygous for 
the rare allele. This may partly explain the anecdotes of some heavy cigarette smokers who 
never succumb to cardiovascular disease, while others succumb at an early age.
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1.2 Superoxide anion
Despite being essential for most forms of life, the high content of 0 2 in the atmosphere 
means that oxidation reactions are commonplace in our environment. Although our body 
uses 0 2 and oxidation reactions to good effect for generating energy and killing invaders, 
unwanted side reactions are unavoidable. Therefore, to support aerobic metabolism, 
mechanisms had to evolve for the biological control of 0 2. Such a mechanism involves its 
complete reduction to water (Figure 5), which produces the free radical 0 2' by the one 
electron reduction of molecular 0 2 as the first intermediate in this pathway. It has been 
estimated that a typical human cell metabolises about 1012 molecules of 0 2 per day and 
generates some 3 x 109 molecules of H20 2 per hour.
Unlike NO, 0 2' is not membrane permeable and is therefore restricted to reacting in the 
compartment in which it is generated. Although associated with so-called ‘oxidative stress’, 
0 2' is an unusual species in that it can act as a reducing agent, donating its extra electron 
e.g. to form ONOO' with NO, or as an oxidising agent, in which case it is reduced to H20 2. 
As described in section 1.1.1.2.5, under normal circumstances the relatively high abundance 
of SOD enzyme ensures that the latter reaction occurs preferentially. However, when NO is 
produced in large quantities, a significant amount of 0 2' reacts with NO to produce ONOO'.
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Figure 5 - Steps in the 4 electron (e') reduction of molecular oxygen (O2) to water (H20), 
via superoxide anion (O2 ), hydrogen peroxide (H2O2) and hydroxyl radical (OH) 
intermediates. The majority of O2 is reduced by the cytochrome oxidase complex, which 
prevents release of the reactive intermediates. However, the evolution of a variety of 
superoxide dismutase (SOD) enzymes, catalase and peroxidase, to remove the reactive 
intermediates, suggests that a significant proportion of O2 is reduced by this route.
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1.2.1 Superoxide anion production
The main sources of 0 2 in vivo have been characterised. In the vasculature, it can be 
generated by xanthine oxidase (XO) (EC 1.1.3.22). Increased vascular 0 2‘ generation by 
XO has been implicated in the endothelial dysfunction of hypercholesterolaemia (section 
1.2.3.1).
The main intracellular source of 0 2' is the respiratory chain of enzymes in the mitochondria 
173, including the reduced nicotinamide adenine dinucleotide (NADH) dehydrogenase and 
ubiquinone Q-cytochrome b complex. Mitochondrial 0 2' generation is greatest when the 
respiratory chain carriers are highly reduced, which is regulated by the availability of NAD- 
linked substrates, succinate, ADP, and 0 2174. Mitochondrial 0 2' spontaneously dismutates to 
H20 2 or the reaction is efficiently catalysed by mitochondrial manganese SOD175. This 
enzyme will be further discussed in section 1.2.2.2. Other minor sources of 0 2' include 
aldehyde oxidase, dihydro-orotic dehydrogenases, flavin dehydrogenases, peroxidases and 
autoxidation of a large group of compounds including catecholamines, flavins and 
ferredoxin176.
Another important source of 0 2' generation within the vasculature is the enzyme NADPH 
cytochrome P-450 oxidoreductase (EC 1.6.2.4), more commonly termed NAD(P)H 
oxidase. This membrane bound enzyme has been identified in cultured rat VSMC177, bovine 
coronary artery endothelium178 and more recently in rat aortas179. Whereas excess 0 2' 
generation by XO has been implicated in hypercholesterolaemia, NAD(P)H oxidase has 
been incriminated in excess 0 2 generation in some forms of hypertension (section 1.2.3.2).
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Paradoxically, NOS can also be a source of 0 2\  Purified rat NOS I has been shown to 
produce 0 2' in a reaction which is inhibitable by L-NAME, but not L-NMMA121. Heinzel et 
showed that purified porcine NOS I can produce H20 2 under conditions of low L- 
arginine concentrations180, and Xia et al confirmed this finding in intact human kidney cells 
stably transfected with the rat Nosl gene181. NOS III has also been suggested as the source 
of native LDL (n-LDL) induced 0 2' by HUVEC described below, as it can be inhibited by 
L-NAME182.
0 2 generation can be influenced by a number of mechanisms. Pritchard et al demonstrated 
that n-LDL can increase 0 2' generation by cultured HUVEC182. Incidentally, n-LDL also 
increases NO generation by the same cells, the combination leading to an increased 
likelihood of ONOO‘ production, which the authors suggest is one of the earliest steps in 
atherogenesis. Increased 0 2" generation, and NO release, have also been demonstrated in 
cultured human aortic endothelial cells in response to high glucose in the culture medium, 
which these authors suggest is a link between diabetes mellitus and early atherogenesis183. 
Holland et al showed that bradykinin can increase 0 2' generation by HUVEC and this could 
be partially inhibited by indomethacin, suggesting that arachadonic acid metabolism is 
involved184.
0 2' generation could be reduced in cultured BAEC by 24 hours exposure to the synthetic 
oestrogen, ethinylestradiol185. The authors do not speculate as to the enzyme(s) involved. 
This effect of oestrogen may explain the gender difference in 0 2' generation observed by 
Brandes and Mtigge, who found that aortas from male Wistar rats produced 34% more 0 2' 
than females186. They determined that the source of the 0 2' excess was the endothelium and 
that neither cycloxygenase nor XO were responsible. Gender differences in 0 2' will be 
further discussed in section 1.3.1.4.
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1.2.2 Superoxide dismutases (EC 1.15.1.1)
As described in section 1.2, organisms which depend on oxidative metabolism have evolved 
a number of enzymes to reduce 0 2, which is formed as an intermediate. One such family of 
enzymes are the superoxide dismutases, which catalyse the reaction of 0 2 with an electron 
and two protons to form H20 2 (Figure 5).
I
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Like the family of NOS enzymes, the SODs have been identified throughout evolution. Iron
| SOD is an enzyme of prokaryotes and some higher plants. Manganese SOD is an enzyme of
(
i  prokaryotes and eukaryotes. Copper/zinc SOD is an enzyme of eukaryotes and certain
| prokaryotes187. Sequence analysis and comparisons make it clear that at least one member
of the family, copper/zinc SOD, arose prior to the divergence of eukaryotes and eubacteria.
|
i
| Although catalase is also involved in the reduction of H20 2 to H20  (Figure 5), SOD was
I shown to be a more important antioxidant protector of NO, as inhibition of SOD by
I
diethyldithiocarbamate (DETCA) had a greater effect on biologically active NO than 
inhibition of catalase by 3-amino-1,2,4-triazole (AT)188.
1.2.2.1 Copper/zinc superoxide dismutase (Cu/Zn SOD)
This enzyme was the first member of the family to be discovered in mammals in 1969189. It 
is composed of two identical 16kDa subunits, each containing one copper and one zinc 
atom. It is located in the cytosol and nucleus of all cell types. The enzyme is very sensitive 
to cyanide, which helps distinguish it from Mn SOD which is relatively resistant.
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The human gene for Cu/Zn SOD (Sodl) has been localised to the 21q22.1 region of 
chromosome 21190. It consists of 5 exons and 4 introns which interrupt the coding region191. 
The 5’ promoter region contains ‘TATA’ and ‘CAAT’ boxes. Three other processed 
pseudogenes have been identified in the haploid human genome, none of which reside on 
chromosome 21192.
As Sodl resides on human chromosome 21, patients with Down’s syndrome (trisomy 21) 
have an extra copy of the gene, and have been shown to have Cu/Zn SOD activity 50% 
greater than the normal diploid population in keeping with the gene dosage effect190. 
Transgenic rats containing an extra copy of the human Sodl gene display some of the 
neurological defects characteristic of Down’s syndrome, including premature ageing, 
suggesting that this gene is involved in the pathogenesis of Down’s syndrome193. Whereas 
the SOD isoenzymes are normally thought to be protective, it is postulated that increased 
Cu/Zn SOD activity produces increased amounts of H20 2, which become toxic in the 
presence of normal catalase activity193. Therefore, increased Cu/Zn SOD activity may only 
be beneficial when balanced with increased catalase activity, and induction of one does not 
lead to induction of the other194.
The role of 0 2' in hypertension will be discussed in section 1.2.3.2. However, the increased 
Cu/Zn SOD activity in Down’s syndrome may further indicate a role for 0 2' in hypertension. 
With a higher Cu/Zn SOD activity, Down’s syndrome patients will have reduced 0 2' levels. 
If 0 2' excess is involved in the pathogenesis of hypertension, then one would expect Down’s 
syndrome patients to have lower blood pressure. This was recently found to be the case in a 
well controlled study195.
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The beneficial effect of increased fluid shear stress on endothelial function has been 
attributed to increased NO production, which has been described in great detail in section 
1.1.1.5.1. However, some of the beneficial effect may also be due to reduced NO 
scavenging by 0 2' as Sodl has been shown to be up-regulated by laminar shear stress in 
human aortic endothelial cells in culture93.
1.2.2.2 Manganese superoxide dismutase (Mn SOD)
This was the second mammalian enzyme to be discovered in 1973196. Mn SOD is a 
homotetramer, each 16kDa subunit containing one manganese atom. It is synthesised in the 
cytoplasm and directed to the mitochondria by a signal peptide, where it is involved in 
dismutating the 0 2 generated by the respiratory chain of enzymes described in section 1.2.1 
above.
The essential role of Mn SOD in maintaining mitochondrial function is demonstrated by the 
neonatal lethality of mice with targeted disruption of the gene for Mn SOD (Sod2)191. Such 
Sod2 ‘knock out’ mice die within the first 10 days of life with dilated cardiomyopathy. 
Another group generated Sod2 ‘knock out’ mice and confirmed the dilated cardiomyopathy 
in -/- homozygotes, but also described several novel pathologic phenotypes including severe 
anaemia, degeneration of neurons in the basal ganglia and brainstem, and progressive motor 
disturbances characterised by weakness, rapid fatigue, and circling behaviour198.
The human Sod2 gene has been localised to the 6q25 region of chromosome 6199, and 
subsequently cloned and characterised200. The single copy gene consists of 5 exons and 4 
introns. The promoter sequences suggest that Sod2 is subject to a degree of transcriptional 
regulation. Indeed, Sod2 has been shown to be up-regulated in cultured fibroblasts exposed
to excess 0 2, whereas Sod3 was down-regulated and Sodl was unaltered201. In a similar 
study, H20 2 increased Sod2 expression in cultured tracheobronchial epithelial cells without 
affecting Sodl expression202. Sod2 can also be up-regulated by TNF-a203 and shear stress204, 
all of which are probably via activation of the NF-kB transcription factor.
As stated above, Mn SOD protein depends on a signal sequence to localise it to the 
mitochondria. Polymorphisms in this signal sequence have been identified in patients with 
genetic diseases of premature ageing205. Such signal sequence polymorphisms could result in 
diseases of distribution, where Mn SOD is not properly targeted, thereby leading to an 
absolute or relative deficiency of the enzyme within the mitochondria. This indicates that 0 2' 
may be involved in the process of ageing, and this will be discussed further in section 1.4.
1.2.2.3 Extra-cellular superoxide dismutase (EC-SOD)
This is the third and currently the last mammalian SOD to be characterised. It was purified 
from human lung by Marklund in 1982206. Most mammalian EC-SOD exists as a 
homotetramer of molecular weight 130,000 and like Cu/Zn SOD, each 30kDa subunit 
contains one copper and one zinc atom. Again like Cu/Zn SOD, EC-SOD activity is 
extremely sensitive to cyanide. EC-SOD is produced in fibroblasts and glial cells207 and 
secreted into the extracellular fluid, where it is the principal SOD. The enzyme is a 
glycoprotein, which binds sulphated polysaccharides, such as heparin and heparan sulphate, 
via a cluster of six basic amino acids. Therefore, EC-SOD will exist in the vasculature 
mainly bound to the surface of the endothelial cells and the extracellular matrix, both of 
which have an abundance of heparan sulphate, although some enzyme activity can be 
detected in the plasma. Because of its location, EC-SOD has been hailed as the principal
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regulator of endothelium derived NO bioavailability208, although cytosolic Cu/Zn SOD is 
also thought to be important188.
The human gene encoding EC-SOD (Sod3) has been characterised209. Southern blot analysis 
suggests the existence of a single gene, with no evidence of pseudogenes. Human Sod3 
contains 3 exons and 2 introns spanning «5.9kb. The 720-bp coding region is uninterrupted 
and located within exon 3. No obvious TATA box was identified, but an Alu-J repetitive 
element was identified 5’ to exon 3 and an Alu-Sx repetitive element was identified 3’ to the 
coding exon. Discrepancy between Sod3 mRNA levels and EC-SOD activity in a variety of 
tissues would suggest that post-transcriptional or post-translational regulation of the gene 
occurs.
The important anti-oxidant role of EC-SOD is shown by mice lacking the Sod3 gene. Such 
Sod3 ‘knock out’ mice have been generated and characterised210. When kept under normal 
laboratory conditions, null mutant mice develop normally and remain healthy until at least 
14 months of age, despite no compensatory induction of Cu/Zn SOD or Mn SOD activity. 
However, when exposed to the oxidative stress of >99% oxygen, the survival time of the 
homozygous -/- mice is significantly reduced compared to homozygous +/+ mice. The cause 
of death was fulminant pulmonary oedema, which is in keeping with the fact that the lung is 
the tissue containing the highest amount of EC-SOD in mice.
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1.2.3 Superoxide anion and cardiovascular disease
1.2.3.1 Hypercholesterolaemia
O’Hara et al demonstrated increased 0 2" production in vessels from hypercholesterolaemic 
rabbits and that the endothelium was the source211. They showed that 0 2’ could be reduced 
to normocholesterolaemic levels by the non-competitive XO inhibitor oxpurinol, suggesting 
that XO is the enzyme responsible. White et al confirmed that the impaired relaxation to 
ACh, induced by hypercholesterolaemia in the rabbit aorta, could be reversed by pre­
treatment of the aortic rings with allopurinol, another XO inhibitor212. They showed that the 
endothelial function could also be restored by pre-treatment with heparin, which competes 
with circulating XO for binding to sulphated glycosaminoglycans on the endothelial cells. 
Plasma XO activity was elevated more than two-fold in hypercholesterolaemic rabbits 
compared to controls in their study.
Further evidence for the involvement of 0 2' in endothelial dysfunction in 
hypercholesterolaemia come from Mtigge et al, who were able to improve endothelium- 
dependent, but not endothelium-independent, relaxations in aortas from 
hypercholesterolaemic rabbits by daily injections of polyethylene-glycolated SOD (PEG- 
SOD)213. They demonstrated a two-fold increase in vascular SOD activity using this 
preparation.
In humans with hypercholesterolaemia, Garcia et al confirmed the blunted vasodilator 
response in the forearm to intrabrachial ACh214. They failed to correct this impairment with 
intrabrachial infusion of SOD, suggesting that increased 0 2' may not be responsible.
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However, the preparation of SOD used would not enter the cells, which is the reason 
Miigge et al used PEG-SOD in the rabbit study above213.
1.2.3.2 Hypertension
Since the landmark study on renovascular hypertension by Goldblatt et al in 1934215, it has 
become clear that the renin-angiotensin system (RAS) plays a major role in hypertension. 
The mechanism of RAS-induced hypertension has generally been attributed to the 
vasoconstrictor effects of angiotensin II and the mineralocorticoid effects of aldosterone. 
However, recent work has revealed an alternative mechanism. Angiotensin II has been 
shown to stimulate 0 2 generation by increasing NAD(P)H oxidase activity in cultured rat 
VSMC177 and in intact aortas of rats made hypertensive by angiotensin II infusion179. This 
seems to be a fairly specific effect as rats made hypertensive to a similar degree by infusion 
of noradrenalin showed no increase in NAD(P)H oxidase activity179. Blood pressure and 
vascular reactivity could be restored by exogenous liposome-encapsulated SOD in the 
angiotensin II hypertensive rats, but not the noradrenalin hypertensive rats, which further 
implicates 0 2‘ in hypertension associated with high renin-angiotensin states216.
0 2' has been implicated in other models of experimental hypertension. As discussed in 
section 1.1.2.1, Grunfeld et a t 14 and Tschudi et alU5 demonstrated excess 0 2' in aortas of 
SHRSP. In the related SHR, Nakazono et al were able to lower blood pressure by 
intravenous injection of a fusion protein of SOD linked to a C-terminal basic domain which 
has high affinity for heparin-like proteoglycans on vascular endothelial cells217. Using 
immunohistochemistry, they demonstrated that the fusion protein was localised to the 
endothelium and tunica interna and elastica interna of the aorta and resistance vessels. They 
also found arterial XO activity and aortic SOD activity to be similar in SHR and WKY. Ito
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et al also found increased 0 2', detected by formazan staining, in the hypertrophied heart of 
SHR compared to WKY, and in this study reduced SOD activity was found to be the 
underlying mechanism218.
Endogenous 0 2‘ has been shown to affect tone in human vessels219. Increased 0 2' 
generation, albeit by neutrophils, has also been demonstrated in human essential 
hypertension220. Although the mechanism remains unclear, the effect can be reversed by p- 
adrenoceptor blockade with celiprolol220. Red blood cell SOD activity was also found to be 
reduced in patients with essential hypertension compared to normotensive controls, 
however the groups were very poorly matched for age221. Although not directly measured in 
this study, the implication is that 0 2 would consequently be increased in the hypertensive 
group, perhaps contributing to the hypertension.
1.3 Gender differences in cardiovascular disease
Human cardiovascular disease is less common in women of reproductive age compared to 
age matched males. This was recognised as early as 1955 when Sir George Pickering stated 
that, “for any given level of arterial pressure, women fare better than men.” From early 
analysis of the now famous Framingham Study, women in the reproductive age group were 
found to be at a lower risk for developing coronary heart disease, and indeed all 
cardiovascular events, compared with men of similar age222. This was confirmed in a West 
of Scotland population where women were shown to have lower coronary mortality than 
men when corrected for age and all other risk factors223. In addition, from adolescence 
onwards, women have lower blood pressure than men224, and the prevalence of essential 
hypertension is lower in premenopausal women than age matched men225.
A similar gender difference exists in animal models. In the SHR, males have a higher 24- 
hour mean arterial pressure (MAP) than females, and a high salt diet increased 24-hour 
MAP in males, but had no effect in females226. There is also evidence from animal models 
for delayed and less severe hypertension227 and atherosclerosis228 in females compared to 
males.
There is evidence for gender differences in endothelial function in humans and animal 
models of genetic hypertension. Chowienczyk et al used forearm venous occlusion 
plethysmography to demonstrate that hypercholesterolaemia produced greater endothelial 
dysfunction in males compared to aged matched females229. Kauser and Rubanyi were the 
first to demonstrate that significant gender differences exist in endothelial function of 
thoracic aortas isolated from SHR, as determined by ACh induced relaxation230. Gender 
differences in myogenic tone have also been demonstrated, where females exhibit attenuated
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pressure-induced constriction of arterioles, from the coronary231 or skeletal muscle232 
circulation, compared to males.
These gender differences in endothelial function have been attributed to NO, and indeed 
reduced basal ‘release’ of NO was demonstrated in the thoracic aortas of male rabbits 
compared to females233. More recently, Kauser and Rubanyi used a bioassay system to 
demonstrate reduced basal NO release in aortas from male rats compared to females234. In 
the same study, they also showed that aortas from female rats relaxed to a greater extent 
after stimulation by ACh, and that the ability of an intact endothelium to suppress serotonin 
or phenylephrine contractions was greater in females, compared to males.
1.3.1 Sex hormones
It has been suggested that the gender differences in cardiovascular disease, endothelial 
function and NO are related to sex hormones, though this has never been proven.
1.3.1.1 Oestrogen in cardiovascular disease
There is evidence from animal models of genetic hypertension that sex hormones are 
important in the development of hypertension. lams and Wexler found in young male SHR 
that gonadectomy prevented the rapid development of spontaneous hypertension, and that 
in young female SHR ovariectomy caused “escape” from the protective effect and led to the 
development of severe hypertension235. They also found that exogenous oestrogen 
prevented the hypertension in gonad-intact male and ovariectomised female SHR. In 
another model of experimental hypertension, the \mRen-2\21 transgenic rat, ovariectomy 
increased mean arterial blood pressure in females and this could be reversed by exogenous
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oestrogen236. Ovariectomy has also been shown to increase fatty streak lesions in the 
proximal aorta of apolipoprotein E-deficient mice without affecting plasma cholesterol, and 
this effect was reversed by exogenous 17(3-oestradiol237. 17J3-oestradiol was also shown to 
reduce aortic accumulation of cholesterol in ovariectomised, cholesterol-fed rabbits238.
In human studies a decline in endogenous oestrogen is associated with increased 
cardiovascular disease. In the Framingham Study, the onset of the menopause was 
associated with an increased incidence of cardiovascular events222. This observation was 
later confirmed by Colditz et al in surgical menopause, where the risk ratio for coronary 
heart disease was 2.2 (95% confidence interval 1.2 to 4.2), but not in natural menopause, 
where the risk ratio was only 1.2 (95% confidence interval 0.8 to 1.8)239.
Exogenous oestrogens in the form of hormone replacement therapy (HRT) have been 
shown to decrease cardiovascular disease. Eight weeks of HRT can lower systolic and 
diastolic blood pressure240. The 10 year report from the Nurses’ Health Study revealed an 
overall relative risk of major coronary heart disease in women currently taking oestrogen of 
0.56 (95% confidence interval, 0.40 to 0.80), after adjustment for age and other risk 
factors241. Around the same time a meta-analysis of all previously published studies revealed 
a remarkably similar overall relative risk of coronary heart disease of 0.56 (95% confidence 
interval, 0.50 to 0.61) in oestrogen users242. However, a less robust study of pooled data 
disputes this beneficial effect by calculating an odds ratio of cardiovascular disease of 1.39 
(95% confidence interval, 0.48 to 3.95) in women taking HRT243. While this increased risk 
does not achieve statistical significance, there is no suggestion of protection from 
cardiovascular disease by HRT. This latter study has subsequently been heavily criticised244 
and is the only study to show an increased cardiovascular risk, albeit non-significant, with 
HRT. The balance of evidence remains in favour of a protective effect of oestrogen,
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therefore it was initially surprising that the anti-oestrogen tamoxifen, given as adjuvant 
therapy for breast cancer, significantly reduced the incidence of fatal myocardial infarction 
in the Scottish adjuvant tamoxifen trial245. The authors attribute this effect to the partial 
agonist oestrogen-like effect of tamoxifen.
Oestrogen exerts a multitude of effects which are potentially cardioprotective, including 
improving the lipid profile by increasing high density lipoprotein (HDL) and lowering LDL 
and fibrinogen levels246. However, it is estimated that the improved lipid profile accounts for 
only 25-50% of the protective effect of oestrogen. Oestrogen is also reported to have a 
calcium channel blocking action247 and also appears to possess anti-oxidant properties248, 
perhaps related to its phenolic structure, which scavenges hydroxyl radicals. It also alters 
responses to other vasoactive molecules, but the main beneficial effect of oestrogen is 
thought to be via its improvement in endothelial function.
1.3.1.2 Oestrogen and endothelial function
The modulation of vascular tone by oestrogens has been recognised since the late 1800s. In 
1884, in a paper curiously entitled ‘Irritation o f the sexual apparatus' , MacKenzie reported 
that the menstrual cycle and pregnancy could cause changes in the degree of vascularity of 
mucous membranes in women249. Almost 60 years later, Reynolds and Foster demonstrated 
that oestrogen could induce dilatation of small vessels in the ear of ovariectomised 
rabbits250. In 1966, Ueland and Parer reported a decrease in systemic vascular resistance in 
ewes during pregnancy251. Much work has been done subsequent to these early studies in an 
attempt to explain the gender differences in cardiovascular disease and the cardioprotective 
effects of oestrogens.
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There have been a multitude of animal studies looking at the effects of oestrogens on 
endothelial function and these have been comprehensively reviewed recently252. There have 
been a few human studies. Sudhir et al used forearm venous occlusion plethysmography to 
demonstrate that oestrogen given to postmenopausal women in the form of HRT increased 
basal NO, as determined by the constrictor response to L-NMMA, but not stimulated NO, 
as determined by the dilator response to ACh240. Pinto et al took this observation further by 
examining endothelial function in women before surgical menopause (hysterectomy and 
bilateral ovariectomy for uterine leiomyoma), afterwards and then again after oestrogen 
HRT253. Before ovariectomy, ACh induced vasodilatation of the forearm was no different 
from control women matched for age and other risk factors. However, within 4 weeks after 
surgery, endothelium-dependent vasodilatation was significant impaired in the ovariectomy 
group compared to pre-surgery. Unlike Sudhir et al, they found that 3 months of oestrogen 
HRT did significantly improve ACh induced vasodilatation back to pre-surgery levels. This 
group did not assess basal NO, but found no significant effect of ovariectomy or HRT on 
endothelium-independent vasodilatation.
Some of the human studies, and indeed some of the animal studies, have shown an acute 
effect of oestrogen. Intrabrachial 17p-oestradiol and ACh produce a significantly greater 
increase in forearm blood flow than ACh alone254, and a similar acute effect was 
demonstrated in the coronary circulation of postmenopausal women, where 17p-oestradiol 
changed ACh induced constriction to dilatation within 20 minutes255. In addition, sublingual 
17p-oestradiol has been shown to significantly improve the treadmill exercise capacity of 
women with coronary heart disease within 40 minutes of administration256. These responses 
are too rapid to be mediated by the conventional genomic actions of oestrogen, but may be 
attributable to the anti-oxidant or calcium channel blocking effects of the hormone 
described in section 1.3.1.1.
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1.3.1.3 Oestrogen and nitric oxide
There are a number of ways in which oestrogen can increase NO. It can increase basal NO 
production, as suggested by Sudhir et al240; increase stimulated NO production, as 
suggested by Pinto et al253; or reduce NO scavenging, which will be discussed in section 
1.3.1.4. Increased NO production can be achieved by increased expression of the Nos3 
gene, increased activity of the NOS III enzyme, or both.
As discussed in section 1.1.1.5.2, there are theoretical reasons why oestrogens may regulate 
Nos3 expression. Oestrogen has been shown to increase Nos3 mRNA in cultured cells in 
105 and in skeletal muscle107 and aorta108 in vivo (Table 2). In only one of these studies 
was NOS III enzyme activity measured and was found to be increased after 17p- 
oestradiol107. This has been confirmed in HUVEC and BAEC after 8 hours of exposure to 
17(3-oestradiol257. NOS III activity was also increased in foetal pulmonary artery endothelial 
cells, which could be inhibited by tamoxifen and other oestrogen receptor antagonists, 
suggesting involvement of the oestrogen receptor258. However, this effect was observed 
within 5 minutes of exposure to 17P-oestradiol, suggesting a non-genomic mechanism. In 
this study Nos3 expression was not altered and Nos2 mRNA was not detected, and the 
increased NOS III activity was not observed in the absence of extracellular Ca2+. Taken 
together, these data suggest a novel action of oestrogen whereby it interacts with the 
oestrogen receptor and very rapidly opens membrane Ca2+ channels on endothelial cells, 
increasing [Ca2+]i, which is a recognised stimulus for increased NOS III activity. This is in 
contrast to the proposed Ca2+ blocking action of oestrogen at the VSMC membrane247.
17P~oestradiol has also been shown to inhibit interferon and lipopolysaccharide induced 
Nos2 expression in cultured macrophages by a receptor mediated mechanism257. The
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authors speculate that this may be yet another mechanism whereby oestrogen is protective 
against atherosclerosis.
1.3.1.4 Oestrogen and superoxide anion
Despite all of the above evidence for oestrogen increasing Nos3 gene expression and/or 
NOS III enzyme activity, Amal et al produced some evidence to the contrary185. In cultured 
BAEC they found no increase in NOS III activity by the L-arginine/L-citrulline assay, no 
increase in NOS III protein levels by western blotting, and no increase in Nos3 mRNA by 
northern blotting, after stimulation by the synthetic oestrogen ethinylestradiol (EE2). They 
did demonstrate increased guanylate cyclase stimulating activity in the supernatant of BAEC 
treated with EE2. In the absence of increased NO production, they hypothesised, then 
demonstrated, that this was due to reduced levels of 0 2\  They conclude that EE2 reduces 
0 2' production, although increased dismutation by SOD remains a possibility.
Some of the conflicting findings of Amal et al may be explained by the synthetic oestrogen 
used, but there are other reports in the literature of oestrogen affecting 0 2‘ production and 
removal. Raj an et al showed that 5 days of subcutaneous oestradiol increased NADH 
oxidase activity in the rat uterus without affecting SOD activity, whereas some synthetic 
oestrogens dose dependently reduced NADH oxidase and SOD activity259. Whiteside et al 
demonstrated that oestrogen increases Cu/Zn SOD in rat mammary tumours260. While there 
are other studies examining the effects of oestrogen on 0 2' in reproductive tissues, the only 
other study in the cardiovascular system showed no effect of gender, gonadectomy or 
graded doses of oestradiol on rabbit myocardial SOD activity261. It therefore remains 
unclear to what extent the improvement in endothelial function by oestrogen is attributable 
to NO or 0 2, although a combination is likely.
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1.4 The effect of age on endothelial function
Cardiovascular disease remains the leading cause of death and a major source of disability in 
the elderly. While risk factors for atherosclerosis such as hypertension, diabetes, and 
hyperlipidaemia become more prevalent with ageing, escalation of cardiovascular disease 
exceeds expected incidence based exclusively on these risks. Ageing itself may 
fundamentally increase the vulnerability of older adults to cardiovascular disease, although 
this remains difficult to study in humans.
There is growing evidence to suggest that alterations which occur in the vessel wall in 
ageing are similar to those seen in hypertension, although in hypertension the changes are 
accelerated262. Many of the functional changes in ageing are also seen in hypertension. In rat 
mesenteric resistance arteries, ageing is associated with reduced basal and ACh induced NO 
release263. Possibly as a result of this, the constrictor effect of endothelin-1 is potentiated by 
ageing in the same vessels, whereas contractions to noradrenaline were unaffected263. In 
humans too, endothelial function in the forearm vasculature, as determined by methacholine 
induced vasorelaxation, declines progressively with age264. Similarly, Taddei et al found 
reduced ACh stimulated vasodilatation in the forearm of an elderly group (>60 years), 
which was remarkably similar to the endothelial dysfunction they found in a young 
hypertensive group (<30 years)265. These studies further suggest that hypertension is an 
accelerated form of ageing.
Another link between hypertension and ageing is 0 2\  As discussed in section 1.2.3.2, 0 2‘ 
appears to be involved in some forms of hypertension, and in section 1.2.2.1, 0 2 has been 
implicated in premature ageing. Indeed, the most popular current theory of ageing holds 
that ageing represents an accumulation of free-radical damage to macromolecules such as
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proteins, lipids and nucleic acids266. One may speculate then, that 0 2 excess, which 
underlies the endothelial dysfunction of some forms of hypertension, may also underlie the 
endothelial dysfunction of ageing. Evidence for this has only very recently become available. 
Tschudi et al found calcium-ionophore stimulated NO concentrations in isolated carotid and 
mesenteric arteries to be significantly reduced in 70 week old WKY rats compared to 15 
week old rats267. They found increased 0 2" release to account for this age-related reduction 
in NO concentration, as NOS III protein levels were not reduced in the aged mesenteric 
artery and even increased in the aged carotid artery.
75
2 Aims
The aims of the current study were:
1) To determine if there are differences in basal and/or stimulated NO availability between 
WKY and SHRSP.
2) To determine if there are differences in basal and/or stimulated NO availability between 
males and females within either strain.
3) To determine if any differences in NO availability are due to differences in NO 
production, NO destruction, or both.
4) To determine what role, if any, that 0 2‘ plays in the strain or gender differences in NO 
availability.
5) To determine what role, if any, 17p-oestradiol plays in gender differences in NO 
availability.
6) To determine the effect of age on basal NO availability, and to determine the 
mechanism(s) involved.
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3 Methods
Appendix 1 lists the suppliers of all chemicals and reagents used. Appendix 2 details the 
recipes for all solutions used.
3.1 Experimental animals
Rats were obtained from WKY and SHRSP colonies established in Glasgow by brother 
sister mating as previously described268. These colonies were originally established from rats 
obtained from the colonies maintained at the University of Michigan, which had obtained 
their breeding stocks from the National Institute of Health (personal communication, 
D.F.Bohr, Department of Physiology, University of Michigan). All experiments were 
approved by the Home Office according to regulations regarding experiments in animals in 
the United Kingdom.
3.1.1 Measurement of systolic blood pressure and body weight
In the week prior to sacrifice, indirect blood pressure was measured by tail plethysmography 
in conscious, restrained rats habituated to the procedure as previously described269. Rats 
were pre-warmed to 34°C for 10-15 minutes before measurements. On the day of sacrifice 
the rats were weighed on bench top scales after anaesthetic and before removal of the 
thoracic aorta.
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3.2 Isometric tension recording
Rats were studied at 16 weeks of age in four groups: WKY females (n=12), WKY males 
(n=17), SHRSP females (n=14) and SHRSP males (n=14). The rats were killed by 
halothane overdose. The thoracic aortas were carefully removed, cleaned of adipose tissue 
and cut into 2-3 mm rings. The rings were suspended under lg tension in individual 10 mL 
muscle baths containing physiological saline solution (PSS) of the following composition 
(mmol/L): NaCl 130, KC14.7, NaHC03 14.9, KH2P 04 1.18, MgS04.7H20  1.17, 
CaCl2.2H20  1.6, glucose 5.5 and CaNa^DTA 0.03. The PSS was aerated with 95%
0 2/5% C 02. Indomethacin was added to a final bath concentration of 1 O'5 mol/L to inhibit 
the production of prostanoids, which can affect vascular tone independently of NO. 170- 
oestradiol (10 5 mol/L) and cocaine HC1 (10'5 mol/L) were also added to block 
extraneuronal and neuronal adrenergic uptake respectively. Isometric tension was measured 
by a force transducer (Grass Medical Instruments, Quincy, USA) and recorded by a 
multichannel pen recorder (Grass Medical Instruments, Quincy, USA). After a 1 hour 
equilibration period, four different protocols were followed on rings from each group. 
These protocols are illustrated in Figures 6 - 9 .
3.2.1 Experimental protocols
Potassium chloride (KC1) was used as a receptor independent vascular smooth muscle cell 
depolarising agent. At 100 mmol/L maximal contraction is obtained. The noradrenaline 
analogue phenylephrine hydrochloride (PE) was used to constrict the rings via oti- 
adrenoceptors. PE has very little 0-agonist effect and has no a 2 effects, which is important 
as the latter may interact with the L-arginine/NO pathway.
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3.2.1.1 Carbamylcholine
Carbamylcholine chloride (carbachol), a more stable analogue of acetylcholine270, was used 
to relax the rings in an endothelium dependent manner via M2 muscarinic receptors 
resulting in stimulated NO release271,272. As shown in Figure 6, aortic rings from each group 
were pre-constricted to the EC5o for PE. Stimulated endothelial NO release was assessed by 
measuring the relaxation to carbachol (10‘8 - 10'5 mol/L).
3.2.1.2 Sodium nitroprusside
The NO donor sodium nitroprusside (SNP) was used to relax the rings in an endothelium 
independent manner. SNP does not release NO until it reaches the vascular smooth muscle 
cell273. As shown in Figure 6, after the concentration response curve was obtained for 
carbachol the bath was washed out. The rings were then preconstricted to the EC50 of PE 
and a concentration response curve was obtained for SNP (10-8 - 10'5 mol/L).
3.2.1.3 NG-nitro-L-arginine methyl ester
The NOS inhibitor NG-nitro-L-arginine methyl ester (L-NAME) was used to inhibit basal 
NOS III activity. The resultant contraction is a measure of basal NO availability125. L- 
NAME also appears to be a competitive antagonist of acetylcholine at muscarinic receptors, 
but competes very poorly with carbachol for the muscarinic receptor274. As shown in Figure 
7, parallel aortic rings from each group were shown to relax to carbachol indicating that a 
functioning endothelium was present. After washout the rings were pre-constricted to the 
EC2q for PE. L-NAME was added to a final bath concentration of 100 pmol/L and the
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resultant contraction taken as a measure of basal NO availability. If the rings were not 
preconstricted to the EC2q for PE, then they would not contract to L-NAME.
3.2.1.4 Diethyldithiocarbamate
The cell membrane permeable copper chelating agent sodium diethyldithiocarbamate 
(DETCA) was used to inhibit copper zinc (Cu/Zn) SOD, both intracellular and 
extracellular188,275. This has the effect of increasing levels of 0 2 within the lumen of the 
vessel and also within the endothelial cell. As shown in Figure 8, the rings were incubated 
with DETCA (10 mmol/L) for 45 minutes, then concentration response curves were 
obtained for PE (10'8 - 10'5 mol/L) and carbachol (10'8 - 10'5 mol/L). This concentration of 
DETCA has been shown to completely and irreversibly inhibit Cu/Zn SOD activity275, 
therefore it was not necessary to add DETCA after each washout.
3.2.1.5 Superoxide dismutase
Exogenous SOD was added to remove extracellular 0 2‘. This form of SOD does not enter 
cells213. As shown in Figure 9, exogenous SOD (45U/mL) was added to the bath and a 
concentration response curve obtained for PE (10'8 - 10'5 mol/L). After washout, 
exogenous SOD (45U/mL) was again added to the bath and a further concentration 
response curve was obtained for carbachol (10_8-10-5 mol/L).
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3.3 Endothelial nitric oxide synthase activity measurement
Rats were studied at 16 weeks of age in four groups: WKY females (n=20), WKY males 
(n=15), SHRSP females (n=20) and SHRSP males (n=20). Measurement of NOS activity 
was as described276. Fresh aortic endothelial cells were obtained by carefully removing and 
cleaning the thoracic aorta as described above. The aorta was opened along its length and 
using a scalpel blade the endothelium was removed into homogenising buffer (Tris 50 
mmol/L, sucrose 3.2 mmol/L, dithiothreitol 1 mmol/L, leupeptin 10 pg/mL, soybean trypsin 
inhibitor 10 pg/mL, aprotonin 2 pg/mL, pH 7.4). The aortas from five rats of the same sex 
and strain were pooled before assaying NOS activity to reduce variability. Endothelial cells 
in buffer were snap frozen in liquid N2 and stored at -70°C until ready to assay.
On the day of the assay, the cells were thawed, sonicated 3 times for 3 seconds and 
centrifuged at 10,000g for 20 minutes. 40pL of the resultant supernatant containing both 
the soluble and particulate NOS protein was incubated at 37°C with the assay buffer (50 
mmol/L KH2P 04, 1 mmol/L MgCl2, 0.2 mmol/L CaCl2, 50 mmol/L valine, 20pmol/L L- 
citrulline, 20pmol/L L-arginine, 1 mmol/L dithiothreitol, lOOpmol/L NADPH, 3pmol/L 
tetrahydrobiopterin, 3pmol/L flavin adenine dinucleotide (FAD), 3pmol/L flavin 
mononucleotide (FMN) and 0.05pCi«lpmol/L L-[U-14C]-arginine, pH 7.2). Incubation was 
repeated in the presence of 3 mmol/L of the calcium chelator EGTA and again in the
presence of 1 mmol/L N03-iminoethyl-L-omithine (L-NIO), a NOS inhibitor118. After 20 
minutes the reaction was terminated by the addition of 1:1 (v/v) double distilled 
water/activated Dowex-AG50W resin (200-400, 8% cross linked, Na+ form) which removes 
arginine from the mixture. The resin was allowed to settle for 30 minutes and the amount of 
labelled citrulline present in the supernatant was quantified in terms of counts per minute
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(cpm) by a liquid scintillation counter. The soluble protein content of the supernatant was 
determined by the Coomassie blue binding method using Bio-Rad Protein Assay with 
bovine serum albumin as standard. NOS activity was expressed as pmol citrulline produced 
per minute per mg of protein. Total NOS activity was calculated by subtracting NOS 
independent citrulline production (i.e. that in the presence of L-NIO) from the overall 
activity and calcium dependent NOS activity calculated as that which was absent in the 
presence of EGTA.
3.4 Rat aortic RNA analysis
3.4.1 Strategies for messenger RNA quantification
A number of widely used procedures exist for determining the abundance of a particular 
messenger RNA (mRNA) in a sample of total RNA. The two methods employed in these 
studies will be introduced and their relative merits discussed.
3.4.1.1 Northern blotting
Northern analysis remains the standard method for detection and quantification of relatively 
high abundance mRNA. Northern analysis allows a direct comparison of mRNA abundance 
between samples on a single blot and is the easiest method of determining transcript size, 
presence of alternatively spliced transcripts or multiple transcripts generated from a single 
locus.
Absolute quantification of a message by northern analysis is possible by running a series of 
different concentrations of an artificial sense strand of target RNA on the gel to construct a
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standard curve of concentration v density of band. Experimental samples on the same gel 
can be compared against this standard.
The advantages of northern analysis are that it is fairly straightforward and exceptionally 
versatile. High specific activity random-primed or nick translated DNA probes, in vitro 
transcribed RNA probes, or oligonucleotide probes can all be used successfully.
Additionally, probes with only partial homology, e.g. a complimentary DNA (cDNA) from a 
different species or a fragment of genomic DNA which might contain an exon(s) may be 
used.
However, northern analysis is the technique most vulnerable to RNA degradation. If RNA 
samples are even slightly degraded, the quality of the data and the ability to quantify 
expression are severely compromised. Thus, ribonuclease (RNase) free technique is 
essential. In addition, northern analysis is the least sensitive technique, although sensitivity 
can be improved by using high specific activity antisense RNA probes and charged nylon 
transfer membranes. Sensitivity can also be improved with oligo deoxythymidine [oligo 
(dT)] selection for enrichment of poly-adenylated [poly (A)] mRNA, which allows more 
target mRNA to be run in each lane without loss of resolution or saturation of the transfer 
membrane. Despite using 20pg of total RNA or lOpg of poly (A) mRNA per lane, rat Nos3 
message was present in too low abundance to be detected by northern analysis. Therefore, 
competitive reverse transcription polymerase chain reaction was used.
3.4.1.2 Reverse Transcription-Polymerase Chain Reaction
Reverse Transcription, coupled with the Polymerase Chain Reaction (RT-PCR), has 
revolutionised the study of gene expression. It is now possible to detect the RNA transcript
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of any gene, irrespective of the paucity of starting material or relative abundance of the 
specific mRNA. In RT-PCR, a retroviral reverse transcriptase enzyme, e.g. Avian 
Myoblastosis Virus (AMV), uses oligo deoxythymidine [oligo (dT)J5] as a primer 
hybridising to the poly (A) tail of all mRNA templates to produce cDNA transcripts. As 
such small quantities of RNA are used, yeast transfer RNA (tRNA) is used in the RT 
reaction to stabilise the RNA. The target cDNA is then specifically amplified exponentially 
using sequence specific oligonucleotide primers in the PCR.
Theoretically, the abundance of a transcript can be determined by knowing the amount of 
total RNA used in the initial cDNA synthesis reaction, the amount of cDNA used in the 
PCR reaction, and the number of PCR cycles necessary to generate enough product to be 
detected either by direct visualisation on an ethidium bromide stained agarose gel or by 
Southern transfer and hybridisation to a radiolabelled probe. In practice, this technique is 
much more complicated. A major drawback to exponential amplification is that small 
sample to sample differences in amplification translate to big differences in yield product. 
Accurate determination of absolute abundance of a specific transcript by RT-PCR requires 
the use of competitive RT-PCR techniques.
Competitive RT-PCR makes use of an exogenous RNA transcript added during the RT 
step. This ‘competitor’ RNA must be accurately quantified and added to replica samples of 
total RNA in amounts that span the range of target mRNA levels. The competitor mRNA 
and target mRNA must RT and PCR with equal efficiency and a method must be available 
to discriminate the products from each other. Therefore, competitor mRNA usually consists 
of the target mRNA with a small (<100 bp) insertion or deletion in order that they can be 
resolved on an agarose gel. Alternatively, the target mRNA may be point mutated to insert
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or remove a restriction enzyme site, allowing digestion with the enzyme to distinguish 
between the two products.
This method is technically laborious and costly as multiple RT and PCR reactions are 
required for each sample. However, competitive RT-PCR remains the accepted approach 
for quantification of low abundance transcripts, such as rat Nos3, which are undetectable by 
northern analysis.
3.4.2 Rat endothelial nitric oxide mRNA quantification
3.4.2.1 Isolation of total aortic RNA
Solutions used in RNA analysis were treated with 0.01% v/v diethylpyrocarbonate (DEPC) 
overnight at room temperature, then autoclaved to remove RNases.
Rats were studied at 16 weeks of age in four groups: WKY females (n=3), WKY males 
(n=3), SHRSP females (n=3) and SHRSP males (n=3). Rats were sacrificed by halothane 
overdose as described above. The thoracic aortas were quickly removed, cleaned of adipose 
tissue in ice cold saline and immediately snap frozen in liquid N2. Frozen aortas were stored
at -70°C until extracted for RNA.
On the day of RNA extraction each frozen aorta was dropped into 4 mL of ice cold RNAzol 
B and homogenised for 10 seconds using a Kinematica polytron homogeniser (Philip Harris 
Scientific, Aberdeen, UK). The polytron head was washed in 100% ethanol then DEPC 
treated distilled water (dH20 ) between samples. 400pL of chloroform was added to each
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homogenate. The samples were then vortexed for 10 seconds and left on ice for 5 minutes. 
The samples were centrifuged at 2,500 r.p.m. at 4°C for 5 minutes in a pre-chilled bench top 
centrifuge (Centra-7R, International Equipment Company). The top layer was carefully 
removed into a 15 mL Corex tube which had been baked to remove RNases and pre-chilled 
on ice. An equal volume (»1.8 mL) of isopropanol was added. Each sample was inverted 
several times and stored overnight at -20°C.
The following day the samples were centrifuged at 10,000 r.p.m. at 4°C for 15 minutes in a 
pre-chilled centrifuge (Model J2-21, Beckman). The supernatant was poured off and the 
RNA pellet washed in 70% ethanol/30% dH20  (DEPC treated). The tubes were
recentrifuged at 10,000 r.p.m. at 4°C for 15 minutes in a pre-chilled centrifuge. The 
supernatant was removed with a pipette and the pellet allowed to dry on ice for 15 minutes. 
The pellet was resuspended in 50pL of dH20  (DEPC treated). Each RNA sample was 
quantified at least twice by measuring the OD260 on a spectrometer (Ultrospec 2000, 
Pharmacia Biotech, St. Albans, UK). The purity of the RNA was determined by the ratio of 
OD26o/280 its integrity confirmed by running 2pg on an ethidium bromide (EtBr) stained 
1% agarose gel. The 28S, 18S and 5S ribosomal RNA bands were identified under U.V. 
light and the RNA was stored at -70°C until required.
3.4.2.2 Removal of contaminating DNA
Genomic DNA contamination of the RNA would interfere with the RT-PCR quantification 
as the PCR reaction will amplify templates of genomic DNA as well as target and 
competitor cDNA. As the amount of contaminating DNA in each sample is unknown and 
variable, it makes quantification of target and competitor RNA impossible. Therefore, to
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remove contaminating genomic DNA lOqg of each RNA was treated with RQ1 
deoxyribonuclease (DNase). This enzyme digests double stranded DNA but has no RNase 
activity therefore leaves the RNA intact. The reaction mixture was as follows
MgCl2 (25 mmol/L)
10X Mg2+ free PCR buffer 
RQ1 DNase (lU/pL)
RNA (200 ng/pL)
20pL
lOpL
20pL
50pL
100pL
The reaction was carried out at 37°C for 1 hour, then terminated by addition of an equal
volume of phenol/chloroform, vortexed for 10 seconds and spun at 14,000 r.p.m. at 4°C for 
5 minutes in a chilled microcentrifuge (Model 5402, Eppendorf). The aqueous top layer was 
removed into a clean tube and an equal volume of chloroform was added, vortexed for 10 
seconds and spun at 14,000 r.p.m. at 4°C for 5 minutes in a microfuge. The aqueous top 
layer was again removed into a clean tube and 3 volumes of 100% ethanol and 1/10th 
volume of DEPC treated sodium acetate (3 mol/L, pH 5.5) were added to precipitate the 
RNA. Each tube was inverted several times and stored at -20°C for 30 minutes. The tubes 
were spun at 14,000 r.p.m. at 4°C for 30 minutes in a microcentrifuge and the supernatant 
poured away. The pellets were washed in 70% ethanol/30% dH20  (DEPC treated) and
spun again at 14,000 r.p.m. at 4°C for 30 minutes in a microcentrifuge. The supernatant was 
aspirated and the pellet air dried on ice for 15 minutes. The pellet was resuspended in lOpL 
dH20  (DEPC treated). Concentration, purity and integrity were determined as above. The
RNA was stored at -70°C until required.
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3.4.2.3 Reverse Transcription-Polymerase Chain Reaction
3.4.2.3.1 Preparation of competitor RNA
An aliquot of a competitor clone was kindly gifted by F.Soubrier (Paris, France). It was 
constructed as described91. The rat Nos3 gene has not yet been cloned, therefore the 
sequence is not known. Oligonucleotide primers were designed from the human Nos3 gene 
sequence28. The sense primer (5'-TGC,CTG,CCC,CAC,TGC,TCC,TC-3') is located within 
exon 21 and the antisense primer (5'-TGC,ACG,GTC,TGC,AGG,ACG,TTG,GT-3') is 
located within exon 25 of the human gene73. These primers were used to PCR amplify a 
fragment of rat cDNA from rat aortic RNA which had been reverse transcribed. This 
amplicon was gel purified and subcloned into the expression vector pBluescript to create the 
plasmid pReNOS 1, which was sequenced to allow the design of rat Nos3 specific PCR 
primers.
The sense primer designed was 5'-TTC,CGG,CTG,CCA,CCT,GAT,CCT,AA-3' and the 
antisense primer designed was 5'-AAC,ATG,TGT,CCT,TGC,TCG,AGG,CA-3\ These 
primers PCR amplify a 340 bp fragment from reverse transcribed Nos3 cDNA. The 
competitor clone pReNIS5 was constructed by inserting a 64 bp fragment of polylinker 
between the above two primers, therefore the same primers will amplify a 404 bp fragment 
from reverse transcribed competitor RNA. One hundred ng of the aliquot of pReNIS5 
plasmid was used to transform competent cells.
92
3.4.2.3.2 Preparation of competent cells
Escherichia coli (DH5a) cells (Cambridge Bioscience, Cambridge,UK) were made 
competent by a modification of the ‘Miller' one-step competent cell procedure277. A 40pL 
aliquot of DH5a cells was inoculated into 2 mL of supplemented LB broth. This was 
incubated in a shaking incubator overnight at 225 r.p.m., 37°C. One mL of the fresh 
overnight culture was inoculated into 100 mL of supplemented LB broth and the OD60o 
measured on a spectrometer . This was incubated in a shaking incubator at 225 r.p.m., 37°C 
until the OD60o was 0.2-0.3. The culture was cooled by rotating the flask in ice/water and 
kept on ice thereafter to maintain maximum competence. The culture was transferred into a 
sterile, pre-chilled 250 mL centrifuge bottle and centrifuged at lOOOg for 10 minutes at 4°C, 
without braking. The supernatant was decanted and the pellet resuspended in 10 mL of ice- 
cold ‘Miller’ transformation solution by swirling gently. The now competent cells were split 
into lOOpL aliquots in 0.5 mL microtubes on dry ice, snap frozen in liquid N2 and stored at
-70°C until required.
3.4.2.3.3 Transformation of competent DH5a cells with pReNIS5 plasmid
A lOOpL aliquot of competent DH5a cells was slowly thawed on ice and added to lpL 
(100 ng) of pReNIS5 plasmid DNA in a sterile 1.5 mL microtube and the mixture kept on 
ice for 20 minutes. 900pL of supplemented LB broth, pre-heated to 37°C, was added and 
the mixture incubated in a shaking incubator at 225 r.p.m., 37°C for 90 minutes. The tube 
was spun at 14,000 r.p.m. for 1 minute in a microcentrifuge. A 700pL aliquot of 
supernatant was removed and the pellet resuspended in the remaining 300pL, which was 
then spread onto an L-amp agar plate. The plate was incubated upright at 37°C for 1 hour
to dry, then inverted and incubated at 37°C overnight. DH5a cells are sensitive to 
ampicillin, therefore should not grow. Only those which have been transformed with 
pReNIS5, which confers ampicillin resistance, should grow.
Competent DH5a cells were also transformed with 1 pL of dH20  as a negative control and 
to lpL  (50 ng) of another plasmid which confers ampicillin resistance as a positive control. 
Resulting colonies were processed similarly to those derived from the pReNIS5 
transfections..
The following day, colonies were present on the pReNIS5 plate and the positive control 
plate, but not the negative control plate. The cells were confirmed to contain pReNIS5 
plasmid by small-scale preparation of plasmid DNA and digestion by Eco RI and Hind III 
restriction enzymes.
3.4.2.3.4 Small scale preparation of pReNIS5 plasmid DNA
Small scale preparation of pReNIS5 plasmid DNA was performed by alkali lysis as 
described278.
Using a sterile pipette tip, 4 colonies were picked from the plate of pReNIS5 transformed 
cells onto a 'master' L-amp agar plate and the tip dropped into 2 mL of LB-amp medium in 
25 mL tubes. These were incubated in a shaking incubator at 225 r.p.m., 37°C overnight. 
The master plate was incubated in a 37°C oven overnight.
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The following day, the master plate was stored at 4°C. A 1.5 mL aliquot of each overnight 
culture was transferred to 1.5 mL microtubes and centrifuged at 14,000 r.p.m. at 4°C for 30 
seconds in a microcentrifuge. The supernatants were then removed by aspiration leaving the 
pellets as dry as possible. The bacterial pellets were resuspended in lOOpL of ice-cold 
Solution I by vigorous vortexing and 200pL of freshly prepared Solution II was added. The 
contents were mixed by inverting 5 times. The tubes were stored on ice for 5 minutes and 
150pL of ice-cold Solution III was added. The contents were mixed by vortexing in an 
inverted position for 10 seconds. The tubes were stored on ice for 5 minutes, then 
centrifuged at 14,000 r.p.m. at 4°C for 5 minutes in a microcentrifuge and the supernatant 
transferred to a fresh tube. Double stranded plasmid DNA was precipitated by adding 2 
volumes of ethanol at room temperature, then vortexing and allowing the mixture to stand 
for 2 minutes at room temperature. The tubes were centrifuged at 14,000 r.p.m. at 4°C for 5 
minutes. The supernatants were removed by aspiration and the pellets dried in an inverted 
position. The pellets were washed in 1 mL of 70% ethanol at 4°C. The centrifugation, 
aspiration and drying steps were repeated and the pellets resuspended in 50pL of TE (pH 
8.0, 10 mmol/L Tris.Cl, 1 mmol/L EDTA) containing DNase-free RNase (20pg/mL). The 
concentration of plasmid DNA was calculated from the OD26o measured on a spectrometer
and the quality assessed by running 2pg on a 1% (w/v) agarose gel.
In theory all of the clones picked should contain pReNIS5 plasmid DNA, but to test this all 
of the plasmid DNA samples were screened by digesting 10pg of DNA with the restriction 
enzymes Eco RI and Hind III as follows:-
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DNA (2pg/pL) 5pL
1 OX Buffer B lpL
Eco RI (10U/pL) lpL
Hind III (IOU/jxL,) lpL
dH20  2uL
lOpL
The reaction mixture was incubated at 37°C for 3 hours in a heating block and the products 
of digestion run on a 1% agarose gel with the undigested plasmid in an adjacent lane. All 4 
of the clones screened dropped out a ~600bp fragment as expected, confirming that they 
had indeed taken up the pReNIS5 plasmid.
3.4.2.3.5 Large scale preparation of pReNIS5 plasmid DNA
Having established that the colonies contained pReNIS5 plasmid, a large quantity of the 
transformed cells was grown up and plasmid isolated by alkali lysis as described279.
Using a sterile pipette tip, one of the colonies was picked from the master plate and dropped 
into 2 mL LB-amp medium in a 25 mL tube. The culture was incubated in a shaking 
incubator at 225 r.p.m., 37°C overnight.
The following day, 500 mL of LB-amp medium in a 1L flask was inoculated with the 2 mL 
overnight culture and again incubated in a shaking incubator at 225 r.p.m., 37°C overnight. 
The following day the culture was split into 2 x 250 mL bottles and centrifuged at 4000 
r.p.m. for 15 minutes at 4°C. The supernatants were poured away and the pellets 
resuspended in 100 mL of ice-cold STE. These suspensions were again centrifuged at 4000 
r.p.m. for 15 minutes at 4°C and the supernatants poured away.
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The washed pellets were resuspended in 9 mL of Solution I. 1 mL of a freshly prepared 
solution of lysozyme was added to each bottle, followed by 20 mL of freshly prepared 
Solution II. The contents were mixed thoroughly by inversion and stored at room 
temperature for 10 minutes. Ten mL of ice-cold Solution III was added and the mixture 
shaken vigorously. The bottles were kept on ice for 10 minutes allowing a flocculent white 
precipitate of chromosomal DNA, high molecular weight RNA and protein/membrane 
complexes to form.
The bacterial lysates were centrifuged at 4000 r.p.m. for 15 minutes at 4°C and the rotor 
allowed to stop without braking. The supernatants were filtered through gauze swabs into 2 
clean 250 mL bottles and 0.6 volumes of isopropanol was added, mixed well and kept at 
room temperature for 10 minutes. Plasmid DNA was recovered by centrifugation at 5000 
r.p.m. for 15 minutes at room temperature, then washed in 5 mL of 70% ethanol and dried 
by aspiration. The dried pellets were resuspended in 1.5 mL of TE and pooled. This volume 
was made up to exactly 5.0 mL in preparation for purification by equilibrium centrifugation 
in a caesium chloride (CsCl)-ethidium bromide gradient.
3.4.2.3.6 Purification of pReNIS5 plasmid DNA by CsCl gradient
The pReNIS5 plasmid obtained from the above large scale preparation was purified by 
equilibrium centrifugation in a CsCl-ethidium bromide gradient as described280.
Exactly 5.0g of CsCl was added to the 5.0 mL of plasmid DNA and the solution warmed to 
37°C for 30 minutes to facilitate the dissolution of the salt. 0.4 mL of an aqueous solution 
of ethidium bromide (10 mg/mL) was added and mixed thoroughly. Using a disposable 
syringe fitted with a large-gauge needle, the clear, red solution was transferred to a Quick-
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Seal Ultra tube (Beckman, High Wycombe, UK), topped up with mineral oil and heat- 
sealed. The density gradients were spun on an ultracentrifuge (Beckman L8-55) at 49,000 
r.p.m. for 16 hours at 20°C with the brake off.
Under ultraviolet light, 3 bands were visible in the tube; an upper band of protein, a middle 
band of nicked circular or linearised DNA and a lower band of closed circular DNA. RNA 
formed a pellet at the bottom. The tube was punctured at the top by a 21G hypodermic 
needle to break the seal and just below the closed circular DNA band with another 21G 
hypodermic needle attached to a disposable syringe. The closed circular DNA was 'pulled' 
into the syringe taking care not to include any nicked circular or linearised DNA.
The DNA solution was added to an equal volume of water saturated butanol and the two 
phases mixed by vortexing. When the two phases had settled, the upper pink organic phase 
was discarded. This was repeated several times until the aqueous and organic phases were 
completely clear.
The DNA was precipitated by aliquotting into 1.5 mL microtubes, adding 2 volumes of 
ethanol and storing at 4°C for 15 minutes. The DNA was pelleted by spinning at 14,000 
r.p.m. for 30 minutes at 4°C in a microcentifuge. The supernatants were removed and the 
pellets washed in 70% ethanol before respinning at 14,000 r.p.m. for 5 minutes at 4°C. The 
supernatants were again aspirated and the pellets resuspended in lOOpL of TE and pooled.
The DNA was quantified by measuring the OD260 on a spectrometer . The quality of the 
DNA was assessed and absence of RNA confirmed by running 2pg on a 1% agarose gel. 
The DNA was stored in aliquots at -20°C.
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3.4.2.3.7 In vitro transcription of pReNIS5 RNA
20pg of pReNIS5 plasmid DNA from the above large scale preparation was linearised with 
Eco RI restriction enzyme as follows
The reaction was incubated at 37°C. After 4 hours, 2pL of the digest mix was run on a 1% 
agarose gel with 2pL of uncut plasmid in an adjacent lane to ensure that the digest was 
complete.
When the Eco RI digest was complete, 2pL of RNase-free Proteinase K (1 mg/mL) was 
added to remove the restriction enzyme and any RNases. The mixture was incubated for a 
further 30 minutes at 37°C. An equal volume of phenol/chloroform/isoamyl alcohol 
(25:24:1) was added, vortexed for 10 seconds, spun for at 14,000 r.p.m. for 5 minutes at 
4°C in a microcentrifuge; and the aqueous top layer removed into a fresh 1.5 mL microtube. 
This was repeated, then the mixture was extracted with 100% chloroform in the same way. 
Three volumes of ethanol and 1/10th volume of sodium acetate (3 mol/L, pH 5.5) were 
added to the purified, linearised DNA. This was mixed and stored at -20°C overnight.
pReNIS5 DNA (lpg/pL) 
Eco RI (lOU/pL)
10X Buffer H 
dH20
20pL
4pL
4pL
12pL
40pL
The DNA was recovered by spinning at 14,000 r.p.m. for 30 minutes at 4°C in a 
microcentrifuge, washing in 70% ethanol/30% dH20  (DEPC treated) and respinning at
14,000 r.p.m. for 30 minutes at 4°C. The supernatant was aspirated and the DNA was dried
and resuspended in 20pL of RNase-ffee TE and quantified by measuring the OD260 on a
spectrometer.
The mCAP mRNA Capping Kit was used to in vitro transcribe pReNIS5. The 5’ cap 
structure of in vitro mRNA transcripts increases stability of the synthesised RNA281. T3 
RNA transcripts, synthesised in vitro with the mCAP Capping Kit, are initiated with the 
7MeGpppG 5’ analogue similar to that present in eukaryotic mRNA. The cap structure is 
incorporated at the 5’ end of 90 - 95% of the resulting RNA transcripts. RNA transcription 
was initiated at the T3 RNA polymerase site on the linearised pReNIS5 plasmid DNA as 
follows:-
5X Transcription Buffer 5.0pL
pReNIS5 DNA template (0.5pg/pL) 2.0pL
rNTP mix l.OpL
mCAP analogue 2.5pL
Dithiothreitol (DTT, 0.75 mol/L) l.OpL
T3 RNA polymerase (5U/pL) 2.0pL
dH20  (DEPC treated) 11.5pL
25.0pL
The reaction was incubated at 37°C. After 30 minutes, lpL (10U) of RNase-ffee DNase 
was added and the incubation continued for a further 5 minutes to remove the template 
DNA. One hundred pL of dH20  (DEPC treated) was added and the RNA was 
phenol/chloroform extracted as described above. The RNA was precipitated in 3 volumes of 
ethanol and 1/10th volume of DEPC treated sodium acetate (3 mol/L, pH 5.5) and stored at 
-20°C for 30 minutes. The RNA was recovered by spinning at 14,000 r.p.m. for 30 minutes 
at 4°C in a microcentrifuge, washing in 70% ethanol/30% dH20  (DEPC treated) and
respinning at 14,000 r.p.m. for 30 minutes at 4°C. The pellet was dried and the RNA was 
resuspended in 25 pL of RNase-free TE and quantified on a spectrometer. A single, intact
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transcript was confirmed by running 2pL on a 1% agarose gel. It has been shown that 
unincorporated nucleotides contribute 20% of the OD26091»therefore the measured 
, concentration was adjusted accordingly. From the adjusted concentration, the pReNIS5
RNA was serially diluted to a range of concentrations between 40-280 fg/pL for use as
I competitor RNA in the RT-PCR reaction.
|
f!
|
3.4.2.3.8 Reverse transcription
|
! For each sample of aortic RNA, 10 RT reactions were set up as follows:
Aortic RNA (ng) Competitor RNA (fg) RT
1) 100 0 +
2) 100 40 +
3) 100 80 +
4) 100 120 +
5) 100 160 +
6) 100 200 +
7) 100 240 +
8) 100 280 +
9) 100 280 -
10) dH2Q (DEPC treated) +
Each reaction mixture consisted of the following:-
MgCl2 (25 mmol/L) 4. OpL
10X Mg2+ free PCR buffer 2.0pL
dNTP's (10 mmol/L) 2.0pL
rRNAsin (40 U/pL) 0.6pL
AMVRT (lOU/pL) 0.6pL
01igo(dT)15 primer (0.5 pg/pL) l.OpL
Yeast tRNA (1 pg/pL) 1. OpL
Target RNA (lOOng/pL) l.OpL
Competitor RNA (0-280fg/pL) 1 .OpL
dH20  (DEPC treated) 6.8pL
20.0pL
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The reaction was left at room temperature for 10 minutes to allow the oligo(dT)15 primer to 
anneal to the mRNA, incubated at 42°C for 45 minutes, then transferred to ice. A 3pL 
aliquot was used for the PCR reaction and the remainder stored at -20°C.
3.4.2.3.9 Polymerase chain reaction
For each sample of aortic RNA, 10 PCR reactions were set up; 1 for each of the above RT 
reactions. Note that the aliquots of cDNA from each RT reaction contained 5 mmol/L 
Mg2+, therefore the amount of MgCl2 added to the PCR was proportionately less to give a 
final reaction concentration of 1.5 mmol/L. Each reaction therefore consisted of the 
following
MgCl2 (25 mmol/L) 0.7pL
1 OX Mg2+ free PCR buffer 2.OpL
dNTP’s (1.25 mmol/L) 3.2pL
Forward primer (10 pmol/L) 1 .OpL
Reverse primer (10 pmol/L) 1 .OpL
Taq DNA polymerase (5 U/pL) 0.2pL
cDNA 3.OpL
dH20  8.9pL
20. OpL
The reaction was subjected to an initial denaturation at 94°C for 5 minutes; then 28 cycles 
of 30 seconds at 94°C, 30 seconds annealing at 62°C and 1 minute elongation at 72°C; then 
completion of ongoing reactions at 62°C for 1 minute and 72°C for 10 minutes in a Hybaid 
Omnigene PCR machine (Life Sciences International, Basingstoke, UK). The expected PCR 
product sizes were 340 bp for the target cDNA and 404 bp for the competitor cDNA.
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3.4.2.3.10 Visualisation of PCR products
The products of all 10 PCR reactions were separated on a 2% agarose gel at 100V for 2 
hours. The unincorporated primers, which run ahead of the PCR products, were cut off and 
the gel blotted onto Hybond N+ nylon membrane by the alkali transfer method.
3.4.2.3.11 Southern blotting of DNA by alkali transfer
The gel was rinsed in dH20  then completely covered in denaturing solution and left for 30 
minutes at room temperature with shaking. Excess liquid was blotted from the gel then it 
was equilibrated for 10 minutes in alkali transfer buffer.
A tray was filled with alkali transfer buffer. A platform was made and covered with a wick 
made from 3 sheets of Whatman 3MM filter paper, saturated with alkali transfer buffer.
Both ends of the wick sat in the buffer underneath. The gel was inverted onto the wick.
Care was taken to avoid trapping air bubbles beneath it. The gel was surrounded by 
Parafilm to prevent the alkali transfer buffer from being absorbed directly into the paper 
towels above. A sheet of Hybond N+ nylon membrane was cut to the exact size of the gel 
and placed on top of the inverted gel. Air bubbles were removed by carefully rolling a sterile 
pipette over the membrane. 3 sheets of Whatman 3MM filter paper were cut to the exact 
size of the gel, wetted in alkali transfer buffer and placed on top of the membrane one at a 
time. Air bubbles were again removed by rolling with a sterile pipette. A stack of absorbent 
tissues was placed on top of the 3MM paper. A glass plate was placed on top of the 
absorbent tissue and a 0.5 Kg weight (500 mL of water) put on top. After 1 hour the 
apparatus was dismantled and any wet tissues replaced with dry ones. The apparatus was 
reassembled and the transfer allowed to proceed overnight.
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The following day the apparatus was dismantled. The membrane was air dried for 15 
minutes, baked at 80°C for 30 minutes, then UV cross-linked (2 x auto setting, Stratalinker 
2000, Stratagene Ltd, Cambridge, UK). The membrane was pre-hybridised in the following 
solution:
20X SSPE 6.25mL (5X)
100X Denhardt's solution 1.25mL(5X)
SDS (10% w/v) 1.25mL (0.5%)
dH20  16.25mL
25.00mL
Prior to adding the membrane, 500pL of sheared salmon sperm DNA (1 mg/mL) was 
denatured at 100°C for 5 minutes, chilled on ice, then added to the pre-hybridisation mix. 
The membrane was pre-hybridised for 1 hour at 65°C in a rotating flask in preparation for 
hybridisation with an end labelled primer probe.
3.4.2.3.12 Making an end labelled primer probe
The forward primer used in the PCR reaction was 3'-end labelled with [a32P]-dCTP using 
the enzyme terminal deoxynucleotidyl transferase (TdT) as follows:-
5X TdT buffer 4.0pL
Forward primer (10 pmol/L) 0.7pL
TdT (15-30 U/pL) 0.5pL
[a32P]-dCTP (0.37 mCi/pL) 1 .OpL
dH20  13.8pL
20pL
The reaction was incubated at 37°C for 30 minutes, then stopped by heating to 68°C for 10 
minutes. The probe was added to the membrane in the pre-hybridisation mix and hybridised 
overnight at 65°C.
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The following day the membrane was washed to remove non-hybridised probe as follows:
2X SSPE/0.1% SDS at room temperature for 10 minutes 
2X SSPE/0.1% SDS at room temperature for 10 minutes 
IX SSPE/0.1% SDS at 65°C for 15 minutes 
0.1X SSPE/0.1% SDS at 65°C for 10 minutes
The membrane was wrapped in 'cling-film' and exposed to film (Hyperfilm-MP) in a 
Hypercassette (Amersham International pic, Amersham, UK) with two intensifying screens 
overnight at -70°C. The film was developed in a KODAK X-OMAT ME-3 Processor. Two 
lines of bands were noted (Figure 10a). The top line of bands of increasing intensity 
corresponds to the competitor, while the lower line corresponds to the target.
3.4.2.3.13 Calculation of target mRNA concentration
A scanned image of the autorad was created by a densitometer (Model GS 670, Bio-Rad 
Laboratories Ltd, Hemel Hempstead, UK). A typical image is shown in Figure 10a. The 
total density of each individual band was measured using Molecular Analyst 2.1 software 
(Bio-Rad Laboratories Ltd, Hemel Hempstead, UK). A plot was drawn of log competitor 
RNA concentration (x-axis) against log ratio of competitor density/target density (y-axis). 
Such a plot is illustrated in Figure 10b. When the log ratio of competitor density/target 
density = 0, then competitor and target concentrations are equal. The competitor 
concentration at this point can be read from x-axis, which therefore corresponds to the 
target mRNA concentration in fg per lOOng total aortic RNA.
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Figure 10 - Quantification of Nos3 mRNA by competitive RT-PCR. A constant amount of 
total RNA from rat aorta (target) was mixed with increasing amounts of internal standard 
mRNA (competitor), reverse transcribed and amplified by PCR with Nos3 specific primers. 
The PCR products were run on a 2% (w/v) agarose gel, blotted onto nylon membrane, 
hybridised with an end labelled primer as a probe and exposed to photographic film. The 
density of each band was measured and the logarithm of the ratio (density of target/density 
of competitor) plotted against the logarithm of the known amount of competitor mRNA in 
each reaction. At the competition equivalence (log ratio = 0), the amount of target mRNA 
(unknown) corresponds to the amount of competitor mRNA (known). In this example, 
lOOng of total aortic RNA from a WKY female contained 39fg of Nos3 mRNA.
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3.4.3 Quantification of rat manganese and copper/zinc superoxide dismutase mRNA 
by northern blotting
3.4.3.1 Isolation of total aortic RNA
Total aortic RNA was isolated by RNAzol B and quantified as described in section 3.4.2.1.
3.4.3.2 Size fractionation by agarose gel electrophoresis
Ten pg samples of total aortic RNA from 4 WKY females and 4 SHRSP females and 2 x 
lOpL aliquots of X Hind III DNA size markers were precipitated by adding 3 volumes of 
ethanol and l/5th volume of DEPC treated sodium acetate (3 mol/L, pH 5.5), mixing and 
storing at -20°C overnight. Ten pg samples of total aortic RNA from 4 WKY males and 4 
SHRSP males and 2 x 1 OpL aliquots of X Hind III DNA size markers were prepared in an 
identical fashion for running on a subsequent gel.
The following day, samples were spun at 14,000 r.p.m. for 15 minutes at 4°C in a 
microcentrifuge. The supernatants were removed and the pellets washed with 180pL of 
70% ethanol/30% dH20  (DEPC treated), then respun at 14,000 r.p.m. for 5 minutes at 4°C 
in a microcentrifuge. The supernatant was removed and the pellet air dried for 5 minutes.
Each pellet was resolubilised in 3.7pL of dH20  (DEPC treated) and 12.3pL of freshly 
prepared glyoxal mix added to each, taking care that the RNA was properly redissolved. 
The samples were glyoxalated at 50°C for 60 minutes.
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While the samples were glyoxalating, a 1.2% (w/v) agarose gel was made by adding 1.8g of 
agarose to 120 mL of dH20  (DEPC treated) and dissolving by microwaving. When the 
agarose had cooled to hand warm, 13.4 mL of sodium phosphate buffer (0.1 mol/L, pH 7.0) 
was added, mixed and poured into a 120 x 140 mm gel tray and allowed to set with a 12- 
tooth comb at one end. The tray, comb and tank were reserved exclusively for RNA gels. 
RNases were removed on the day prior to running the gel by soaking in 3% (v/v) hydrogen 
peroxide for 15 minutes, rinsing with dH20  then leaving in an inverted position overnight to 
dry.
When the denaturation was completed, the samples were cooled on ice and 4pL of 5X RNA 
loading buffer added to each. They were immediately loaded into the wells with the DNA 
size markers in lanes 1 and 12 and the RNA samples in lanes 3-10. The gel was run 
submerged in sodium phosphate buffer (10 mmol/L, pH 7.0) at 100V for 4 hours. Glyoxal 
dissociates from RNA at pH > 8.0, therefore a Hybaid 'Buffer Puffer' tank (Life Sciences 
International, Basingstoke, UK) was used to circulate the buffer, thus preventing the pH at 
either electrode reaching 8.0. When the run was completed, the RNA was transferred to 
nylon membrane.
3.4.3.3 Transfer to nylon membrane
The transfer apparatus was very similar to that used for transfer of the RT-PCR products 
described in section 3.4.2.3.11.
A tray was filled with 20X SSC (DEPC treated). A platform was made and covered with a 
wick made from 3 sheets of Whatman 3MM filter paper, saturated with 20X SSC (DEPC 
treated). Both ends of the wick sat in the buffer underneath. The gel was slid onto the wick.
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Care was taken to avoid trapping air bubbles beneath it. The gel was surrounded by 
Parafilm to prevent the 20X SSC from being absorbed directly into the paper towels above. 
A sheet of Hybond N+ nylon membrane was cut to the exact size of the gel and placed on 
top of the gel. Air bubbles were removed by carefully rolling a sterile pipette over the 
membrane. 6 sheets of Whatman 3MM filter paper were cut to the exact size of the gel, 
wetted in 2X SSC (1:10 dilution of 20X SSC) and placed on top of the membrane one at a 
time. Air bubbles were again removed by rolling with a sterile pipette. A stack of absorbent 
tissues was placed on top of the 3MM paper. A glass plate was placed on top of the paper 
towels and a 0.5 Kg weight (500 mL of water) put on top. After 1 hour the apparatus was 
dismantled and any wet tissues replaced with dry ones. The apparatus was reassembled and 
the transfer allowed to proceed overnight.
The following day the apparatus was dismantled. The membrane was air dried for 30 
minutes, baked at 80°C for 30 minutes to deglyoxalate the RNA, then UV cross-linked (2X 
auto setting, Stratalinker 2000, Stratagene Ltd, Cambridge, UK). Resolution and transfer of 
the samples were confirmed by cutting off the DNA size marker tracks and staining for 5 
minutes in methylene blue (0.4% w/v) in sodium acetate (0.5 mol/L, pH 5.5), followed by 
destaining for 20 minutes in dH20.
The membrane was pre-hybridised in the following solution:
Deionised formamide 20.0mL (50%)
20X SSPE lO.OmL (5X)
100X Denhardt's solution 2.0mL (5X)
SDS (10% w/v) 2.0mL (0.5%)
EDTA (0.4 mol/L, pH 8.0) 0.1 mL (lmmol/L)
dH20  (DEPC treated) 5.9mL
40.0mL
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This was heated to 65°C to ensure complete dissolution of the components, then 20 mL was 
added to the membrane in a hybridisation tube and pre-hybridised at 42°C for at least 4 
hours. The remaining 20 mL was kept at 42°C.
3.4.3.4 Preparation of radiolabelled probes
3.4.3.4.1 Glyceraldehyde phosphate dehydrogenase
An aliquot of the plasmid pRP-GAP was kindly gifted by MJ Brosnan within the 
department. This plasmid consists of a 216 bp fragment from the 5' end of the murine 
glyceraldehyde phosphate dehydrogenase (GAPDH) cDNA inserted into the pGEMl vector 
which confers ampicillin resistance. Competent DH5a cells were transformed with lOOng of 
pRP-GAP as described for pReNIS5 in section 3.4.2.3.3. Small scale preparation, large 
scale preparation and CsCl gradient purification were carried out for pReNIS5 in sections 
3.4.2.3.4-6.
Fifty pg of CsCl purified pRP-GAP was digested with Eco RI and Hind III restriction 
enzymes to drop out the 248 bp GAP fragment (including 32 bp of plasmid polylinker) as 
follows
pRP-GAP DNA (1 pg/pL) 50pL
1 OX Buffer B lOpL
Eco RI (lOU/pL) lOpL
Hind III (lOU/pL) lOpL
dH20  20pL
lOOpL
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The reaction mixture was incubated at 37°C for 3 hours, then a 2pL aliquot was run on an 
ethidium bromide stained 1% w/v agarose gel with undigested plasmid in an adjacent lane. 
When complete digestion was confirmed, the remainder of the digest was run on a 1% w/v 
agarose gel to separate the GAPDH fragment from the remainder of the plasmid. The band 
corresponding to the GAPDH fragment was cut out using a scalpel blade and stored in a 
microfuge tube, wrapped in tin-foil at 4°C.
Ten cm lengths of dialysis tubing were prepared by boiling in NaHC03 (2% w/v) and EDTA 
(1 mmol/L, pH 8.0) for 10 minutes; rinsing thoroughly in distilled water; then boiling for 10 
minutes in EDTA (1 mmol/L, pH 8.0). They were allowed to cool and stored in EDTA (1 
mmol/L, pH 8.0) at 4°C.
A 10 cm length of dialysis tubing was washed in distilled water and sealed with a clip at one 
end. The gel containing the GAPDH fragment was placed in the dialysis tubing along with 
500pL of IX TAE buffer. The other end was sealed with a clip and the 'bag' placed 
transversely in a gel tank containing IX TAE buffer. The GAPDH fragment DNA was 
electroeluted from the gel onto the inside of the dialysis tubing. After 1 hour, the 'bag' was 
examined on a UV light box to ensure that all of the ethidium bromide stained DNA had left 
the gel and was adherent to the wall of the tubing. One of the clips was carefully removed 
and the gel discarded. The DNA was resuspended in the 500pL of buffer, transferred to a 
microfuge tube and precipitated with 2 volumes of ethanol and 1/10th volume of sodium 
acetate (3 mol/L, pH 5.5). The pellet was washed in 70% ethanol, dried and resuspended in 
50pL of TE (pH 8.0).
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The concentration of the GAPDH fragment DNA was calculated from the OD260 and 2pg 
run on a 2% w/v agarose gel to confirm that a single band of «250 bp was present. The 
GAPDH fragment was diluted to 50 ng/pL and stored at -20°C.
3.4.3.4.2 Rat manganese superoxide dismutase
The plasmid pSP65-RMS was kindly gifted by Y-S Ho (Detroit, USA). This plasmid 
consists of the entire 1.4kb rat MnSOD cDNA cloned into the Eco RI site of the pSP65 
vector which confers ampicillin resistance. Competent DH5a cells were transformed with 
lOOng of pSP65-RMS as described for pReNIS5 in section 3.4.2.3.3. Small scale 
preparation, large scale preparation and CsCl gradient purification were carried out for 
pReNIS5 in sections 3.4.2.3.4-6.
Fifty pg of CsCl purified pSP65-RMS was digested with Eco RI restriction enzyme to drop 
out the 1.4kb Mn SOD fragment as follows:-
pSP65-RMS DNA (1 pg/pL) 50pL
10X Buffer B lOpL
Eco RI (lOU/pL) lOpL
dH20  30pL
lOOpL
The reaction mixture was incubated at 37°C for 3 hours, then a 2pL aliquot was run on an 
ethidium bromide stained 1% w/v agarose gel with undigested plasmid in an adjacent lane. 
When complete digestion was confirmed, the remainder of the digest was run on a 1% w/v 
agarose gel to separate the Mn SOD fragment from the remainder of the plasmid. The band 
corresponding to the Mn SOD fragment was cut out using a scalpel blade. The MnSOD 
DNA was electroeluted, ethanol precipitated, washed, resuspended in 50pL TE, quantified,
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diluted to 50 ng/pL and stored at -20°C as described for the GAPDH fragment in section
3.4.3.4.1.
3.4.3.4.3 Rat copper/zinc superoxide dismutase
The plasmid pUC13-RCS was also kindly gifted by Y-S Ho (Detroit, USA). This plasmid 
consists of the entire 0.6kb of rat Cu/Zn SOD cDNA inserted into the Eco RI site of the 
vector pUC13 which confers ampicillin resistance. Competent DH5a cells were transformed 
with lOOng of pUC13-RCS as described for pReNIS5 in section 3.4.2.3.3. Small scale 
preparation, large scale preparation and CsCl gradient purification were carried out for 
pReNIS5 in sections 3.4.2.3.4-6.
Fifty pg of CsCl purified pUC13-RCS was digested with Eco RI restriction enzyme to drop 
out the 0.6kb Cu/Zn SOD fragment as described for the MnSOD fragment in section
3.4.3.4.2. The Cu/Zn SOD DNA was separated, electroeluted, ethanol precipitated, 
washed, resuspended in 50pL TE, quantified, diluted to 50 ng/pL and stored at -20°C as 
described for the GAPDH fragment in section 3.4.3.4.I.
3.4.3.4.4 Random primer radiolabelling
A random primers DNA labelling kit was used to radiolabel the cDNA probes with [a 32P]- 
dCTP. Fifty ng of template cDNA (GAP, MnSOD or Cu/Zn SOD) was labelled in each 
reaction as follows:
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Template cDNA (50 ng/pL) 1 pL
dH20  22pL
This was heated to 100°C for 5 minutes then cooled on ice.
dATP 2pL
dGTP 2pL
dTTP 2pL
Random Primers Buffer 15pL
[a32P]-dCTP (0.37 mCi/pL) 5pL
Klenow fragment DNA polymerase lpL
50pL
This was incubated at room temperature for at least 1 hour. The incorporation of radiolabel 
into the probe was calculated by aliquotting 1 pL of the reaction mix onto a small filter disc 
and counting the disintegrations per minute (d.p.m.) in a scintillation counter (TRI-CARB 
2100TR, Canberra Packard). Unincorporated label was removed by washing the filter disc 
five times in Na2HP04 (0.5 mol/L), twice in dH20  and twice in 100% ethanol. The filter 
disc was air dried and the d.p.m. counted again. The post-wash d.p.m. expressed as a 
percentage of the pre-wash d.p.m. was taken as a measure of incorporation. 75-85% 
incorporation was usually achieved.
3.4.3.5 Hybridising membrane with radiolabelled probes
When the membrane had been pre-hybridising for at least 4 hours (section 3.4.3.3), the pre­
hybridisation solution was discarded and replaced with the remaining 20 mL of hybridisation 
solution at 42°C. The radiolabelled probe was denatured at 100°C for 5 minutes, cooled on 
ice for 5 minutes, then added to the hybridisation solution. The membrane was hybridised at 
42°C overnight.
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The following day, non-hybridised probe was removed by washing the membrane as 
follows :-
2X SSPE/0.1% SDS, room temperature, 10 minutes
2X SSPE/0.1% SDS, room temperature, 10 minutes
2X SSPE/0.1% SDS, 65°C, 15 minutes
2X SSPE/0.1% SDS, 65°C, 15 minutes
IX SSPE/0.1% SDS, 65°C, 10 minutes
IX SSPE/0.1% SDS, 65°C, 10 minutes
IX SSPE/0.1% SDS, 65°C, 30 minutes
IX SSPE/0.1% SDS, 65°C, 30 minutes
The membrane was wrapped in 'cling-film' and exposed to film (Hyperfilm-MP) in a 
Hypercassette (Amersham International pic, Amersham, UK) with two intensifying screens 
overnight at -70°C. The film was developed in a KODAK X-OMAT ME-3 Processor. The 
membrane was exposed to film for a further 2-7 days depending on the darkness of the 
bands on the autorad.
3.4.3.6 Quantification of band density
A scanned image of the autorad was created by a densitometer (Model GS 670, Bio-Rad 
Laboratories Ltd, Hemel Hempstead, UK) and the density of each band measured using 
Molecular Analyst 2.1 software (Bio-Rad Laboratories Ltd, Hemel Hempstead, UK). A 
background density was measured above each band and subtracted from the corresponding 
band density to produce a net density for each band corrected for any background changes
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across the autorad. The net density of each band was expressed as a ratio to GAPDH for 
that lane to correct for unequal loading of the lanes.
3.5 Effect of age on endothelial function
In addition to the 4 groups of rats studied at 4 months of age in 3.2.2, basal NO availability 
was also assessed in a further 8 groups of rats at 6 and 12 months of age to give a total of 
12 groups as follows:-
WKY females 4 months (n=15) 
6 months (n=7)
WKY males 4 months (n=19) 
6 months (n=8)
12 months (n=l 1) 12 months (n=7)
SHRSP females 4 months (n=16) 
6 months (n=l 1) 
12 months (n=9)
SHRSP males 4 months (n=16) 
6 months (n=7) 
12 months (n=7)
The rats were killed by halothane overdose. The thoracic aortas were carefully removed, 
cleaned of adipose tissue and cut into 2-3 mm rings. The rings were suspended under lg 
tension in individual 10 mL muscle baths as described in section 3.2. Basal NO availability 
was assessed by observing the contraction in response to L-NAME as described in section
3.2.2.
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3.6 The effect of 17p-oestradiol in vivo
3.6.1 17P-oestradiol administration
Five female WKY rats at 12 months of age were treated with 17(3-oestradiol, 20pg in 
200pL arachis oil per day intraperitoneally for 14 days. A further group of 5 female WKY 
rats at 12 months of age were given arachis oil, 200pL per day, intraperitoneally for 14 days 
as controls.
3.6.2 Isometric tension recording
The rats were killed by halothane overdose. The thoracic aortas were carefully removed 
from 17p-oestradiol treated and control rats, cleaned of adipose tissue and cut in half. One 
half of each aorta was cut into 2-3 mm rings and the other half snap frozen in liquid N2 for 
RNA analysis (see section 3.6.3). The rings were suspended under lg  tension in individual 
10 mL muscle baths as described in section 3.2. After a 1 hour equilibration period, 
stimulated NO release was assessed by obtaining a concentration response curve for 
carbachol (10'8 - 105 mol/L) as described in section 3.2.1. Basal NO availability was then 
assessed by observing the contraction in response to L-NAME (100 mmol/L) as described 
in section 3.2.2.
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3.6.3 The effect of 17P-oestradiol in vivo on mRNA expression
3.6.3.1 Isolation of total aortic RNA
RNA was extracted from the frozen half aortas by RNAzol B as described in section
3.4.2.1.
3.6.3.2 Endothelial nitric oxide synthase mRNA quantification
Endothelial NOS mRNA was quantified in aortas from 17(3-oestradiol treated and control 
rats by RT-PCR as described in sections 3.4.2.2-3.
3.7 Statistical analysis
3.7.1 Phenylephrine, carbachol, sodium nitroprusside and L-NAME
The concentration response curves to PE, carbachol and SNP were characterised by the 
maximum effect (Emax) and the concentration which produced 50% maximum effect (EC50) 
These parameters were calculated from the raw data for each pharmacological intervention 
for each aorta using Microsoft Excel®. The response to L-NAME for each aorta was taken 
as the maximal contraction expressed as a percentage of the contraction to EC20 of PE.
The means and standard errors of the mean (SEM) for each group were calculated and the 
following comparisons made by two way ANOVA followed by unpaired two-tailed t-tests 
with Bonferroni correction for three comparisons: all SHRSP (males and females) v all
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WKY (males and females), WKY females v WKY males, SHRSP females v SHRSP males. 
Therefore, p<0.017 was considered to be statistically significant.
3.7.2 Endothelial NOS activity
The mean NOS III activity for each group (±SEM) was calculated and groups compared as 
above by two way ANOVA followed by unpaired two-tailed t-tests with Bonferroni 
correction for three comparisons. Again p<0.017 was considered to be statistically 
significant.
3.7.3 DETCA and SOD
As one might expect from the doses used, the effect of DETCA or exogenous SOD was 
invariably statistically significant as determined by a paired t-test p<0.05 (before v after 
DETCA; with v without SOD). However, of greater interest was whether or not DETCA 
and/or SOD had a greater effect in one group compared to another. Therefore, the 
percentage change in Emax and EC50 after DETCA or in the presence of SOD was 
calculated for each ring as follows:
The mean percentage change (+SEM) was calculated for each group and groups compared 
by two way ANOVA followed by unpaired t-tests as above, with p<0.017 for the difference 
in percentage change being considered statistically significant.
a f t e r  -  p x 100
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3.7.4 Endothelial NOS and SOD mRNA
The mean (+SEM) quantity of Nos3 message and SOD/GAPDH ratio was calculated for 
each group and groups compared by two way ANOVA followed by unpaired t-tests as 
above, with p<0.017 being considered statistically significant.
3.7.5 17P-oestradiol
The effect of 17p-oestradiol was analysed by comparing the mean (±SEM) response to L- 
NAME for the treated group with the control group using an unpaired two-tailed t-test. A p 
value <0.05 was considered statistically significant. The mean (±SEM) carbachol Emax and 
EC5o for each group were compared in the same way. The mean (±SEM) quantity of Nos3 
message was calculated for each group and groups compared by an unpaired t-test. The 
mean for the control group at one year was also compared to the mean for WKY females at 
4 months of age. Therefore, with Bonferroni correction for double comparisons, p<0.025 
was considered statistically significant.
120
4 Results
4.1 Systolic blood pressure and body weight
Four groups of rats were studied at 16 weeks of age. Systolic blood pressure in the week 
prior to sacrifice and body weight on the day of sacrifice were measured in rats to be 
sacrificed for isometric tension recording and NOS III enzyme activity. Mean systolic blood 
pressure, measured by tail cuff plethysmography, and mean body weight at sacrifice for each 
of the four groups are shown in Table 3 and Figure 11.
Systolic blood pressure (mmHg ± SEM) was significantly higher in SHRSP (172 ± 4.4, n = 
67) compared to WKY (128 ± 2.0, n = 69) (95% Cl: 34.2, 53.4; p<0.0001). Within the 
SHRSP strain males had a significantly higher systolic blood pressure (196 ± 5.5, n = 33) 
than females (148 ± 3.7, n = 34) (95% Cl: 34.8, 61.3; p<0.0001). However, within the 
WKY strain there was no significant difference in systolic blood pressure between males 
(130 ± 1.5, n = 37) and females (125 ± 4.0, n = 32) (95% Cl: -3.4, 14.0; p=0.22).
Body weight (g + SEM) was significantly higher in WKY (265 ± 8.5, n = 69) compared to 
SHRSP (215 ± 5.9, n = 67) (95% Cl: 29.4, 70.4; p<0.0001) and in WKY males (318 ± 8.8, 
n = 37) compared to WKY females (205 ± 4.6, n = 32) (95% Cl: 93.5, 133.2; p<0.0001). 
Similarly, body weight was significantly higher in SHRSP males (255 ± 6.6, n = 33) 
compared to SHRSP females (176 ± 2.2, n = 34) (95% Cl: 64.3, 92.5; p<0.0001).
These data confirm the increased blood pressure in SHRSP compared to WKY and in males 
compared to females in SHRSP. However, in the this study there is only a small difference,
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which is not statistically significant, between WKY males and WKY females. The lack of a 
gender difference in blood pressure within the WKY strain may be related to the lack of 
gender differences in some of the other parameters described later.
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Figure 11 - Mean systolic blood pressure and body weight, a) Systolic blood pressure 
(mmHg) was measured by tail cuff plethysmography in the week prior to sacrifice, b) Body 
weight (g) was measured on bench top scales immediately prior to sacrifice. The mean (± 
SEM) was calculated for each of the four groups: WKY females (F) (n = 32), WKY males 
(M) (n = 37), SHRSP females (n = 34) and SHRSP males (n = 33). 
p<0.017 is statistically significant.
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4.2 Isometric tension recording
Fifty-seven rats were studied at 16 weeks of age in four groups: WKY females (n = 12), 
WKY males (n = 17), SHRSP females (n = 14) and SHRSP males (n = 14). Thoracic aortas 
were removed, cut into 2-3 mm rings, suspended in standard 10 mL organ baths and 
equilibrated under lg resting tension.
4.2.1 Effect of L-NAME
A concentration response curve to PE (10'8 - 10'5 mol/L) was obtained. When L-NAME 
(10'4 mol/L) was added to the rings at the EC2o of PE, the resultant contraction, relative to 
the initial PE EC2o contraction (% of PE ± SEM), was significantly greater in WKY (379 ± 
31, n = 29) compared to SHRSP (282 ± 23, n = 28) (95% Cl: 20, 174; p=0.015). Further, 
the contraction in rings from WKY females (519 ± 37, n = 12) was significantly greater than 
WKY males (280 ± 26, n = 17) (95% Cl: 143, 333; p=0.00004). Similarly, the contraction 
in rings from SHRSP females (356+29, n = 14) was significantly greater than SHRSP males 
(209 ± 24, n = 14) (95% Cl: 70, 224; p=0.0006) (Figure 12).
These data suggest that basal NO availability is greater in WKY compared to SHRSP and in 
females compared to males in both strains.
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Figure 12 - Basal NO availability. The effect of adding N°-nitro-L-arginine methyl ester (L- 
N AME, 1 O'4 mol/L) after the dose of phenylepherine (PE) producing 20% of maximum 
contraction (EC2o). The resultant increase in tension for each ring is expressed as a 
percentage of the PE EC2o and the mean increase (± SEM) for each group calculated. WKY 
females, n = 12. WKY males, n = 17. SHRSP females, n = 14. SHRSP males, n = 14. 
p<0.017 is statistically significant.
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4.2.2 Effect of carbachol
After the concentration response curve to PE (10'8 - 10'5 mol/L) was obtained, the rings 
were pre-contracted to the EC5o of PE and concentration response curves obtained for 
carbachol (10'8 - 10'5 mol/L). Figure 13 shows the concentration response curves for all 
WKY v all SHRSP (3a), WKY females v WKY males (3b), and SHRSP females v SHRSP
| males (3c). The Emax for carbachol relaxation (% of PE ± SEM) of WKY rings (94.4 ± 1.6,
i
I n = 29) was significantly greater than that of SHRSP rings (86.3 ± 2.7, n = 27) (95% Cl:
1.7, 14.4; p=0.015). There was no significant difference in the mean maximum relaxation
t
|
I when WKY females were compared to WKY males or when SHRSP females were
i
| compared to SHRSP males (Table 4).
| There was no significant difference in the log transformed EC5o for carbachol relaxation (log
iI
| mol/L ± SEM) when the mean concentration response curve for WKY rings was compared
| to that of SHRSP rings, or when WKY females were compared to WKY males (Table 4).
However, within the SHRSP strain, there was a significant difference in the mean log 
transformed EC50 when females (-0.39 ± 0.14, n = 14) were compared to males (0.29 ± 
0.15, n = 13) (95% Cl: -1.1, -0.2; p=0.003) (Figure 13c, inset).
These data confirm that a functioning endothelium is present in each case. They also suggest 
that stimulated NO availability is greater in WKY compared to SHRSP and in females 
compared to males within the SHRSP strain. However, there was no significant difference 
in either the Emax or EC50 when the carbachol concentration response curve of WKY 
females was compared to WKY males, which may be related to the lack of a blood pressure 
difference between these two groups.
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4.2.3 Effect of sodium nitroprusside
After the concentration response curve to PE (10'8 - 105 mol/L) was obtained, the rings 
were pre-contracted to the EC50 of PE and concentration response curves obtained for 
sodium nitroprusside (SNP, 10'8 - 10"5 mol/L). As shown in Figure 14, there was no 
significant difference in the mean Emax for SNP relaxation (% of PE+SEM) when WKY 
rings (100 ± 1.7, n = 11) were compared to SHRSP rings (100 ± 1.9, n = 9) (95% Cl: -5.7, 
5.4; p=0.95). Similarly when WKY females (99.3 ± 3.4, n = 5) were compared to WKY 
males (100 ± 1.3, n = 6) (95% Cl: -9.6, 6.6; p=0.69) there was no significant difference or 
when SHRSP females (100 ± 0.5, n = 4) were compared to SHRSP males (100±4 .1 ,n  =
5) (95% Cl: -9.6, 10.6; p=0.91).
There was no significant difference in the mean log transformed EC5o for SNP relaxation 
(log mol/L ± SEM) when WKY rings (1.59 ± 0.45, n = 11) were compared to SHRSP rings 
(2.40 ± 0.54, n = 9) (95% Cl: -2.3, 0.7; p=0.27); when WKY females (1.17 ± 0.8, n = 5) 
were compared to WKY males (1.93 ± 0.6, n = 6) (95% Cl: -3.0, 1.5; p=0.44) or when 
SHRSP females (2.72 ± 0.3, n = 4) were compared to SHRSP males (2.14 ± 1.0, n = 5) 
(95% Cl: -2.3, 3.5; p=0.60).
These data suggest that there is no significant difference in the sensitivity of the vascular 
smooth muscle to NO between WKY and SHRSP, or between males and females in either 
strain.
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Figure 14 - Endothelium-independent relaxation. The concentration response curves to 
sodium nitroprusside (SNP, 10‘8 - 10'5 mol/L) for each group after the dose of
phenylepherine (PE) producing 50% of maximum contraction (EC5o) expressed as a percent
of the PE EC5o (± SEM). WKY females, n = 11. WKY males, n = 9. SHRSP females, n = 4.
SHRSP males, n = 5.
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4.2.4 Effect of DETCA on relaxation to carbachol
Carbachol concentration response curves (10'8 - 10'5 mol/L) were obtained for each ring 
pre- and post-incubation with the SOD inhibitor DETCA (10 mmol/L) or exogenous SOD 
(45U/mL). The mean changes in Emax and EC50 (± SEM) between pre- and post-incubation 
(expressed as a percentage of pre-incubation) were calculated for each group: WKY 
females (n = 7), WKY males ( n = 8), SHRSP females (n = 4), and SHRSP males (n = 6).
Figure 15 shows that DETCA attenuated the relaxation to carbachol in all WKY and all 
SHRSP. As shown in Figure 16a, DETCA attenuated the relaxation (% change in Emax ± 
SEM) to carbachol of SHRSP (59 ± 5.1, n = 10) (Figure 15b) significantly more than WKY 
(29 ± 6.0, n = 15) (95% Cl: 14.3, 47.0; p=0.0008) (Figure 15a). Figure 16a also shows that 
the % change in Emax by DETCA on rings from WKY females did not differ significantly 
from WKY males. Similarly, the attenuation in rings from SHRSP females did not differ 
significantly from SHRSP males after DETCA pre-incubation.
Figure 16c shows that DETCA. pre-incubation tended to increase the EC50 (xlO'7 mol/L) for 
carbachol relaxation. However, there was no significant difference in this increase (% 
change in EC50 ± SEM) between strains or between genders within each strain.
4.2.5 Effect of exogenous SOD on relaxation to carbachol
Figure 16b shows the effect of co-administration of exogenous SOD to the rings on their 
response to carbachol. Exogenous SOD tended to improve the relaxation to carbachol, 
especially in SHRSP. However, the improvement (% change in Emax ± SEM) did not differ 
significantly between strains or between genders within each strain.
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Figure 16d shows that exogenous SOD tended to reduce the EC5o (xlO'7 mol/L) of the 
carbachol response curves. However, when the % change in EC5o was compared between 
strains or between genders within each strain, there was no significant difference.
4.2.6 Effect of DETCA on contraction to PE
Phenylephrine concentration response curves (IO 8 - 10‘5 mol/L) were obtained for each ring 
pre- and post-incubation with the SOD inhibitor DETCA (10 mmol/L) or exogenous SOD 
(45U/mL). The mean changes in Emax and EC50 (± SEM) between pre- and post-incubation 
(expressed as a percentage of pre-incubation) were calculated for each group: WKY 
females (n = 8), WKY males ( n = 8), SHRSP females (n = 6), and SHRSP males (n = 9).
The effect of pre-incubation of the rings with DETCA on the contraction to PE is shown in 
Figure 17. Pre-incubating the rings with DETCA increased the mean Emax and EC50 to PE 
(relative to KC1) in all groups. However, there was no significant difference in the % change 
when strains or genders within each strain were compared (Figures 17a and 17c).
4.2.7 Effect of exogenous SOD on contraction to PE
Figure 17 also shows the effect of co-administration of exogenous SOD to the rings on their 
response to PE. Exogenous SOD reduced the maximum contraction to PE and increased 
the EC50 in all groups. This effect (% change ± SEM) did not differ significantly between 
strains or between genders within each strain (Figures 17b and 17d).
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Figure 16 - Effect of DETCA and SOD on carbachol. Carbachol concentration response 
curves (10'8 - 10~5 mol/L) were obtained for each ring pre- and post-incubation with 
DETCA (10 mmol/L) or SOD (45U/mL). The mean changes in Emax and EC50 (± SEM) 
between pre- and post-incubation (expressed as a percentage of pre-incubation) were 
calculated for each group.
a) Emax pre- and post-DETCA. b) Emax pre- and post-SOD. c) EC50 pre- and post-DETCA. 
d) EC50 pre- and post-SOD. WKY females (F) n = 7, WKY males (M) n = 8 , SHRSP 
females n = 4, SHRSP males n = 6 . p<0.017 is statistically significant.
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Figure 17 - Effect of DETCA and SOD on phenylephrine (PE). PE concentration response 
curves (10'8 - 10'5 mol/L) were obtained for each ring pre- and post-incubation with 
DETCA (10 mmol/L) or SOD (45U/mL). The mean changes in Emax and EC50 (± SEM) 
between pre- and post-incubation (expressed as a percentage of pre-incubation) were 
calculated for each group.
a) Emax pre- and post-DETCA. b) Emax pre- and post-SOD. c) EC50 pre- and post-DETCA. 
d) EC50 pre- and post-SOD. WKY females (F) n = 8, WKY males (M) n = 8, SHRSP 
females n = 6, SHRSP males n = 9. p<0.017 is statistically significant.
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The only significant effect of these crude manipulations of the 0 2"/SOD system was that 
DETCA attenuated the relaxation to carbachol in SHRSP significantly more than WKY.
This may suggest that SOD is more active in SHRSP, or that when SOD is inhibited by 
DETCA, 0 2' accumulates faster in SHRSP, or perhaps a combination of both. The 
manipulations of the 0 2 /SOD system produced the predicted effects, but significant strain 
or gender differences may have been masked by the large variation in the measurements.
4.3 NOS HI activity
To investigate the possibility that the strain and gender differences in NO availability are due 
to differences in NO production, NOS III activity was measured in endothelial cells 
removed from aortas of the same four groups of animals at 16 weeks of age: WKY females 
(n -= 20), WKY males (n = 15), SHRSP females (n = 20) and SHRSP males (n = 20). NOS 
III activity was quantified by the radiolabelled L-arginine to L-citrulline assay and corrected 
for the amount of protein in each assay.
NOS III activity (pmol/min/mg protein ± SEM) was significantly greater in the aortas from 
SHRSP (24.6 ± 3.1, n = 40) compared to WKY (14.6 ± 1.3, n = 35) (95% Cl: 2.3, 17.6; 
p=0.016). NOS III activity tended to be greater in WKY males compared to WKY females 
and similarly in SHRSP males compared to SHRSP females, but these differences did not 
achieve statistical significance (Figure 18).
These data suggest that reduced NO availability in SHRSP compared to WKY is not due to 
reduced NOS III activity, which is significantly higher in SHRSP. The gender differences in 
NO availability are also unlikely to be due to differences in NOS III activity, which tends to 
be higher in males compared to females.
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Figure 18 - Activity of endothelial nitric oxide synthase (NOS III) (pmol citrulline/min/mg 
protein ± SEM) in endothelial cells obtained from aortas of WKY and SHRSP males and 
females (see methods). WKY females, n = 20. WKY males, n = 15. SHRSP females, n = 20. 
SHRSP males, n = 20. p<0.017 is statistically significant.
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4.4 Nos3 mRNA expression
To determine if strain and/or gender differences in NOS III activity were related to gene 
expression, Nos3 mRNA was quantified in total RNA isolated from thoracic aortas. Due to 
the low abundance of Nos3 mRNA in rat tissue, northern blotting was not sensitive enough 
to quantify the gene expression, even when lOpg of poly (A) mRNA was used. Instead a 
reverse transcription-polymerase chain reaction (RT-PCR) system was developed to 
quantify Nos3 mRNA levels.
As shown in Figure 19, Nos3 mRNA expression (fg/lOOng total aortic RNA ± SEM) is 
greater in SHRSP (302 + 69, n = 6) compared to WKY (71.7 ± 15, n = 6) (95% Cl: 50, 
412; p=0.02), which just fails to reach statistical significance when corrected for triple 
comparisons. Although there is a tendency for Nos3 mRNA expression to be greater in 
males compared to females, in neither strain did this achieve statistical significance. WKY 
males (95.0 ± 22, n = 3), WKY females (48.3 ± 5.2, n = 3) (95% Cl: -144, 51; p= 0.18). 
SHRSP males (435 ± 76, n = 3), SHRSP females (170 ± 17, n = 3) (95% Cl: -600, 68;
p=0.08).
The trend in these data between groups matches that of NOS III activity (Figure 18) 
providing further evidence that strain and gender differences in NO availability are not due 
to differences in NO production. These data would also suggest that NOS III activity is 
largely related to Nos3 gene expression without much in the way of post-transcriptional or 
post-translational regulation.
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Figure 19 - Endothelial nitric oxide synthase (Nos3) mRNA expression (fg/lOOng total 
RNA ± SEM) measured by reverse transcription-polymerase chain reaction in total aortic 
RNA from WKY and SHRSP males and females. n=3 in each group. p<0.017 is statistically 
significant.
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4.5 SOD mRNA expression
As the DETCA data suggested that there may be differences in SOD activity between 
SHRSP and WKY, SOD gene expression was quantified as an indirect measure of SOD 
activity. SOD mRNA is abundant enough in the rat aorta to be quantified by northern 
blotting. cDNA probes were available for rat manganese SOD (Mn SOD), rat copper/zinc 
SOD (CuZn SOD) and murine house-keeping gene, glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH), which was used as an internal standard to correct for slight 
variations in total RNA in each sample. Figure 20 shows representative northern blots of a 
membrane hybridised with the above probes. Bands on the autoradiographs corresponding 
to MnSOD and CuZn SOD were quantified by densitometry and expressed as a ratio to 
GAPDH.
4.5.1 Manganese SOD (Sod2) mRNA expression
As shown in Figure 21b, Sod2 mRNA expression (ratio to GAPDH ± SEM) is significantly 
greater in SHRSP males (0.68 ± 0.05, n = 3) compared to WKY males (0.32 ± 0.01, n = 4) 
(95% Cl: 0.15 0.57; p=0.02). There was no significant difference in Sod2 mRNA expression 
between SHRSP females (0.38 ± 0.12, n = 4) and WKY females (0.44 ± 0.12, n = 3) (95% 
Cl: -0.67, 0.78; p=0.82) (Figure 21a).
4.5.2 Copper/Zinc SOD (Sodl) mRNA expression
Figures 21c and 2 Id show that there is no significant difference in Sodl mRNA expression 
(ratio to GAPDH ± SEM) between WKY females (0.46 ± 0.14, n = 4) and SHRSP females
141
(0.74 ± 0.05, n = 4) (95% Cl: -0.74, 0.18; p=0.14) or between WKY males (2.04 ± 0.59, n 
= 4) and SHRSP males (1.12 ± 0.08, n = 3) (95% Cl: -0.98, 2.81; p=0.22).
The fact that Sod2 mRNA expression is significantly greater in SHRSP males compared to 
WKY males provides some evidence that MnSOD activity may be greater in the former 
group, although this was not directly measured. This would explain the greater effect of the 
SOD inhibitor DETCA on SHRSP carbachol relaxation compared to WKY reported in 
section 4.2.4. Sod2 gene expression may be up-regulated in SHRSP males to compensate 
for increased oxidative stress or some other blood pressure raising effect.
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Figure 21 - Expression of superoxide dismutase (SOD) mRNA. SOD mRNA was 
quantified by northern blotting and expressed as a ratio to glyceraldehyde phosphate 
dehydrogenase (GAPDH). a) Manganese SOD in females (WKY n = 3, SHRSP n = 4). 
b) Manganese SOD in males (WKY n = 4, SHRSP n = 3). c) Copper/Zinc SOD in females 
(WKY n = 4, SHRSP n = 4). d) Copper/Zinc SOD in males (WKY n = 4, SHRSP n = 3). 
p<0.05 is statistically significant.
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4.6 Effect of age on L-NAME response
To investigate changes in endothelial function with advancing age, changes in isometric 
tension were used to quantify basal NO in four groups of rats at 4 months of age (WKY 
females n = 15, WKY males n = 19, SHRSP females n = 16 and SHRSP males n = 16), 6 
months of age (WKY females n = 7, WKY males n = 8, SHRSP females n = 11 and SHRSP 
males n = 7), and 12 months of age (WKY females n = 11, WKY males n = 7, SHRSP 
females n = 8 and SHRSP males n = 7). As before, a PE concentration response curve was 
obtained (10'8 - 1 0 5 mol/L), then rings were pre-contracted to the PE EC2o and L-NAME 
added to a final bath concentration of 10 4 mol/L.
As shown in Figures 22a and 22b, there is progressive reduction in the response to L- 
NAME from 4 months to 12 months in WKY females and SHRSP females respectively. In 
the WKY females the response to L-NAME (% of PE ± SEM) is significantly lower at 12 
months (296 ± 30, n = 11) than 4 months (523 ± 51, n = 15) (95% Cl: 104, 349; 
p=0.0009). In the SHRSP females the response to L-NAME is also significantly lower at 12 
months (220 ± 28, n = 8) compared to 4 months (341 ± 26, n = 16) (95% Cl: 41, 201; 
p=0.0054).
In the males there is a tendency for the response to L-NAME to increase with age between 
4 months and 12 months (Figures 22c and 22d). However, in WKY males there is no 
significant difference in the response to L-NAME (% of PE ± SEM) at 12 months (408 ± 
64, n = 7) compared to 4 months (269 ± 25, n = 19) (95% Cl: -300, 22; p=0.081). The 
same is true of SHRSP males, where there is no significant difference in L-NAME response
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at 12 months (270 ± 26, n = 7)) compared to 4 months (227 ± 24, n -  16) (95% Cl: -118, 
33; p=0.25).
These data suggest that basal NO availability declines with age in females of both strains, 
but not in males of either strain, which if anything tends to increase. As before, this could be 
due to reduced NO production in older females, or increased scavenging by say 0 2\  or a 
combination of the two.
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Figure 22 - Effect of age on basal NO. L-NAME, 10"4 mol/L was added at the PE EC20. 
The resultant increase in tension for each ring is expressed as a percentage of the PE EC20 
and the mean increase (± SEM) calculated for each group at 4, 6 and 12 months of age. 
a) WKY females (4 months n = 15, 6 months n = 7, 12 months n = 11). b) SHRSP females 
(4 months n = 16, 6 months n = 11, 12 months n = 8). c) WKY males (4 months n = 19, 6 
months n = 8, 12 months n = 7). d) SHRSP males (4 months n = 16, 6 months n = 7, 12 
months n = 7). p<0.017 is statistically significant.
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4.7 Effect of 17p-oestradiol
Although not measured in this study due to technical difficulties, circulating 17p-oestradiol 
is likely to be reduced in the 12 month old females compared to the 4 month old females. 
This, together with the absence of an age related decline in male animals, may lead one to 
hypothesise the level of circulating 17P-oestradiol determines NO availability in the 
vasculature.
4.7.1 Effect of 17P-oestradiol on basal NO
To test this hypothesis, changes in isometric tension in response to L-NAME (10'4 mol/L) 
were used to quantify basal NO in aortas removed from one year old WKY females (n = 5) 
treated with intraperitoneal 17P-oestradiol (20pg per day) for 14 days compared to age 
matched WKY females (n = 5) treated with intraperitoneal vehicle for the same time period.
The response to L-NAME (% of PE ± SEM) was greater in the group treated with 17p- 
oestradiol (207 ± 25, n = 5) compared to the group treated with vehicle (146 ± 16, n = 5). 
This difference just achieves statistical significance (95% Cl: 0, 128; p=0.05) (Figure 23a).
4.7.2 Effect of 17P-oestradiol on carbachol stimulated NO
Concentration response curves to carbachol were used to measure stimulated NO in aortic 
rings from the same 17P-oestradiol or vehicle treated WKY females.
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As shown in Figure 23b, there was no significant difference in the carbachol Emax (% of PE 
± SEM) in rings from 17(3-oestradiol treated WKY females (80.9 ± 3.9, n = 5) compared to 
vehicle treated age matched WKY females (84.4 + 2.8, n = 5) (95% Cl: -13.4, 6.4; p=0.48). 
Similarly, there was no significant difference in the EC50 (xlO'7 mol/L ± SEM) between 17(3- 
oestradiol treated WKY females (1.22 ± 0.29, n = 5) and vehicle treated age matched WKY 
females (1.01 ± 0.13, n = 5) (95% Cl: -0.45, 0.86; p=0.51).
These data provide further evidence that 17P-oestradiol can increase basal NO availability 
with apparently having little effect on stimulated NO availability. It is not possible from 
these data to tell whether this is due to increased NO production, reduced NO scavenging, 
or both. This could be determined by measuring NOS III activity in both groups of animals. 
Quantifying Nos3 gene expression in both groups may give some indication of NOS III 
enzyme activity.
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Figure 23 - Effect of 17P-oestradiol on basal and stimulated NO. 17p-oestradiol (E2, n = 5) 
or vehicle (V, n = 5) were administered subcutaneously to 1 year old WKY females for 2 
weeks, a) Basal NO availability was assessed in rings of thoracic aorta by measuring the 
increase in tension after addition of L-NAME (1CT4 mol/L) after the PE EC20. b) Stimulated 
NO was assessed by the concentration response curve for carbachol (10‘8 to 10'5 mol/L). 
p<0.05 is statistically significant.
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4.8 Effect of age and 170-oestradiol on Nos3 mRNA expression
As before, RT-PCR was used to quantify Nos3 mRNA in total aortic RNA isolated from the 
same vehicle treated WKY females (n = 4) and 17p-oestradiol treated WKY females (n = 4) 
at one year of age. Comparisons could be made to Nos3 mRNA levels quantified in aortas 
from 4 month old WKY females (n = 3) reported in section 4.4.
Nos3 mRNA expression (fg/lOOng total RNA ± SEM) was significantly greater in aortas 
from WKY females at 12 months of age (487 ± 75, n = 4) compared to aortas from WKY 
females at 4 months of age (48.3 ± 5.2, n = 3) (95% Cl: 200, 677; p=0.01). Treatment of 
the WKY females at 12 months of age with 17P-oestradiol for two weeks did not 
significantly affect Nos3 mRNA expression (342 ± 101, n = 4) compared to vehicle treated 
age matched WKY females (487 ± 75, n = 4) (95% Cl: -469, 178; p=0.30) (Figure 24).
These data suggest that the reduced basal NO availability in females at 12 months of age 
compared to 4 months of age is not due to reduced NO production, as Nos3 gene 
expression is increased 10-fold in aortas from the older females. Increased NO production 
does not appear to be responsible for the increased basal NO availability in 17p-oestradiol 
treated one year old females as there is no significant change in Nos3 gene expression in 
17P-oestradiol treated animals compared to vehicle treated controls. The decline in basal 
NO availability with age is more likely to be related to increased scavenging and the 
increased basal NO availability when the older females are treated with 17P-oestradiol is 
likely to be due to a reduction in this scavenging.
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Figure 24 - Effect of age and 17p-oestradiol on Nos3 expression. Nos3 mRNA expression 
was quantified (fg/lOOng total RNA ± SEM) using reverse transcription-polymerase chain 
reaction on total RNA extracted from aortas of WKY females at 4 months of age (n = 3), 
WKY females at 12 months of age treated with vehicle (V, n = 4) and WKY females at 12 
months of age treated with 17(3-oestradiol (E2, n = 4). p<0.025 is statistically significant.
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5 Discussion
5.1 NO availability
These studies demonstrate reduced basal NO availability in aortas of SHRSP compared to 
WKY at 16 weeks of age by examining the response of aortic rings to the NOS inhibitor L- 
NAME in vitro. This is in accordance with Malinski et al282 who found stimulated NO 
release in response to bradykinin in cultured aortic endothelial cells isolated from SHRSP to 
be significantly reduced compared to WKY. In addition, these studies demonstrate reduced 
basal NO availability in males compared to females in both strains. Hayashi et al have 
previously shown reduced basal NO ‘release’ in aortic rings from male rabbits compared to 
females233, and others have demonstrated similar gender differences in myogenic tone in rats 
as an alternative measure of basal NO availability231,232. In addition, Kauser and Rubanyi 
used a bioassay system to demonstrate reduced basal NO ‘release’ in aortas from male rats 
compared to females234.
Stimulated NO release in response to the ACh analogue carbachol was also examined in 
aortic rings in vitro. A strain difference in carbachol Emax, but not EC5o was found as 
SHRSP rings relaxed to a significantly lesser extent than WKY rings. This has been 
demonstrated previously by some groups, but not others (see ref. 113 for review). A gender 
difference was found within the SHRSP strain. Whereas there was no difference in the Emax, 
males were less sensitive to carbachol having a significantly greater carbachol EC50 than 
females. Such a gender difference in stimulated NO was first described by Kauser and 
Rubanyi, who demonstrated significantly greater ACh induced relaxation in aortas from 
female SHR compared to males230. Despite the gender difference in basal NO in WKY, no 
such gender difference was detected in the carbachol Emax or EC50 within the WKY strain.
This suggests a different mechanism for regulation of basal and stimulated NO availability. 
Such a difference has been reported by Kauser and Rubanyi234 and Mian and Martin116. The 
latter authors speculate that 0 2' may be responsible for this difference by scavenging the 
small amounts of basal NO, but being unable to scavenge the relatively large amounts of 
stimulated NO116. The presence of a gender effect within the SHRSP strain, but not within 
the WKY strain is contrary to Kauser and Rubanyi who found a gender difference in both 
SHR and WKY230, but may be related to the large gender difference in blood pressure in 
SHRSP, while WKY show only a small gender difference.
The question of whether the endothelial dysfunction is primary or secondary to hypertension 
is frequently raised. This question is impossible to answer, but the fact that endothelial 
dysfunction is found in secondary forms of hypertension127, and can be improved by 
treatment of hypertension with captopril283 or other antihypertensive agents284, would 
suggest that, at least in some cases, it is a result of hypertension rather than a cause. 
However, this may not always be the case as Taddei et al have recently shown a defective 
L-arginine-nitric oxide pathway in normotensive offspring of essential hypertensive patients 
compared to matched normotensive offspring of normotensive parents285. The authors 
conclude from this that endothelial dysfunction is primary and pre-dates the onset of 
hypertension. The offspring in this study are in their 20’s, so it would be interesting to 
determine which subjects develop hypertension in later life.
No strain or gender differences were detected in the response of aortic rings to SNP in 
, suggesting that the responsiveness of the vascular smooth muscle to NO is not 
altered. The absence of a gender difference in the response of aortic rings to SNP has been 
described before230. One would not expect differences in luminal or endothelial 0 2" to affect
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the response to SNP, which is an endothelium independent vasodilator and does not give up 
its NO until it reaches the vascular smooth muscle273.
In summary, there have been several reports of blood pressure or gender differences in basal 
or stimulated NO, but there are no previous reports describing the effects of blood pressure 
and gender on basal and stimulated nitric oxide availability in the same model. These results 
examine only the functional levels of basal and stimulated NO that are available to the 
underlying vascular smooth muscle. The reduced availability of basal and stimulated NO in 
SHRSP may be due to reduced production, increased scavenging or both. Therefore, 
subsequent experiments were designed to address this issue.
5.2 NO production
NOS III activity was measured directly by the L-arginine/L-citrulline method in endothelial 
cells isolated from the aortas of SHRSP and WKY rats. NOS III activity was increased in 
SHRSP compared to WKY, suggesting NO production is increased rather than decreased in 
the hypertensive animals. This is mirrored in Nos3 gene expression, quantified by reverse 
transcription-polymerase chain reaction (RT-PCR), where Nos3 mRNA was more abundant 
in the aortas of SHRSP compared to WKY. The difference in Nos3 gene expression just 
fails to achieve statistical significance when corrected for triple comparisons, possibly 
because of the small numbers studied. The increased NOS III activity (and Nos3 expression) 
may represent a compensatory mechanism to some other blood pressure increasing 
factor(s). Schini et al also found impaired endothelium-dependent vasorelaxation in aortas 
of rats with genetic hypertension which was not due to reduced NOS III activity286. It 
therefore seems likely that the reduced NO availability in SHRSP is not due to reduced NO 
production, but instead due to increased scavenging.
In addition, a small reduction in NOS III activity was demonstrated in females compared to 
males of both strains. Although this gender difference does not reach statistical significance, 
it has not been demonstrated before. Again the pattern of NOS III activity is mirrored in the 
levels of Nos3 gene expression. The gender differences in Nos3 expression, while large in 
SHRSP, do not reach statistical significance again possibly due to the very small numbers 
involved. It would therefore also appear that reduced NO availability in males compared to 
females is not due to reduced NO production, which if anything is greater in males.
The reduced NO availability in males and SHRSP in general, for whatever reason, may lead 
to increased Nos3 expression and NOS III activity as a compensatory mechanism, which 
fails to correct the relative deficiency of NO. Although by no means certain, there is some 
evidence that NO can reversibly and dose-dependently inhibit NOS III enzyme activity in 
21. This may be the mechanism whereby reduced NO availability could increase NOS III 
activity by removal of the auto-inhibition, although it is less clear how reduced NO could 
up-regulate Nos3 expression. Conceivably, the vasoconstriction produced by reduced NO 
would increase fluid shear stress, which is known to up-regulate Nos3 gene expression90,91.
Although differences in Nos3 expression and NOS III activity cannot explain the strain and 
gender differences in NO availability, other NOS isoforms may be responsible. 170- 
oestradiol has been shown to increase activity of purified NOS I in vitro251. However, 
despite having a number of interesting phenotypes, Nosl ‘knock out’ mice have normal 
blood pressure36. In any case, NOS I is unlikely to have an effect on denervated aortic rings 
in vitro.
NOS II has greater potential to contribute to differences in NO availability. If NOS II were 
at least partially responsible, then it might explain some of the discrepancies between basal
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NO detected by L-NAME and stimulated NO detected by ACh. L-NAME would inhibit all 
isoforms of NOS, but ACh would only stimulate NOS III. In addition, Deng and Rapp 
found linkage between a QTL for hypertension and the Nos2 gene on rat chromosome 10 in 
an F2 population derived from a cross of inbred Dahl salt-sensitive rats with Milan 
normotensive rats123. The Ace locus, encoding angiotensin I converting enzyme, also 
mapped to this region and is another, and possibly more likely candidate. This implicates 
Nos2 in hypertension, however, as with Nosl described above, Nos2 ‘knock out’ mice have 
normal blood pressure124. As far as gender differences are concerned, 170-oestradiol has 
also been shown to alter Nos2 expression after IFN or LPS induction, but the effect is an 
attenuation of induction257, which would not explain the increased NO availability in 
females.
In summary, there is no evidence for reduced NO production by SHRSP compared to 
WKY. In fact, when NOS III enzyme activity and Nos3 gene expression are examined, there 
is evidence that SHRSP may produce more NO. The same is true of males compared to 
females. There is no evidence, from studies of NOS III enzyme activity or Nos3 gene 
expression, of reduced NOS III activity in males compared to females. If anything, NOS III 
activity may be increased in males. Isoforms of NOS other than NOS III may be responsible 
for the observed differences in NO availability, but there is little evidence from the literature 
and no data from these studies that this is the case.
5.3 NO scavenging
It is known that NO can be scavenged by the free radical 0 2" to form peroxynitrite54. 
Although being itself a weak vasodilator287, the formation of peroxynitrite would reduce the 
availability of NO. In addition, peroxinitrite (or one of its decomposition products) has been
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shown to be directly toxic to the endothelium172. There is evidence that the apparent
j reduced NO availability demonstrated in the SHRSP can be exactly accounted for by
! increased levels of 0 2-114 and that in SHRSP mesenteric resistance vessels NO production is
[
normal, but scavenging by 0 2' is increased115. There is also evidence that 0 2" can influence 
the vascular reactivity of human vessels219 and may contribute to the hypertension in some 
animal models217. Excess of 0 2" is therefore a likely candidate for reducing basal and/or
I stimulated NO availability in SHRSP. To investigate this possibility the effects of exogenous
SOD and the SOD inhibitor DETCA on carbachol and PE response curves were studied in 
, together with quantification of Sodl and Sod2 mRNA expression.
i
| As one would expect, by inhibiting endogenous SOD and thereby increasing 0 2“ levels,
DETCA attenuated the carbachol relaxation in WKY and SHRSP and also in males and
I
t
| females within both strains. It has previously been demonstrated in male animals that the
attenuation by DETCA is significantly greater in SHRSP than WKY114. This is confirmed in 
the current study when males and females of both strains are combined. The attenuation of 
the carbachol response by DETCA remains significantly greater in SHRSP compared to 
WKY. This could mean that SOD is more active or present in higher concentrations in the 
aorta of SHRSP and therefore inhibiting the enzyme produces a greater effect. When SOD 
mRNA was quantified by northern blotting this turned out to be the case, at least as far as 
Mn SOD in males is concerned, where Sodl expression in SHRSP aortas was significantly 
greater than in WKY aortas. No strain difference in Sod2 expression was detected in 
females. The reason for this is not clear, but again may reflect the relatively smaller blood 
pressure difference and/or possibly a smaller difference in oxidative stress.
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Alternatively, the DETCA result could mean that when SOD is completely inhibited, 0 2~ 
accumulates faster in SHRSP and thus impairs relaxation to carbachol to a greater extent. 
There is now evidence from further work by our group288 and others186 to suggest that 0 2 
does accumulate faster in aortas from SHRSP compared to WKY. It remains unclear why 
0 2' production should be greater in the vasculature of SHRSP, although Kerr et al provide 
evidence that the endothelium is responsible288. Hypercholesterolaemia has been shown to 
increase 0 2' generation by endothelial XO211, although there is no evidence for 
hypercholesterolaemia in SHRSP. A more likely candidate enzyme is NAD(P)H oxidase, 
which has been shown to produce more 0 2' in models of angiotensin II dependent 
hypertension179. Angiotensin II has been shown to up-regulate expression of the p22phox 
gene, which encodes NAD(P)H oxidase289. However, there is very little evidence for 
angiotensin II excess in SHRSP, at least at 16 weeks of age before any renal damage has 
occurred. Other factors, as yet undetermined, may increase p22phox expression in SHRSP.
A possible mechanism which may explain both an increased XO activity and NAD(P)H 
oxidase activity in SHRSP and males is the reduced availability of NO itself. NO has been 
shown to suppress XO activity in vitro, reversibly and dose-dependently290. The suppression 
occurred irrespective of the presence or absence of xanthine; indicating that the reaction 
product of NO and 0 2', peroxynitrite, is not responsible for the suppression. Similarly, NO 
inhibits 0 2' production in vitro by NAD(P)H oxidase, albeit isolated from neutrophils and 
not endothelial cells291. These findings may indicate that a vicious cycle exists where 
increased 0 2' leads to reduced NO, which leads to increased XO and/or NAD(P)H oxidase 
activity, which leads to increased 0 2' etc.
An alternative source of 0 2' is NOS III itself. HUVEC can be stimulated to produce 0 2' by 
native LDL (n-LDL), which can be inhibited by L-NAME, suggesting that NOS III is the
enzyme responsible182. Again there is no reason to believe that SHRSP have more 
circulating n-LDL than WKY. More work is required, and indeed is underway, to determine 
the possible mechanism(s) for 0 2' excess in SHRSP.
Of course, increased 0 2’ production and increased SOD activity are not mutually exclusive, 
and may both occur within the SHRSP vasculature. Increased 0 2' may cause a 
compensatory up-regulation of Sod gene expression. As discussed in section 1.2.2.2, other 
groups have shown induction of Sod2 gene expression in response to increased 0 2' and 
other oxidative stress201,202. In these studies Sodl gene expression was unaltered201’202, 
therefore it is less surprising that no differences were detected in Sodl mRNA in males or 
females in the current study. Although Sodl gene expression is thought not to be regulated 
by oxidative stress, there is evidence that laminar shear stress of 0.6 to 15 dyne/cm2 can 
increase Sodl mRNA in a time- and dose-dependent manner in human aortic endothelial 
cells by a 1.6-fold increase in transcriptional activity93. Therefore, one might have expected 
that the increased laminar shear stress of higher blood pressure would have increased Sodl 
expression in SHRSP compared to WKY. In the above study the 1.6-fold increase in mRNA 
was detected by nuclear run-on assays, so northern blotting used in the current study may 
not have been sensitive enough to detect such a difference.
Because of its localisation on endothelial cells and the extracellular matrix of the 
vasculature, EC-SOD has been hailed as the principal regulator of endothelium derived NO 
bioavailability208. There are no data from the current study as to whether or not there are 
differences in Sod3 mRNA expression between SHRSP and WKY. Although there is some 
evidence for post-transcriptional or post-translational regulation of the human Sod3 gene209, 
there is no evidence in the literature for up-regulation in response to oxidative stress or any
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other stimulus. If a difference in Sod3 expression did exist between SHRSP and WKY, then 
it is likely to be primary and not secondary to differences in 0 2' levels or shear stress.
There were no gender differences in the attenuation of carbachol relaxation by DETCA in 
the current study. This would suggest that if a difference in 0 2 is responsible for the gender 
differences in NO availability, then this crude manipulation of S0D /02 was not sensitive 
enough to detect it. There are data in the literature to suggest gender differences in 0 2 
production. Kerr et al recently found 0 2 production to be greater in male WKY compared 
to female WKY, but found no gender difference in SHRSP288. Brandes and Miigge also 
found a gender difference in Wistar rats, with 0 2 production being greater in males186. 
Despite this, these latter authors failed to detect a significant gender difference in the effect 
of DETCA186, as in the current study. An alternative explanation is that some other 
mechanism may be responsible for gender differences in NO availability, but it is not clear 
what this may be, as NO production does not seem to be greater in females.
DETCA increased the mean Emax and mean EC50 of the PE concentration response curves in 
all groups as one would expect from its action of indirectly removing the vasodilator tone of 
NO. The changes in individual groups were variable and no significant strain or gender 
effects were detected.
The addition of exogenous SOD to the rings tended to augment the carbachol relaxation. 
This effect was most marked in SHRSP males who had the poorest relaxation to begin with. 
Nonetheless, the control relaxations were so good (>85% of PE in most cases) that there 
was very little room for improvement. The responses to SOD were consequently relatively 
small and quite variable resulting in no significant strain or gender differences. Again as one 
might expect, exogenous SOD attenuated the contraction to PE in all groups. As before, the
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effects were relatively small and variable resulting in no significant strain or gender 
differences.
Another reason for the small effects of exogenous SOD, and perhaps even the lack of strain 
or gender differences, may be that increased SOD activity is thought to be beneficial only 
when balanced by an increase in catalase activity194. If SOD activity is increased on its own 
then 0 2 will be converted to H20 2, which may become toxic to the vessel if not removed by 
catalase193.
As mentioned in section 1.2.2.1, an imbalance of SOD and catalase has been proposed as a 
common mechanism for the premature ageing of the central nervous system found in 
humans with Down’s syndrome and transgenic rats containing an extra copy of the human 
Sodl gene. In both of these situations there is increased Cu/Zn SOD activity in keeping with 
the gene dosage effect190193, but this seems to produce detrimental effects as there is no 
associated increase in catalase activity. This places some importance on catalase as an 
antioxidant defence mechanism, but it must not be forgotten that inhibition of SOD by 
DETCA had a greater detrimental effect on endothelium-dependent relaxations than the 
catalase inhibitor 3-amino-1,2,4-triazole188, suggesting that SOD is more important.
Exogenous SOD added to the water-bath is unable to enter the cells and therefore only 
removes extracellular 0 2‘. This may also partly explain the relatively small effect. Others 
have encountered the same problem, but Mugge et al managed to overcome this by 
employing polyethylene-glycolated SOD to scavenge 0 2' and reduce atherogenesis in 
hypercholesterolaemic rabbits213. Similarly, Nakazono et al were able to lower blood 
pressure in SHR by intravenous injection of a fusion protein of SOD linked to a C-terminal
162
basic domain, which has high affinity for heparin-like proteoglycans on vascular endothelial 
cells217. However, such compounds are not widely available.
In summary, there is evidence from previous studies114’115, and more recently from Kerr et 
288, that the vessels of SHRSP have 0 2 in excess. This is confirmed in the current study 
and is likely to be responsible for reduced basal NO in SHRSP. The consequent increased 
oxidative stress appears to upregulate Sod2 gene expression in male SHRSP, as described 
by others201,202. Both of these differences are likely to contribute to the marked difference in 
the effect of DETCA on the carbachol response between SHRSP and WKY.
5.4 Effect of age
There was an age related decline in basal NO availability in female rats, as measured by the 
contraction of aortic rings to L-NAME. Basal NO at 12 months was significantly reduced 
compared to 4 months in both WKY and SHRSP female aortas. There was a slight tendency 
for basal NO measurements to increase with age in both WKY and SHRSP males, although 
basal NO availability at 12 months did not differ significantly from 4 months. As discussed 
in section 1.4, a decline in endothelial function with age has been reported in rats263,267 and 
humans264,265. In these studies only males were studied267 or males and females were 
analysed together without comparison between genders265. The present study agrees with 
these data, but suggests that the effect is more marked in females.
As with the blood pressure and gender differences, reduced basal NO in the older females 
may be due to reduced NO production, increased NO scavenging or both. Nos3 gene 
expression was quantified by RT-PCR in the aortas from a small number of 12 month old 
female rats and was found to be significantly increased compared to 4 month old females.
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Accepting that increased Nos3 gene expression does not necessarily equate with increased 
NOS III activity, this provides some evidence that NO production is not reduced. Instead,
NO production may be increased, perhaps to compensate for increased 0 2‘ which Harman 
suggests is the underlying mechanism of ageing266. Tschudi et al provide some evidence that 
increased 0 2' is indeed responsible for age related reduction in NO in male WKY rats267. A 
recent study by Barton et al suggests a possible mechanism for increased 0 2' in older rats292. 
They found reduced plasma SOD activity in older rats, but aortic SOD activity was 
unaffected by age. As with the current study they found basal NO availability to be reduced 
in the older animals. However, they also measured Nos3 gene expression by RT-PCR and 
found it to be reduced in the aortas from the older animals, which is contrary to the current 
study.
In summary, there was an age related decline in basal NO availability in females, with an age 
related increase in Nos3 gene expression, suggesting that age related increases in 0 2 within 
the aorta may be responsible for the associated decline in endothelial function.
5.5 Effect of oestrogen
Although circulating 17p-oestradiol was not measured in these animals, it is tempting to 
speculate, from the gender differences in NO availability and decline with age in females, 
that 17p-oestradiol alters the N 0 /0 2' balance. To address this point basal NO availability 
was measured by the response of aortic rings to L-NAME as before. Aortic rings from one 
year old WKY females treated with intraperitoneal 17P-oestradiol for two weeks were 
compared with rings from one year old WKY females treated with intraperitoneal vehicle. 
Basal NO availability was greater in the 17P-oestradiol treated group, but the difference 
only bordered on statistical significance.
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As discussed in section 1.1.1.5.2, the Nos3 gene contains several copies of the oestrogen 
response element half-palindrome71’74, which can, in combination, up-regulate transcription 
of Nos3 in response to oestrogen95. One may speculate, that this is the mechanism whereby 
in vivo 17P-oestradiol augments basal NO availability in the current study. Indeed, as 
discussed in section 1.3.1.3, there are many reports in the literature where oestrogen has 
been shown to directly increase Nos3 mRNA105'107. However, when Nos3 mRNA was 
quantified by RT-PCR in a small number of aortas from 17P-oestradiol and vehicle treated 
WKY females at one year of age, there was no significant difference between the two 
groups. The trend was towards a decrease after 17p-oestradiol treatment, rather than an 
increase. The reason why this result contradicts other reports is unclear. Perhaps at one year 
of age Nos3 gene expression has been maximally stimulated by the oxidative stress of 
ageing. Therefore, further stimulation would be difficult, if not impossible, with the dose of 
17p-oestradiol used. In addition, at one year of age female rats are still fertile, although less 
so. Therefore, their endogenous oestrogen may also be stimulating Nos3 gene expression in 
both groups. Whatever the reason, the lack of a difference in Nos3 gene expression makes a 
difference in NO production less likely as the mechanism for the oestrogen effect on NO 
availability. However, it is still possible that oestrogen increases NOS III activity in the 
absence of increased Nos3 expression.
It may therefore be that oestrogen prevents NO scavenging. There are no data from the 
current study to support this hypothesis, but there is at least one report in the literature by 
Amal et allss, who found evidence of increased NO effect (i.e. increased guanylate cyclase 
stimulation) from BAEC treated with the synthetic oestrogen ethinylestradiol, which they 
showed was due to reduced 0 2. They found no effect of ethinylestradiol on Nos3 gene 
expression or NOS III enzyme activity. More recently, a couple of studies, including data
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from our own group, have demonstrated gender differences in 0 2", with male rats having 
more 0 2‘ compared to females186,288.
As with NO, the amount of 0 2' present in the aorta at any one time will depend on the rate 
of production and the rate of dismutation. Neither of the above two studies provides 
evidence as to which mechanism is responsible for the increased 0 2' in males, although there 
is evidence for reduced activity of the 0 2" generating enzyme NADH oxidase by 
ethinylestradiol from another study259. The only previous study to look at the effects of 
oestrogen on SOD activity within the cardiovascular system found no effect of gender, 
gonadectomy or graded doses of oestradiol on the rabbit myocardium261. However, 
oestrogen has been shown to increase Cu/Zn SOD activity in non-vascular tissue such as rat 
mammary tumours260.
As well as by dismutation, 0 2' can be reduced by interaction with anti-oxidant molecules. 
Oestrogen appears to possess anti-oxidant properties248, perhaps related to its phenolic 
structure, and may also reduce 0 2" by this means. It therefore seems possible, if not likely, 
that oestrogen can reduce 0 2' by reducing production and increasing removal. This would 
explain the increased NO availability in the current study after 17{3-oestradiol treatment, 
with no apparent increase in Nos3 expression. As 0 2' is thought to be important in 
atherogenesis, some of the cardioprotective effects of oestrogen in animals237,238 and 
humans241,242 may be due to a reduction in 0 2', in addition to increasing NO production.
There was no difference it the carbachol concentration response curves between the 170- 
oestradiol treated group and the vehicle treated group. This is further evidence for a 
difference in regulation between basal and stimulated NO availability, as discussed in section
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5 .1. As 0 2' is thought to underlie the difference in availability of basal and stimulated NO 
availability, then this is further evidence for oestrogen affecting 0 2\
Grculating oestrogen is not the only difference between males and females. Progestogens 
may also be important. There is much debate about whether progestogens diminish the 
beneficial effect of oestrogen. This is an important issue as most women, certainly those 
with an intact uterus, are given a progestogen in conjunction with an oestrogen as 
conventional HRT. The Postmenopausal Estrogen/Progestin Intervention (PEPI) Trial 
showed that cyclical medroxyprogesterone acetate marginally attenuated the improved lipid 
profile obtained from conjugated equine oestrogen, although the combination was still 
highly significant compared to placebo246. However, a recent report from the Nurses’
Health Study293 show a marked decrease in the risk of major coronary heart disease among 
women who took oestrogens with progestogens, as compared with the risk among women 
who did not use hormones (multivariate adjusted relative risk, 0.39; 95 percent confidence 
interval, 0.19 to 0.78) or oestrogens alone (relative risk, 0.60; 95 percent confidence 
interval, 0.43 to 0.83). Some of the cardiovascular benefit may be obtained by inhibition of 
VSMC proliferation, which has been demonstrated for oestrogen and progesterone 
independently, without synergistic or additive effects of the two steroids294.
What about vascular reactivity? Jiang et al showed that progesterone on its own, albeit at 
micromolar concentrations, caused relaxation of rabbit coronary artery and rat aorta in 
295. However, this effect was endothelium-independent and not inhibited by 
haemoglobin or methylene blue, suggesting that neither NO nor guanylyl cyclase are 
involved. Administration of more conventional HRT doses of medroxyprogesterone acetate 
to cynomolgus monkeys, either cyclically or continuously, attenuated the improvement in 
endothelium-dependent dilatation, at coronary angiography, elicited by conjugated equine
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oestrogen296. It has been speculated that part of the difference between the progestogen 
effect in these two studies is due to structural differences between progesterone and 
medroxyprogesterone acetate. However, Miller and Vanhoutte had previously shown that 
progesterone in vivo reversed the beneficial effects of oestrogen on endothelium-dependent 
relaxations to ACh in canine coronary arteries in vitro291.
It would appear that in terms of endothelial function, an oestrogen/progestogen 
combination is less beneficial than oestrogen alone. However, the improved lipid profile of 
the combination may still outweigh this and confer an overall benefit in cardiovascular 
disease prevention.
An additional difference between males and females is the much higher levels of 
testosterone in males. Relatively little attention has been paid to the role of androgens in the 
sexual dimorphism in cardiovascular disease. The Rancho Bernardo population study of 
1132 men aged between 30 and 79 years found that those with systolic blood pressure 
greater than 160mmHg and/or diastolic blood pressure greater than 95mmHg had 
significantly lower testosterone than the normotensive population298. Indeed, systolic and 
diastolic blood pressure were inversely correlated with testosterone levels in the whole 
cohort, even after adjusting for age and body mass index. This inverse correlation between 
testosterone levels and blood pressure was confirmed in a 12 year prospective population- 
based study of 1,009 normotensive white men, although no significant correlation was 
detected between testosterone levels and cardiovascular disease299. The lack of correlation 
between testosterone and cardiovascular disease is especially surprising since testosterone 
has now been shown to increase cardioprotective high density lipoprotein (HDL) 
cholesterol and lower atherogenic very low density lipoprotein (VLDL)300. Nonetheless, 
these studies were the first indication that androgens may affect vascular reactivity.
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The role of androgens in blood pressure regulation was subsequently studied in animals. 
Ganten et al used the SHR and SHRSP as models of hypertension to investigate the effect 
of androgens and found the opposite effect to the human studies301. They found in male rats 
at nine weeks of age that castration, or treatment with one of two different testosterone 
receptor antagonists, reduced blood pressure in both models. These interventions failed to 
reduce blood pressure at 25 weeks of age when hypertension was established. It is not clear 
why the rat studies are in conflict with the human studies, but perhaps high levels of 
testosterone during adolescence may be a better predictor of developing hypertension, 
rather than looking at older men in whom hypertension has or has not been established.
The studies which have examined the direct effects of testosterone on vascular reactivity 
seem to favour a dilator response in keeping with a hypotensive action. The first such in 
study was carried out by Yue et al, who found that testosterone added to the organ 
bath directly and immediately relaxed rings of rabbit aorta and coronary artery302. This 
effect was similar if the vessels were removed from males or females, and was not 
attenuated by removal of the endothelium or inhibition of NOS. The mechanism of this 
relaxation therefore remains unclear, although the investigators provide some evidence that 
K+ channels, but not ATP-sensitive K+ channels, may be partly responsible. This in vitro 
observation was confirmed in vivo in the coronary circulation of anaesthetised dogs303. In 
this study, the vasodilatation in response to testosterone was again independent of sex, but 
was attenuated by the NOS inhibitor L-NAME. The involvement of endothelium derived 
NO was also suggested by another in vitro study of Sprague-Dawley rat thoracic aortic 
rings304. Again these authors report an acute, dose dependent vasodilator effect of 
testosterone on endothelium intact rings, which was attenuated, but not completely 
abolished, by L-NAME. Interestingly, they observed the same vasodilator effect in 
endothelium intact aortic rings from male testicular-feminised rats, which do not possess a
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functional testosterone receptor, suggesting that the classical receptor is not involved in this 
effect.
Therefore, although the precise mechanism remains unclear, testosterone seems to have a 
vasodilator, and consequent blood pressure lowering effect, which together with its 
beneficial effect on lipid profile should make it cardioprotective. There are no data from the 
current study on the role of testosterone on the gender differences in blood pressure and 
NO availability, but such a role cannot be excluded. It may be that testosterone does 
improve endothelial function, but not as much as oestrogen, resulting in the observed 
gender difference. Alternatively, other differences between males and females, such as the Y 
chromosome, may contribute to the sexual dimorphism in blood pressure and cardiovascular 
disease.
The earliest experimental evidence that the Y chromosome may influence blood pressure 
came from Ely and Turner in 1990305. They crossed SHR and WKY rats and found that 
blood pressure was significantly higher from 12 to 20 weeks in the male offspring derived 
from WKY mothers and SHR fathers as compared with male offspring derived from SHR 
mothers and WKY fathers. The blood pressure in the female offspring was not related to the 
strain of the male progenitor, further supporting Y chromosome linkage and not parental 
imprinting. This observation was confirmed in a cross between the closely related SHRSP x 
WKY306.
Again no attempt was made in the current study to assess the role the Y chromosome in 
gender differences in blood pressure or NO availability. The precise mechanism of the Y 
chromosome effect on blood pressure remains unclear, but there is no evidence it affects the 
N 0 /0 2 balance directly. The androgen receptor is thought to be involved as the effect is not
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apparent in a cross between SHR fathers and mothers heterozygous for the gene for 
testicular feminisation, where some male offspring will have no functional androgen 
receptor307. However, the increases in blood pressure may contribute to secondary gender 
differences in endothelial function.
In summary, oestrogen increases basal NO availability, without apparently increasing Nos3 
gene expression. It is reasonable to speculate that oestrogen reduces NO scavenging by 0 2\  
although it is not clear whether the mechanism is increased 0 2' removal, reduced 0 2' 
production or both. The contributions of progesterone, testosterone and the Y chromosome 
were not investigated, but are likely to be significant, considering what is known from the 
literature and previous work performed in our laboratory.
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6 Conclusion
The main conclusion from these studies is that the N 0 /0 2‘ balance seems to be more 
important than the absolute amount of either molecule alone. Data presented in this thesis, 
and that of others, support the idea that 0 2' excess is responsible for the reduced basal, if 
not stimulated, NO availability and hence endothelial dysfunction and cardiovascular disease 
in SHRSP. Nos3 and Sod2 gene expression appear to be up-regulated to compensate, but 
are unable to correct the N 0 /0 2' imbalance. It remains unclear whether 0 2' excess results
from the primary genetic defect in SHRSP, or if it is simply a consequence of the 
hypertension.
Neither differences in Nos3 gene expression, nor differences in NOS III enzyme activity can 
explain the gender differences in basal NO availability. Therefore, although not supported 
by these data, one may speculate that scavenging by 0 2', at least in part, accounts for 
gender differences in NO availability. However, the effect of oestrogen on NO production 
may still be important. One may further speculate that both of these effects contribute to the 
gender differences in blood pressure and cardiovascular disease and the beneficial effects of 
postmenopausal hormone replacement therapy.
Figure 25 shows a schematic representation of the factors and enzymes thought to be 
involved in controlling NO availability within the vasculature.
Further work is required to fully elucidate the enzyme(s) responsible for the 0 2' excess in 
SHRSP, including EC-SOD. Such enzyme dysfunction may underlie the pathogenesis of 
some forms of human essential hypertension. The assumption that enzyme activity equates 
with gene expression needs to be confirmed by further functional studies, especially of the
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SOD isoenzymes. One can speculate that males are in a state of 0 2 excess combined with a 
relative NO deficiency; a vascular status which predisposes to cardiovascular disease.
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Appendices
Appendix 1 - List of suppliers
Amersham International pic. Amersham. UK 
[cc32P]-dCTP
Hybond N+ nylon membrane 
Hyperfilm-MP
Biogenesis. Poole. UK 
RNAzolB
Bio-Rad Laboratories Ltd. Hemel Hempstead. UK 
AG 501-X8 mixed bed resin 
Bio-Rad protein assay
Dowex-AG50W resin (200-400, 8% cross linked, Na+ form) 
Sodium dodecyl sulphate (SDS)
Boehringer Mannheim. Lewes. UK 
DNase free RNase 
Eco RI restriction enzyme 
Hind III restriction enzyme 
Lysozyme
Restriction enzyme buffer B 
Restriction enzyme buffer H
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Fluka Chemicals. Gillingham. UK 
Dimethylsulphoxide (DMSO)
Gibco BRL. Paisley. UK 
Agarose 
Yeast tRNA
Random primers DNA labelling kit consisting of:- 
dATP, dGTP, dTTP 
Klenow fragment DNA polymerase 
Random primers buffer
ICN Biomedicals Ltd. Thame. UK 
L- [U-14C] -arginine,
Promega. Southampton. UK
AMV reverse transcriptase 
dNTP’s
Magnesium chloride (MgCl2) for PCR
01igo(dT)i5 primer
10X PCR buffer (Mg2+ free)
RQ1 DNase 
rRNAsin
Taq DNA polymerase
Terminal deoxynucleotidyl tranferase (TdT)
5X TdT buffer
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Sigma-Aldrich. Poole. UK
A: Aprotonin, L-arginine
C: Caesium chloride (CsCl), Calcium chloride (CaCl2.2H20), Calcium disodium 
ethylenediaminetetra-acetate (CaNa2EDTA), Carbamylcholine chloride 
(carbachol), L-citrulline, Cocaine HC1 
D: Diethylpyrocarbonate (DEPC), Disodium phosphate (Na2HP04), Dithiothreitol 
(DTT)
E: Ethidium bromide (EtBr), Ethylene glycol-bis(p-aminoethyl ether)-N,N,N’, N’- 
tetra-acetic acid (EGTA)
F: Flavin adenine dinucleotide (FAD), Flavin mononucleotide (FMN)
G: Glucose
H: Hydrogen peroxide
I: N“-iminoethyl-L-omithine (L-NIO), Indomethacin 
O: 17p-oestradiol
L: X Hind III DNA size markers, Leupeptin
M: Magnesium chloride (MgCl2), Magnesium sulphate (MgS04.7H20), Methylene 
blue, Monopotassium phosphate (KH2P 04)
N: Nicotinamide adenine dinucleotide phosphate reduced form (NADPH), NG-nitro- 
L-arginine methyl ester (L-NAME)
P: Potassium chloride (KC1), Phenylephrine (PE)
S: Sheared salmon sperm DNA, Sodium acetate, Sodium bicarbonate (NaHC03), 
Sodium chloride (NaCl), Sodium diethyldithiocarbamate (DETCA), Sodium 
nitroprusside (SNP), Soybean trypsin inhibitor (SBTI), Sucrose, Superoxide 
dismutase (SOD)
T: Tetrahydrobiopterin, Tris 
V: Valine
224
Stratagene Ltd. Cambridge. UK
mCAP mRNA Capping Kit consisting of:- 
Dithiothreitol 
mCAP analogue 
Proteinase K 
RNase free DNase 
RNase free TE 
rNTP mix
T3 RNA polymerase 
5X Transcription buffer
Zeneca. Macclesfield. UK 
Halothane
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Appendix 2 - Recipes for solutions
All chemicals were obtained from Sigma-Aldrich Co. Ltd, Poole, UK, unless otherwise 
stated in appendix 1.
Alkali Lvsis Solution I
Glucose (lmol/L)
Tris.Cl (0.lmol/L, pH 8.0) 
EDTA (0.lmol/L, pH 8.0) 
dH20
This was autoclaved, allowed to cool and stored at 4°C.
Alkali Lysis Solution II
NaOH (5mol/L) 0.2mL
SDS (10% w/v) 0.5mL
dH20  4.3mL
5.0mL
This was freshly prepared on the day of use.
Alkali Lvsis Solution ITT
Potassium acetate (5mol/L) 
Glacial acetic acid 
dH20
This was prepared and stored at 4°C.
Alkali transfer buffer
NaCl (5mol/L) 
NaOH (5mol/L) 
dH20
60mL 
11.5mL 
28.5mL 
lOOmL
150mL
25mL
325mL
500mL
5mL
25mL
lOmL
60mL
lOOmL
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Deionised formamide
Formamide 200mL
AG501-X8 mixed bed resin 1 Og
This was stirred for 1 hour, filtered, split into 20mL aliquots, gassed in 0 2-free N2 and 
stored at -70°C.
Deionised glvoxal (Ethanediah
Glyoxal (40% w/v)
AG 501-X8 mixed bed resin
This was mixed by stirring until pH > 
free N2 and stored at -70°C.
Denaturation solution
NaCl (5mol/L) 150mL
NaOH (5mol/L) 50mL
dH20  300mL
500mL
100X D enhardt's Solution (2% BSA. 2% FicolL 2% PVP)
Bovine serum albumine (BSA, Fraction V) 2g
Ficoll (Type 400) 2g
Polyvinylpyrollidone (PVP, Mw 360,000) 2g
dH20  lOOmL
This was split into l-2mL aliquots and stored at -70°C.
Dimethvlsulphoxide fDMSO)
A fresh bottle of spectroscopy grade DMSO was separated into lOOpL aliquots, gassed in 
0 2-free N2 and stored at -70°C.
Gloxal mix
Spectroscopy grade DMSO 160pL
Sodium phosphate buffer (0. lmol/L, pH 7.0) 32pL
Deionised glyoxal (40% w/v) 54pL
246pL
This was freshly prepared on the day of use.
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20mL
20g
5.0, filtered, split into 30pL aliquots, gassed in 0 2-
L-amp agar plates
LB agar tablets 16.8g (10 tabs)
dH20  500mL
This was autoclaved and allowed to cool to hand warm.
Ampicillin sodium (25mg/mL stock) 2mL
502mL
This was poured into sterile 100mm plates, allowed to set at room temperature and stored 
at 4°C.
LB-amp medium
LB-broth
Ampicillin sodium (25mg/mL stock)
This was prepared and stored at 4°C.
LB broth
LB broth tablets 11 g (10 tabs)
dH20  500mL
This was autoclaved, allowed to cool and stored at 4°C.
Lvsozvme (10mg/mL in lOmmol/L Tris.CL p H 8.0)
Lysozyme
Tris-Cl (0.lmol/L, pH 8.0) 
dH20
This was freshly prepared on the day of use.
‘M iller’ transform ation solution
Polyethylene glycol (Mw 8000, 50% w/v) lOOmL
M gS04 (lmol/L) 25mL
Dimethyl sulphoxide (DMSO) 25mL
dH20  + 10 LB broth tablets 350mL
500mL
This was autoclaved, allowed to cool and stored at 4°C.
50mg
0.5mL
4.5mL
5.0mL
500ml 
2m L 
502mL
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5X RNA loading buffer
Bromophenol blue 160mg
Glycerol 20mL
Sodium phosphate buffer (0. lmol/L, pH 7.0) 4mL
DEPC H20  16mL
40mL
This was incubated at 37°C in a shaking incubator for 60 minutes to dissolve and mix the 
components, treated with DEPC (0.01% v/v) overnight, autoclaved, then stored at -20°C in 
small aliquots.
Sodium Dodecvl Sulphate (SDS. 10% w/v)
Wearing a face mask, 1 OOg of electrophoresis grade SDS was added to 900mL of dH20  and 
heated to 68°C to facilitate dissolution. The pH was adjusted to 7.2 with concentrated HC1 
and the volume made up to 1 OOOmL.
Sodium phosphate buffer (0.lm ol/L. p H 7.0)
NaH2P 0 4 (0.5mol/L)
Na2H P04 (0.5mol/L)
DEPC H20
78mL 
122mL 
800mL 
1 OOOmL
This was treated overnight with DEPC (0.01% v/v) and then autoclaved.
20X SSC
NaCl 175.3g
Na3Citrate 88.2g
dH20 800mL
This was adjusted to pH 7.0 with HC1 (lmol/L), made up to 1 OOOmL and autoclaved.
20XSSPE
NaCl 175.3g
NaH2P 0 4 27.6g
Na2EDTA.2H20  7.4g
dH20  900mL
This was adjusted to pH 7.4 with IN NaOH, made up to 1 OOOmL and autoclaved.
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2X SSPE/0.1% SDS
20X SSPE 50mL
SDS (10% w/v) 5mL
dH20  445mL
500mL
IX SSPE/0.1% SDS
20X SSPE 25mL
SDS (10% w/v) 5mL
dH20  470mL
500mL
0.IX SSPE/0.1% SDS
20X SSPE 2.5mL
SDS (10% w/v) 5.0mL
dH20  492.5mL
500mL
STE
NaCl (5mol/L) lOmL
Tris-Cl (0.lmol/L, pH 8.0) 50mL
EDTA (0.lmol/L, pH 8.0) 5mL
dH20  435mL
500mL
Supplemented LB broth (lOmmol/L MeSCh. 0.2% w/v glucose)
Sterile LB broth 98mL
Sterile MgS04 (lmol/L) lmL
Filter sterilised glucose (20% w/v) lmL
lOOmL
